primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
134013572,13401357,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,B 186322,,204042.0,300.0,MG,Capsule,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,20150709.0,20170328.0,20170404,20220310,EXP,,MY-JNJFOC-20150707879,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,65.1,KG,20220310,,MD,MY,MY,2022,Q1,Adult
147086956,14708695,49,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,6,F,20151201.0,20211221.0,20180403,20220113,EXP,,US-AstraZeneca-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20220113,,LW,US,,2022,Q1,Elderly
147086956,14708695,49,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Chronic kidney disease,,2022,Q1,6,F,20151201.0,20211221.0,20180403,20220113,EXP,,US-AstraZeneca-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20220113,,LW,US,,2022,Q1,Elderly
147086956,14708695,49,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,6,F,20151201.0,20211221.0,20180403,20220113,EXP,,US-AstraZeneca-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20220113,,LW,US,,2022,Q1,Elderly
147086956,14708695,49,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Renal failure,,2022,Q1,6,F,20151201.0,20211221.0,20180403,20220113,EXP,,US-AstraZeneca-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20220113,,LW,US,,2022,Q1,Elderly
147086956,14708695,49,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Renal injury,,2022,Q1,6,F,20151201.0,20211221.0,20180403,20220113,EXP,,US-AstraZeneca-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20220113,,LW,US,,2022,Q1,Elderly
1566392233,15663922,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,,,,,100.0,MG,Tablet,QD,2022,Q1,Tubulointerstitial nephritis,,2022,Q1,33,F,20181001.0,20220131.0,20181128,20220209,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-091356,BRISTOL MYERS SQUIBB,"Matsunaga K,et al. A case of suspected prolongation of immune checkpoint inhibitor-related myocarditis (a possibility of detecting inflammation by 18-F-FDG-PET/CT after 18-hour fasting). The 3rd Annual Meeting of Japanese Onco-Cardiology Society;Programs and Abstract. 2020;82",71.0,YR,,M,Y,60.3,KG,20220209,,MD,JP,JP,2022,Q1,Elderly
1566392233,15663922,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,,,,,100.0,MG,Tablet,QD,2022,Q1,Prescribed overdose,,2022,Q1,33,F,20181001.0,20220131.0,20181128,20220209,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-091356,BRISTOL MYERS SQUIBB,"Matsunaga K,et al. A case of suspected prolongation of immune checkpoint inhibitor-related myocarditis (a possibility of detecting inflammation by 18-F-FDG-PET/CT after 18-hour fasting). The 3rd Annual Meeting of Japanese Onco-Cardiology Society;Programs and Abstract. 2020;82",71.0,YR,,M,Y,60.3,KG,20220209,,MD,JP,JP,2022,Q1,Elderly
1566392233,15663922,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,,,,,100.0,MG,Tablet,QD,2022,Q1,Immune-mediated myocarditis,,2022,Q1,33,F,20181001.0,20220131.0,20181128,20220209,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-091356,BRISTOL MYERS SQUIBB,"Matsunaga K,et al. A case of suspected prolongation of immune checkpoint inhibitor-related myocarditis (a possibility of detecting inflammation by 18-F-FDG-PET/CT after 18-hour fasting). The 3rd Annual Meeting of Japanese Onco-Cardiology Society;Programs and Abstract. 2020;82",71.0,YR,,M,Y,60.3,KG,20220209,,MD,JP,JP,2022,Q1,Elderly
1566392233,15663922,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,,,,,100.0,MG,Tablet,QD,2022,Q1,Cardiogenic shock,,2022,Q1,33,F,20181001.0,20220131.0,20181128,20220209,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-091356,BRISTOL MYERS SQUIBB,"Matsunaga K,et al. A case of suspected prolongation of immune checkpoint inhibitor-related myocarditis (a possibility of detecting inflammation by 18-F-FDG-PET/CT after 18-hour fasting). The 3rd Annual Meeting of Japanese Onco-Cardiology Society;Programs and Abstract. 2020;82",71.0,YR,,M,Y,60.3,KG,20220209,,MD,JP,JP,2022,Q1,Elderly
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Ear disorder,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Influenza,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Heart rate increased,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Therapeutic response shortened,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Cough,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Neck pain,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Hypotension,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Constipation,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Tinnitus,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Polyp,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Hepatic cirrhosis,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Neuralgia,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Hepatic steatosis,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Viral infection,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Tympanic membrane perforation,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Eyelid infection,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Localised infection,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Bronchitis,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Weight increased,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Ear infection,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Musculoskeletal pain,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Sinusitis,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Malaise,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Pain in extremity,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
172368293,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Paranasal cyst,,2022,Q1,3,F,,20220110.0,20200106,20220119,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20220119,,HP,CA,CA,2022,Q1,Adult
178101748,17810174,5,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,Beginning of dosage day: Trial preinitiation,,,,,,,,,,Tablet,QD,2022,Q1,Multiple injuries,,2022,Q1,8,F,20200506.0,20220111.0,20200521,20220124,EXP,,JP-ROCHE-2602163,ROCHE,,68.0,YR,,M,Y,86.5,KG,20220124,,MD,JP,JP,2022,Q1,Elderly
178101748,17810174,5,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,Beginning of dosage day: Trial preinitiation,,,,,,,,,,Tablet,QD,2022,Q1,Adrenocorticotropic hormone deficiency,,2022,Q1,8,F,20200506.0,20220111.0,20200521,20220124,EXP,,JP-ROCHE-2602163,ROCHE,,68.0,YR,,M,Y,86.5,KG,20220124,,MD,JP,JP,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Therapeutic response shortened,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Dyspnoea,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Localised infection,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Cough,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Eyelid infection,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Ear infection,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Tinnitus,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Polyp,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Viral infection,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Malaise,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Neuralgia,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Heart rate increased,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Tympanic membrane perforation,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Hypotension,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Ear disorder,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Influenza,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Weight increased,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Bronchitis,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Paranasal cyst,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Sinusitis,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179072092,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Constipation,,2022,Q1,2,F,,20220209.0,20200617,20220221,EXP,,CA-ROCHE-2619589,ROCHE,,68.0,YR,,F,Y,120.0,KG,20220221,,HP,CA,,2022,Q1,Elderly
179366134,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Asthma,,2022,Q1,4,F,,20220103.0,20200624,20220112,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,,F,Y,,,20220112,,CN,CA,CA,2022,Q1,Elderly
179366134,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Full blood count abnormal,,2022,Q1,4,F,,20220103.0,20200624,20220112,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,,F,Y,,,20220112,,CN,CA,CA,2022,Q1,Elderly
179366134,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,4,F,,20220103.0,20200624,20220112,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,,F,Y,,,20220112,,CN,CA,CA,2022,Q1,Elderly
179366134,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,4,F,,20220103.0,20200624,20220112,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,,F,Y,,,20220112,,CN,CA,CA,2022,Q1,Elderly
179366134,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,4,F,,20220103.0,20200624,20220112,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,,F,Y,,,20220112,,CN,CA,CA,2022,Q1,Elderly
179709966,17970996,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q1,Subdural haematoma,,2022,Q1,6,F,20200427.0,20220104.0,20200701,20220113,EXP,,JP-PFIZER INC-2020215107,PFIZER,,75.0,YR,,M,Y,71.0,KG,20220113,,PH,JP,JP,2022,Q1,Elderly
179709966,17970996,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,6,F,20200427.0,20220104.0,20200701,20220113,EXP,,JP-PFIZER INC-2020215107,PFIZER,,75.0,YR,,M,Y,71.0,KG,20220113,,PH,JP,JP,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Rhabdomyolysis,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Laboratory test abnormal,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Muscle disorder,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Drug interaction,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Drug level above therapeutic,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Gait disturbance,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Hepatocellular injury,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Drug-induced liver injury,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
181569285,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q1,Drug level increased,,2022,Q1,5,F,,20211227.0,20200817,20220103,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220101,,MD,CA,CA,2022,Q1,Elderly
182176015,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",200.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Dizziness,,2022,Q1,5,F,20200515.0,20220314.0,20200901,20220322,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20220322,,HP,JP,JP,2022,Q1,Adult
182176015,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",200.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Enteritis infectious,,2022,Q1,5,F,20200515.0,20220314.0,20200901,20220322,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20220322,,HP,JP,JP,2022,Q1,Adult
182176015,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",200.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Nasopharyngitis,,2022,Q1,5,F,20200515.0,20220314.0,20200901,20220322,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20220322,,HP,JP,JP,2022,Q1,Adult
182176015,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",200.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Dyshidrotic eczema,,2022,Q1,5,F,20200515.0,20220314.0,20200901,20220322,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20220322,,HP,JP,JP,2022,Q1,Adult
182176015,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",200.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Erythema multiforme,,2022,Q1,5,F,20200515.0,20220314.0,20200901,20220322,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20220322,,HP,JP,JP,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Oropharyngeal discomfort,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Drug ineffective,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Tachycardia,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Blood pressure diastolic increased,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Off label use,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Pneumonia,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Condition aggravated,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Heart rate irregular,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Flushing,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Drug hypersensitivity,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Hypertension,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
183988603,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,3,F,,20220202.0,20201019,20220208,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20220209,,HP,CA,CA,2022,Q1,Adult
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Bladder cancer,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Needle issue,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Infusion site pain,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Urinary tract infection,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Device infusion issue,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
187421913,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Expired product administered,,2022,Q1,3,F,20200916.0,20220202.0,20210114,20220211,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220211,,CN,IE,IE,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Cystitis,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Hypothyroidism,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Oxygen saturation decreased,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Fibromyalgia,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Nasopharyngitis,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Vascular stenosis,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Lower respiratory tract infection,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Intercepted medication error,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Finger deformity,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Rheumatoid arthritis,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Kidney infection,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Pain,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Intentional product use issue,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Blood pressure diastolic decreased,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Breast disorder,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Hypertension,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Contusion,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Blood pressure diastolic abnormal,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Heart rate increased,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Fall,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Hypotension,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Nodule,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
189236272,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Steroid diabetes,,2022,Q1,2,F,,20220303.0,20210222,20220315,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220315,,HP,CA,CA,2022,Q1,Elderly
192716814,19271681,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q1,Peptic ulcer,,2022,Q1,4,F,20210422.0,20220128.0,20210518,20220207,EXP,,JP-ROCHE-2831583,ROCHE,"Hirakawa S, Shibata N, Gushima T, Takahashi K, Mochidome N. A Case of Hepatocellular carcinoma in which Rectal Perforation Developed during the Combination Therapy with Atezolizumab and Bevacizumab. (Abstract number: 22). The 118th Kyushu Branch Meeting of the Japanese Society of Gastroenterology/The 112th Kyushu Branch Meeting of Japan Gastroenterological Endoscopy Society. ;:-.",69.0,YR,,M,Y,59.55,KG,20220207,,MD,JP,JP,2022,Q1,Elderly
192716814,19271681,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q1,Rectal perforation,,2022,Q1,4,F,20210422.0,20220128.0,20210518,20220207,EXP,,JP-ROCHE-2831583,ROCHE,"Hirakawa S, Shibata N, Gushima T, Takahashi K, Mochidome N. A Case of Hepatocellular carcinoma in which Rectal Perforation Developed during the Combination Therapy with Atezolizumab and Bevacizumab. (Abstract number: 22). The 118th Kyushu Branch Meeting of the Japanese Society of Gastroenterology/The 112th Kyushu Branch Meeting of Japan Gastroenterological Endoscopy Society. ;:-.",69.0,YR,,M,Y,59.55,KG,20220207,,MD,JP,JP,2022,Q1,Elderly
192716814,19271681,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q1,Pyelonephritis acute,,2022,Q1,4,F,20210422.0,20220128.0,20210518,20220207,EXP,,JP-ROCHE-2831583,ROCHE,"Hirakawa S, Shibata N, Gushima T, Takahashi K, Mochidome N. A Case of Hepatocellular carcinoma in which Rectal Perforation Developed during the Combination Therapy with Atezolizumab and Bevacizumab. (Abstract number: 22). The 118th Kyushu Branch Meeting of the Japanese Society of Gastroenterology/The 112th Kyushu Branch Meeting of Japan Gastroenterological Endoscopy Society. ;:-.",69.0,YR,,M,Y,59.55,KG,20220207,,MD,JP,JP,2022,Q1,Elderly
194766584,19476658,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",48200.0,MG,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Pancreatic carcinoma,,2022,Q1,4,F,20180526.0,20211029.0,20210630,20220302,EXP,,JP-JNJFOC-20210666252,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
194766584,19476658,2,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q1,Pancreatic carcinoma,,2022,Q1,4,F,20180526.0,20211029.0,20210630,20220302,EXP,,JP-JNJFOC-20210666252,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
195920922,19592092,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Jaundice cholestatic,,2022,Q1,2,F,,20220124.0,20210722,20220208,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-305168,RANBAXY,,64.0,YR,,M,Y,,,20220208,,PH,GB,GB,2022,Q1,Adult
196987764,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"400 milligram, qd",,,Y,U,,,204042.0,400.0,MG,Tablet,QD,2022,Q1,Lactic acidosis,,2022,Q1,4,F,20210804.0,20210922.0,20210813,20220302,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,22.0,MON,I,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Youth
196987764,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"400 milligram, qd",,,Y,U,,,204042.0,400.0,MG,Tablet,QD,2022,Q1,Accidental overdose,,2022,Q1,4,F,20210804.0,20210922.0,20210813,20220302,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,22.0,MON,I,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Youth
196987764,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"400 milligram, qd",,,Y,U,,,204042.0,400.0,MG,Tablet,QD,2022,Q1,Polyuria,,2022,Q1,4,F,20210804.0,20210922.0,20210813,20220302,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,22.0,MON,I,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Youth
199404543,19940454,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Pancytopenia,,2022,Q1,3,F,20210724.0,20220315.0,20211012,20220323,EXP,,JP-SA-2021SA295289,SANOFI AVENTIS,,67.0,YR,E,F,Y,,,20220323,,MD,JP,JP,2022,Q1,Elderly
199811074,19981107,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,Y,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Fournier's gangrene,,2022,Q1,4,F,20210830.0,20220203.0,20211021,20220210,EXP,,JP-JNJFOC-20211034343,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,,,20220210,,MD,JP,JP,2022,Q1,Adult
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Skin lesion,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Blister,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Ocular hyperaemia,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Oral candidiasis,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Toxic epidermal necrolysis,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Ulcerative keratitis,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Visual impairment,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Macule,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Stevens-Johnson syndrome,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Cholestasis,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Dysphagia,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Odynophagia,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Lip oedema,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200341255,20034125,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,SJS-TEN overlap,,2022,Q1,5,F,,20220105.0,20211104,20220110,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220110,,MD,PT,PT,2022,Q1,Elderly
200821083,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q1,Gastrointestinal haemorrhage,,2022,Q1,3,F,,20220125.0,20211117,20220201,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220201,,MD,JP,JP,2022,Q1,Child
200821083,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q1,Disseminated intravascular coagulation,,2022,Q1,3,F,,20220125.0,20211117,20220201,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220201,,MD,JP,JP,2022,Q1,Child
200821083,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q1,Vascular stent thrombosis,,2022,Q1,3,F,,20220125.0,20211117,20220201,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220201,,MD,JP,JP,2022,Q1,Child
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Odynophagia,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blister,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Dysphagia,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Macule,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Skin lesion,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Stevens-Johnson syndrome,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,SJS-TEN overlap,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Visual impairment,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Lip oedema,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Ulcerative keratitis,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Oral candidiasis,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Ocular hyperaemia,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Rash macular,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Cholestasis,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200846356,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Toxic epidermal necrolysis,,2022,Q1,6,F,,20211228.0,20211118,20220106,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220106,,MD,PT,PT,2022,Q1,Elderly
200947292,20094729,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Hyperglycaemia,,2022,Q1,2,F,,20220207.0,20211122,20220214,EXP,,CA-BAUSCH-BL-2021-037810,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220214,,CN,CA,CA,2022,Q1,Elderly
200947292,20094729,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,2,F,,20220207.0,20211122,20220214,EXP,,CA-BAUSCH-BL-2021-037810,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220214,,CN,CA,CA,2022,Q1,Elderly
200947292,20094729,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Asthma,,2022,Q1,2,F,,20220207.0,20211122,20220214,EXP,,CA-BAUSCH-BL-2021-037810,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220214,,CN,CA,CA,2022,Q1,Elderly
200947292,20094729,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Full blood count abnormal,,2022,Q1,2,F,,20220207.0,20211122,20220214,EXP,,CA-BAUSCH-BL-2021-037810,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220214,,CN,CA,CA,2022,Q1,Elderly
200947292,20094729,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,2,F,,20220207.0,20211122,20220214,EXP,,CA-BAUSCH-BL-2021-037810,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220214,,CN,CA,CA,2022,Q1,Elderly
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Oxygen saturation decreased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Abdominal pain upper,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Oropharyngeal pain,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Lower respiratory tract infection,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Peripheral swelling,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Gastrointestinal disorder,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Medication error,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Nasopharyngitis,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Soft tissue injury,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure diastolic abnormal,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Weight fluctuation,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Muscle tightness,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure diastolic decreased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Lower respiratory tract congestion,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure decreased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Disability assessment scale score increased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Swelling face,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Dizziness,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Tooth disorder,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure systolic decreased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Headache,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Bladder disorder,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Constipation,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Sinus congestion,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Cough,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Road traffic accident,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Weight increased,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Nasopharyngitis,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Bronchitis,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201507302,20150730,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Nasal congestion,,2022,Q1,2,F,,20220124.0,20211206,20220131,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220131,,HP,CA,CA,2022,Q1,Adult
201784173,20178417,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,300.0,MG,N,,,,204042.0,100.0,MG,Tablet,,2022,Q1,Fournier's gangrene,,2022,Q1,3,F,20211112.0,20220119.0,20211213,20220123,EXP,IT-MINISAL02-816688,IT-JNJFOC-20211221384,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,132.0,KG,20220124,,MD,IT,IT,2022,Q1,Elderly
201787723,20178772,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,peroral medicine,QD,2022,Q1,Disease progression,,2022,Q1,3,F,20181115.0,20220120.0,20211214,20220203,EXP,,JP-JNJFOC-20211206069,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,36.9,KG,20220203,,MD,JP,JP,2022,Q1,Elderly
201787723,20178772,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,peroral medicine,QD,2022,Q1,Hypoxia,,2022,Q1,3,F,20181115.0,20220120.0,20211214,20220203,EXP,,JP-JNJFOC-20211206069,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,36.9,KG,20220203,,MD,JP,JP,2022,Q1,Elderly
201787723,20178772,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,peroral medicine,QD,2022,Q1,Middle lobe syndrome,,2022,Q1,3,F,20181115.0,20220120.0,20211214,20220203,EXP,,JP-JNJFOC-20211206069,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,36.9,KG,20220203,,MD,JP,JP,2022,Q1,Elderly
201787723,20178772,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,peroral medicine,QD,2022,Q1,Pneumonia,,2022,Q1,3,F,20181115.0,20220120.0,20211214,20220203,EXP,,JP-JNJFOC-20211206069,JOHNSON AND JOHNSON,,82.0,YR,E,F,Y,36.9,KG,20220203,,MD,JP,JP,2022,Q1,Elderly
202061414,20206141,37,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Pulmonary arterial hypertension,,2022,Q1,4,F,20211126.0,20220113.0,20211220,20220119,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202112008207,ELI LILLY AND CO,,19.0,YR,,M,Y,57.8,KG,20220119,,CN,JP,JP,2022,Q1,Youth
202096852,20209685,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg,,,,,unk,,,,,,,2022,Q1,Death,,2022,Q1,2,F,,20211225.0,20211221,20220104,EXP,,JP-NOVOPROD-876996,NOVO NORDISK,,63.0,YR,,M,Y,71.0,KG,20220104,,MD,JP,JP,2022,Q1,Adult
202096852,20209685,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg,,,,,unk,,,,,,,2022,Q1,Weight increased,,2022,Q1,2,F,,20211225.0,20211221,20220104,EXP,,JP-NOVOPROD-876996,NOVO NORDISK,,63.0,YR,,M,Y,71.0,KG,20220104,,MD,JP,JP,2022,Q1,Adult
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hepatic failure,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood bilirubin increased,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Platelet count decreased,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Palmar-plantar erythrodysaesthesia syndrome,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypoalbuminaemia,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Malignant neoplasm progression,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Jaundice,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Leiomyosarcoma,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Decreased appetite,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202112713,20211271,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Ascites,,2022,Q1,3,F,20181121.0,20220125.0,20211221,20220127,EXP,,NVSJ2021JP018612,NOVARTIS,"Narahara S, Nagaoka K, Tateyama M, Miyamoto H, Tanaka K, Tokunaga T, et al.. A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Hepatology Research. 2021;62:538-547",67.0,YR,,M,Y,72.4,KG,20220127,,HP,JP,JP,2022,Q1,Elderly
202225423,20222542,34,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,,2022,Q1,Pulmonary arterial hypertension,,2022,Q1,3,F,20211001.0,20220113.0,20211223,20220124,EXP,,JP-JNJFOC-20211240640,JOHNSON AND JOHNSON,,19.0,YR,A,M,Y,57.8,KG,20220124,,PH,JP,JP,2022,Q1,Youth
202225423,20222542,34,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,,2022,Q1,Dysphagia,,2022,Q1,3,F,20211001.0,20220113.0,20211223,20220124,EXP,,JP-JNJFOC-20211240640,JOHNSON AND JOHNSON,,19.0,YR,A,M,Y,57.8,KG,20220124,,PH,JP,JP,2022,Q1,Youth
202627972,20262797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",1500.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Thyroid stimulating hormone-producing pituitary tumour,,2022,Q1,2,F,20210403.0,20220127.0,20211231,20220203,EXP,,JP-JNJFOC-20211124084,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,,,20220204,,MD,JP,JP,2022,Q1,Elderly
202627972,20262797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",1500.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Lactic acidosis,,2022,Q1,2,F,20210403.0,20220127.0,20211231,20220203,EXP,,JP-JNJFOC-20211124084,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,,,20220204,,MD,JP,JP,2022,Q1,Elderly
202627972,20262797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",1500.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Thyrotoxic crisis,,2022,Q1,2,F,20210403.0,20220127.0,20211231,20220203,EXP,,JP-JNJFOC-20211124084,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,,,20220204,,MD,JP,JP,2022,Q1,Elderly
202627972,20262797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",1500.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,20210403.0,20220127.0,20211231,20220203,EXP,,JP-JNJFOC-20211124084,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,,,20220204,,MD,JP,JP,2022,Q1,Elderly
202693332,20269333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Nephrotic syndrome,,2022,Q1,2,F,,20220106.0,20220101,20220112,EXP,,JP-JNJFOC-20211257700,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220112,,PH,JP,JP,2022,Q1,Elderly
202693332,20269333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Hypoglycaemia,,2022,Q1,2,F,,20220106.0,20220101,20220112,EXP,,JP-JNJFOC-20211257700,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220112,,PH,JP,JP,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Cerebrovascular accident,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Malaise,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Facial paralysis,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Mobility decreased,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Respiratory rate increased,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Asthenia,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Diarrhoea,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203050271,20305027,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200530.0,20211231.0,20220106,20220106,EXP,GB-MHRA-EYC 00270319,GB-MYLANLABS-2022M1000131,MYLAN,,70.0,YR,,M,Y,,,20220106,,PH,GB,GB,2022,Q1,Elderly
203055941,20305594,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20211227.0,20220106,20220106,EXP,,CA-TEVA-2021-CA-1995716,TEVA,,48.0,YR,A,F,Y,,,20220106,,HP,CA,CA,2022,Q1,Adult
203055941,20305594,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20211227.0,20220106,20220106,EXP,,CA-TEVA-2021-CA-1995716,TEVA,,48.0,YR,A,F,Y,,,20220106,,HP,CA,CA,2022,Q1,Adult
203055941,20305594,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Haematochezia,,2022,Q1,1,I,,20211227.0,20220106,20220106,EXP,,CA-TEVA-2021-CA-1995716,TEVA,,48.0,YR,A,F,Y,,,20220106,,HP,CA,CA,2022,Q1,Adult
203055941,20305594,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20211227.0,20220106,20220106,EXP,,CA-TEVA-2021-CA-1995716,TEVA,,48.0,YR,A,F,Y,,,20220106,,HP,CA,CA,2022,Q1,Adult
203055941,20305594,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Therapeutic response shortened,,2022,Q1,1,I,,20211227.0,20220106,20220106,EXP,,CA-TEVA-2021-CA-1995716,TEVA,,48.0,YR,A,F,Y,,,20220106,,HP,CA,CA,2022,Q1,Adult
203087031,20308703,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 mg OD,,,,,,,,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200530.0,20211231.0,20220107,20220107,EXP,GB-MHRA-ADR 26417627,GB-Accord-249449,ACCORD,,70.0,YR,,M,Y,,,20220107,,PH,GB,GB,2022,Q1,Elderly
203087031,20308703,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 mg OD,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200530.0,20211231.0,20220107,20220107,EXP,GB-MHRA-ADR 26417627,GB-Accord-249449,ACCORD,,70.0,YR,,M,Y,,,20220107,,PH,GB,GB,2022,Q1,Elderly
203130031,20313003,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,,,,,,300.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200530.0,20211231.0,20220109,20220109,EXP,,GB-AUROBINDO-AUR-APL-2022-000170,AUROBINDO,,70.0,YR,,M,Y,,,20220109,,PH,GB,GB,2022,Q1,Elderly
203130031,20313003,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,,,,,,300.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200530.0,20211231.0,20220109,20220109,EXP,,GB-AUROBINDO-AUR-APL-2022-000170,AUROBINDO,,70.0,YR,,M,Y,,,20220109,,PH,GB,GB,2022,Q1,Elderly
203305861,20330586,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Soft tissue necrosis,,2022,Q1,1,I,20211020.0,20220105.0,20220113,20220113,EXP,JP-PMDA-i21104946001,JP-JNJFOC-20220121023,JOHNSON AND JOHNSON,,52.0,YR,A,F,Y,,,20220113,,MD,JP,JP,2022,Q1,Adult
203329271,20332927,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Chromaturia,,2022,Q1,1,I,20220101.0,20220107.0,20220113,20220113,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202201002392,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20220113,,HP,GB,GB,2022,Q1,Elderly
203329271,20332927,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Urine odour abnormal,,2022,Q1,1,I,20220101.0,20220107.0,20220113,20220113,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202201002392,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20220113,,HP,GB,GB,2022,Q1,Elderly
203329271,20332927,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Glomerular filtration rate decreased,,2022,Q1,1,I,20220101.0,20220107.0,20220113,20220113,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202201002392,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20220113,,HP,GB,GB,2022,Q1,Elderly
203329271,20332927,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20220101.0,20220107.0,20220113,20220113,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202201002392,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20220113,,HP,GB,GB,2022,Q1,Elderly
203541011,20354101,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Lactic acidosis,,2022,Q1,1,I,20210804.0,20220118.0,20220120,20220120,EXP,SE-MPA-2021-077553,SE-JNJFOC-20220133878,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,,,20220120,,MD,SE,SE,2022,Q1,Adult
203541532,20354153,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,,,,100.0,MG,,QD,2022,Q1,Vitreous haemorrhage,,2022,Q1,2,F,20211214.0,20220201.0,20220120,20220211,EXP,,JP-NOVOPROD-883681,NOVO NORDISK,,55.0,YR,,M,Y,87.8,KG,20220211,,MD,JP,JP,2022,Q1,Adult
203593971,20359397,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg/d,,,U,,,,,300.0,MG,,,2022,Q1,Hypoglycaemia,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203593971,20359397,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg/d,,,U,,,,,300.0,MG,,,2022,Q1,Treatment noncompliance,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203593971,20359397,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg/d,,,U,,,,,300.0,MG,,,2022,Q1,Vomiting,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203593971,20359397,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg/d,,,,,,,,100.0,MG,,,2022,Q1,Hypoglycaemia,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203593971,20359397,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg/d,,,,,,,,100.0,MG,,,2022,Q1,Treatment noncompliance,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203593971,20359397,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg/d,,,,,,,,100.0,MG,,,2022,Q1,Vomiting,,2022,Q1,1,I,,20220109.0,20220121,20220121,EXP,,"CA-Saptalis Pharmaceuticals,LLC-000164",SAPTALIS PHARMACEUTICALS,"CA-Saptalis Pharmaceuticals,LLC-000164-01_Intial Source Document",17.0,YR,T,M,Y,,,20220121,,MD,CA,,2022,Q1,Youth
203682092,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Tinea pedis,,2022,Q1,2,F,20201015.0,20220314.0,20220124,20220324,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220324,,CN,JP,JP,2022,Q1,Elderly
203682092,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Gastric cancer,,2022,Q1,2,F,20201015.0,20220314.0,20220124,20220324,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220324,,CN,JP,JP,2022,Q1,Elderly
203682092,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Chronic gastritis,,2022,Q1,2,F,20201015.0,20220314.0,20220124,20220324,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220324,,CN,JP,JP,2022,Q1,Elderly
203712581,20371258,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,Suspected suicide,,2022,Q1,1,I,20180101.0,20220121.0,20220124,20220124,EXP,,US-GLAXOSMITHKLINE-US2020GSK001433,GLAXOSMITHKLINE,"Gummin DD, Mowry JB, Spyker DA, Brooks DE, Beuhler MC, Rivers LJ, Hashem HA, Ryan ML. 2018 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 36th Annual Report. Clinical Toxicology. 2019;57(12):1220-1413",47.0,YR,,M,Y,,,20220124,,HP,US,US,2022,Q1,Adult
203726851,20372685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Off label use,,2022,Q1,1,I,,20220119.0,20220125,20220125,EXP,,CA-JNJFOC-20220141218,JOHNSON AND JOHNSON,,48.0,YR,A,F,Y,88.0,KG,20220125,,HP,CA,CA,2022,Q1,Adult
203726851,20372685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Visual impairment,,2022,Q1,1,I,,20220119.0,20220125,20220125,EXP,,CA-JNJFOC-20220141218,JOHNSON AND JOHNSON,,48.0,YR,A,F,Y,88.0,KG,20220125,,HP,CA,CA,2022,Q1,Adult
203726851,20372685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Crohn's disease,,2022,Q1,1,I,,20220119.0,20220125,20220125,EXP,,CA-JNJFOC-20220141218,JOHNSON AND JOHNSON,,48.0,YR,A,F,Y,88.0,KG,20220125,,HP,CA,CA,2022,Q1,Adult
203726851,20372685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Intentional product use issue,,2022,Q1,1,I,,20220119.0,20220125,20220125,EXP,,CA-JNJFOC-20220141218,JOHNSON AND JOHNSON,,48.0,YR,A,F,Y,88.0,KG,20220125,,HP,CA,CA,2022,Q1,Adult
203726851,20372685,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Ocular discomfort,,2022,Q1,1,I,,20220119.0,20220125,20220125,EXP,,CA-JNJFOC-20220141218,JOHNSON AND JOHNSON,,48.0,YR,A,F,Y,88.0,KG,20220125,,HP,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Hypoacusis,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Diabetes mellitus,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Depression,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Sleep disorder due to a general medical condition,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Asthma,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Loss of personal independence in daily activities,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204031841,20403184,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,unknown,,,,,,,2022,Q1,Wheezing,,2022,Q1,1,I,,20220119.0,20220131,20220131,EXP,CA- HEALTHCANVIG- E2B_04528744,CA-NOVOPROD-884882,NOVO NORDISK,,51.0,YR,,F,Y,,,20220131,,CN,CA,CA,2022,Q1,Adult
204057312,20405731,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",2100.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Sudden hearing loss,,2022,Q1,2,F,20211221.0,20220131.0,20220131,20220209,EXP,,JP-JNJFOC-20220153349,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,,,20220209,,MD,JP,JP,2022,Q1,Elderly
204109431,20410943,4,C,CANAGLIFLOZIN ANHYDROUS,CANAGLIFLOZIN ANHYDROUS,1,Unknown,"100 mg, daily",,,U,,,,,100.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220120.0,20220201,20220201,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202201008423,ELI LILLY AND CO,,50.0,YR,,F,Y,,,20220201,,CN,JP,JP,2022,Q1,Adult
204190331,20419033,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Orthostatic hypotension,,2022,Q1,1,I,,20220131.0,20220203,20220203,EXP,,US-MLV Pharma LLC-2124559,MLV PHARMA,,71.0,YR,,M,Y,,,20220203,,,COUNTRY NOT SPECIFIED,US,2022,Q1,Elderly
204190331,20419033,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Balance disorder,,2022,Q1,1,I,,20220131.0,20220203,20220203,EXP,,US-MLV Pharma LLC-2124559,MLV PHARMA,,71.0,YR,,M,Y,,,20220203,,,COUNTRY NOT SPECIFIED,US,2022,Q1,Elderly
204190331,20419033,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20220131.0,20220203,20220203,EXP,,US-MLV Pharma LLC-2124559,MLV PHARMA,,71.0,YR,,M,Y,,,20220203,,,COUNTRY NOT SPECIFIED,US,2022,Q1,Elderly
204190331,20419033,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Asthenia,,2022,Q1,1,I,,20220131.0,20220203,20220203,EXP,,US-MLV Pharma LLC-2124559,MLV PHARMA,,71.0,YR,,M,Y,,,20220203,,,COUNTRY NOT SPECIFIED,US,2022,Q1,Elderly
204544401,20454440,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Anaemia,,2022,Q1,1,I,20220208.0,,20220209,20220209,DIR,603016,,FDA-CTU,,72.0,YR,,F,N,77.0,KG,20220209,N,PH,US,,2022,Q1,Elderly
204544401,20454440,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Gastrointestinal haemorrhage,,2022,Q1,1,I,20220208.0,,20220209,20220209,DIR,603016,,FDA-CTU,,72.0,YR,,F,N,77.0,KG,20220209,N,PH,US,,2022,Q1,Elderly
204987612,20498761,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,U,,,,,100.0,MG,,,2022,Q1,Atrial fibrillation,,2022,Q1,2,F,,20220307.0,20220222,20220311,EXP,,NVSJ2022JP003196,NOVARTIS,,68.0,YR,,M,Y,,,20220311,,MD,JP,JP,2022,Q1,Elderly
205147232,20514723,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,,,,,,,,,,2022,Q1,Gait inability,,2022,Q1,2,F,,20220225.0,20220224,20220304,EXP,,JP-OTSUKA-2022_006476,OTSUKA,,8.0,DEC,,M,Y,58.5,KG,20220304,,MD,JP,JP,2022,Q1,Child
205147232,20514723,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,2,F,,20220225.0,20220224,20220304,EXP,,JP-OTSUKA-2022_006476,OTSUKA,,8.0,DEC,,M,Y,58.5,KG,20220304,,MD,JP,JP,2022,Q1,Child
205147232,20514723,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,,,,,,,,,,2022,Q1,Decreased appetite,,2022,Q1,2,F,,20220225.0,20220224,20220304,EXP,,JP-OTSUKA-2022_006476,OTSUKA,,8.0,DEC,,M,Y,58.5,KG,20220304,,MD,JP,JP,2022,Q1,Child
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Breast disorder,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Nodule,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Contusion,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypothyroidism,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Steroid diabetes,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Pain,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Lower respiratory tract infection,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Kidney infection,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Nasopharyngitis,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Vascular stenosis,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Intercepted medication error,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypertension,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Cystitis,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure diastolic abnormal,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Fibromyalgia,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Rheumatoid arthritis,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure diastolic decreased,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Oxygen saturation decreased,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Finger deformity,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205209901,20520990,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypotension,,2022,Q1,1,I,,20220217.0,20220225,20220225,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-027100,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20220225,,CN,CA,CA,2022,Q1,Elderly
205364851,20536485,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Ketosis,,2022,Q1,1,I,,20211207.0,20220302,20220302,EXP,,JP-JNJFOC-20211203269,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220302,,MD,JP,JP,2022,Q1,Adult
205384351,20538435,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,Tablet,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20210831.0,20220302,20220302,EXP,,JP-JNJFOC-20210911036,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,63.0,KG,20220302,,HP,JP,JP,2022,Q1,Elderly
205384351,20538435,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,Tablet,,2022,Q1,Metabolic acidosis,,2022,Q1,1,I,,20210831.0,20220302,20220302,EXP,,JP-JNJFOC-20210911036,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,63.0,KG,20220302,,HP,JP,JP,2022,Q1,Elderly
205384351,20538435,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,Tablet,,2022,Q1,Sinus arrest,,2022,Q1,1,I,,20210831.0,20220302,20220302,EXP,,JP-JNJFOC-20210911036,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,63.0,KG,20220302,,HP,JP,JP,2022,Q1,Elderly
205387821,20538782,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Metabolic acidosis,,2022,Q1,1,I,,20210924.0,20220302,20220302,EXP,,JP-JNJFOC-20210900098,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205387821,20538782,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20210924.0,20220302,20220302,EXP,,JP-JNJFOC-20210900098,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205387821,20538782,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Sinus arrest,,2022,Q1,1,I,,20210924.0,20220302,20220302,EXP,,JP-JNJFOC-20210900098,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205389251,20538925,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Alopecia,,2022,Q1,1,I,20210101.0,20211109.0,20220302,20220302,EXP,,CA-JNJFOC-20210942774,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,91.0,KG,20220302,,HP,CA,CA,2022,Q1,Adult
205389251,20538925,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Pulpitis dental,,2022,Q1,1,I,20210101.0,20211109.0,20220302,20220302,EXP,,CA-JNJFOC-20210942774,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,91.0,KG,20220302,,HP,CA,CA,2022,Q1,Adult
205389251,20538925,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,1,I,20210101.0,20211109.0,20220302,20220302,EXP,,CA-JNJFOC-20210942774,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,91.0,KG,20220302,,HP,CA,CA,2022,Q1,Adult
205389251,20538925,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Tooth fracture,,2022,Q1,1,I,20210101.0,20211109.0,20220302,20220302,EXP,,CA-JNJFOC-20210942774,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,91.0,KG,20220302,,HP,CA,CA,2022,Q1,Adult
205389251,20538925,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Off label use,,2022,Q1,1,I,20210101.0,20211109.0,20220302,20220302,EXP,,CA-JNJFOC-20210942774,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,91.0,KG,20220302,,HP,CA,CA,2022,Q1,Adult
205391561,20539156,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Hyperhidrosis,,2022,Q1,1,I,,20211001.0,20220302,20220302,EXP,,JP-JNJFOC-20210623627,JOHNSON AND JOHNSON,,92.0,YR,E,M,Y,,,20220302,,CN,JP,JP,2022,Q1,Elderly
205391561,20539156,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Surgery,,2022,Q1,1,I,,20211001.0,20220302,20220302,EXP,,JP-JNJFOC-20210623627,JOHNSON AND JOHNSON,,92.0,YR,E,M,Y,,,20220302,,CN,JP,JP,2022,Q1,Elderly
205391561,20539156,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Proctalgia,,2022,Q1,1,I,,20211001.0,20220302,20220302,EXP,,JP-JNJFOC-20210623627,JOHNSON AND JOHNSON,,92.0,YR,E,M,Y,,,20220302,,CN,JP,JP,2022,Q1,Elderly
205391561,20539156,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Penile pain,,2022,Q1,1,I,,20211001.0,20220302,20220302,EXP,,JP-JNJFOC-20210623627,JOHNSON AND JOHNSON,,92.0,YR,E,M,Y,,,20220302,,CN,JP,JP,2022,Q1,Elderly
205397511,20539751,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,U,,,204042.0,100.0,MG,Tablet,,2022,Q1,Hyperglycaemic hyperosmolar nonketotic syndrome,,2022,Q1,1,I,,20211102.0,20220302,20220302,EXP,,JP-JNJFOC-20211124250,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205400271,20540027,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,204042.0,,,Tablet,,2022,Q1,Gastroduodenal ulcer,,2022,Q1,1,I,,20211109.0,20220302,20220302,EXP,,JP-JNJFOC-20211139070,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205400271,20540027,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,204042.0,,,Tablet,,2022,Q1,Emphysematous cystitis,,2022,Q1,1,I,,20211109.0,20220302,20220302,EXP,,JP-JNJFOC-20211139070,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205400271,20540027,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,204042.0,,,Tablet,,2022,Q1,Emphysematous pyelonephritis,,2022,Q1,1,I,,20211109.0,20220302,20220302,EXP,,JP-JNJFOC-20211139070,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205400271,20540027,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,204042.0,,,Tablet,,2022,Q1,Hyperthyroidism,,2022,Q1,1,I,,20211109.0,20220302,20220302,EXP,,JP-JNJFOC-20211139070,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205400271,20540027,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,204042.0,,,Tablet,,2022,Q1,Thyrotoxic crisis,,2022,Q1,1,I,,20211109.0,20220302,20220302,EXP,,JP-JNJFOC-20211139070,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205417311,20541731,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Altered state of consciousness,,2022,Q1,1,I,20211001.0,20211125.0,20220302,20220302,EXP,,JP-JNJFOC-20211203271,JOHNSON AND JOHNSON,,72.0,YR,E,M,Y,,,20220302,,MD,JP,JP,2022,Q1,Elderly
205573882,20557388,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q1,Product use issue,,2022,Q1,2,F,20220215.0,20220224.0,20220307,20220307,EXP,,JP-009507513-2202JPN003584J,MERCK,,72.0,YR,,M,Y,,,20220307,,MD,JP,JP,2022,Q1,Elderly
205573882,20557388,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q1,Rash,,2022,Q1,2,F,20220215.0,20220224.0,20220307,20220307,EXP,,JP-009507513-2202JPN003584J,MERCK,,72.0,YR,,M,Y,,,20220307,,MD,JP,JP,2022,Q1,Elderly
205636011,20563601,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,unknown,,,100.0,MG,Tablet,QD,2022,Q1,Vitreous haemorrhage,,2022,Q1,1,I,20220221.0,20220225.0,20220308,20220308,EXP,,JP-NOVOPROD-896429,NOVO NORDISK,,48.0,YR,,M,Y,82.9,KG,20220308,,MD,JP,JP,2022,Q1,Adult
205705362,20570536,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Gastroenteritis,,2022,Q1,2,F,,20220313.0,20220309,20220318,EXP,,JP-JNJFOC-20220309358,JOHNSON AND JOHNSON,,4.0,DEC,A,F,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205710091,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Intentional product use issue,,2022,Q1,1,I,,20220304.0,20220309,20220309,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20220309,,HP,CA,CA,2022,Q1,Adult
205710091,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Off label use,,2022,Q1,1,I,,20220304.0,20220309,20220309,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20220309,,HP,CA,CA,2022,Q1,Adult
205710091,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Visual impairment,,2022,Q1,1,I,,20220304.0,20220309,20220309,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20220309,,HP,CA,CA,2022,Q1,Adult
205710091,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Crohn's disease,,2022,Q1,1,I,,20220304.0,20220309,20220309,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20220309,,HP,CA,CA,2022,Q1,Adult
205710091,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Ocular discomfort,,2022,Q1,1,I,,20220304.0,20220309,20220309,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20220309,,HP,CA,CA,2022,Q1,Adult
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Delusion,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Orthostatic hypotension,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Fatigue,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Affective disorder,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Hallucination,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
206106881,20610688,3,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,,,,,,,,,,,Tablet,,2022,Q1,Renal impairment,,2022,Q1,1,I,20210312.0,20220315.0,20220318,20220318,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202110001283,ELI LILLY AND CO,,60.0,YR,,F,Y,85.0,KG,20220318,,CN,JP,JP,2022,Q1,Adult
206114781,20611478,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,20220117.0,,20220317,20220317,DIR,607330,,FDA-CTU,,63.0,YR,,F,N,86.4,KG,20220317,N,,US,,2022,Q1,Adult
206114781,20611478,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Nausea,,2022,Q1,1,I,20220117.0,,20220317,20220317,DIR,607330,,FDA-CTU,,63.0,YR,,F,N,86.4,KG,20220317,N,,US,,2022,Q1,Adult
206115341,20611534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2022,Q1,Skin ulcer,,2022,Q1,1,I,,20220310.0,20220318,20220318,EXP,,GB-JNJFOC-20220325501,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,81.0,KG,20220318,,CN,GB,GB,2022,Q1,Adult
206115341,20611534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2022,Q1,Medication error,,2022,Q1,1,I,,20220310.0,20220318,20220318,EXP,,GB-JNJFOC-20220325501,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,81.0,KG,20220318,,CN,GB,GB,2022,Q1,Adult
206115341,20611534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2022,Q1,Cellulitis,,2022,Q1,1,I,,20220310.0,20220318,20220318,EXP,,GB-JNJFOC-20220325501,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,81.0,KG,20220318,,CN,GB,GB,2022,Q1,Adult
206218081,20621808,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,,,,,,100.0,MG,Tablet,QD,2022,Q1,Diabetes mellitus inadequate control,,2022,Q1,1,I,,20220315.0,20220322,20220322,EXP,,NVSJ2022JP004764,NOVARTIS,,46.0,YR,,M,Y,65.3,KG,20220322,,MD,JP,JP,2022,Q1,Adult
206295931,20629593,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q1,Immune-mediated renal disorder,,2022,Q1,1,I,,20220315.0,20220323,20220323,EXP,,JP-009507513-2203JPN002008J,MERCK,,73.0,YR,,M,Y,,,20220323,,MD,JP,JP,2022,Q1,Elderly
206377611,20637761,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20220317.0,20220325,20220325,EXP,,CA-TEVA-2022-CA-2020035,TEVA,,76.0,YR,E,F,Y,,,20220325,,MD,CA,CA,2022,Q1,Elderly
206377611,20637761,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,1,I,,20220317.0,20220325,20220325,EXP,,CA-TEVA-2022-CA-2020035,TEVA,,76.0,YR,E,F,Y,,,20220325,,MD,CA,CA,2022,Q1,Elderly
206377611,20637761,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,1,I,,20220317.0,20220325,20220325,EXP,,CA-TEVA-2022-CA-2020035,TEVA,,76.0,YR,E,F,Y,,,20220325,,MD,CA,CA,2022,Q1,Elderly
206377611,20637761,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Asthma,,2022,Q1,1,I,,20220317.0,20220325,20220325,EXP,,CA-TEVA-2022-CA-2020035,TEVA,,76.0,YR,E,F,Y,,,20220325,,MD,CA,CA,2022,Q1,Elderly
206377611,20637761,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Full blood count abnormal,,2022,Q1,1,I,,20220317.0,20220325,20220325,EXP,,CA-TEVA-2022-CA-2020035,TEVA,,76.0,YR,E,F,Y,,,20220325,,MD,CA,CA,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Pulmonary thrombosis,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Pulmonary haemorrhage,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Disease progression,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Abdominal distension,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206379411,20637941,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,General physical health deterioration,,2022,Q1,1,I,20220323.0,,20220324,20220324,DIR,FDA-CDER-CTU-2022-23234,,FDA-CTU,,68.0,YR,,M,N,76.0,KG,20220324,Y,HP,US,,2022,Q1,Elderly
206401081,20640108,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20220317.0,20220326,20220326,EXP,,CA-TEVA-2022-CA-2020159,TEVA,,76.0,YR,E,F,Y,,,20220326,,CN,CA,CA,2022,Q1,Elderly
206401081,20640108,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Asthma,,2022,Q1,1,I,,20220317.0,20220326,20220326,EXP,,CA-TEVA-2022-CA-2020159,TEVA,,76.0,YR,E,F,Y,,,20220326,,CN,CA,CA,2022,Q1,Elderly
206401081,20640108,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,1,I,,20220317.0,20220326,20220326,EXP,,CA-TEVA-2022-CA-2020159,TEVA,,76.0,YR,E,F,Y,,,20220326,,CN,CA,CA,2022,Q1,Elderly
206401081,20640108,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,1,I,,20220317.0,20220326,20220326,EXP,,CA-TEVA-2022-CA-2020159,TEVA,,76.0,YR,E,F,Y,,,20220326,,CN,CA,CA,2022,Q1,Elderly
206401081,20640108,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Full blood count abnormal,,2022,Q1,1,I,,20220317.0,20220326,20220326,EXP,,CA-TEVA-2022-CA-2020159,TEVA,,76.0,YR,E,F,Y,,,20220326,,CN,CA,CA,2022,Q1,Elderly
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diabetic gangrene,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Weight fluctuation,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Osteomyelitis,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Sepsis,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Leg amputation,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
143553805,14355380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diabetic foot,,2022,Q2,5,F,20160502.0,20220616.0,20180105,20220629,EXP,,JP-JNJFOC-20180105352,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220629,,HP,JP,JP,2022,Q2,Adult
1445851811,14458518,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,11,F,,20220404.0,20180130,20220412,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20220412,,MD,CA,CA,2022,Q2,Elderly
1445851811,14458518,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,11,F,,20220404.0,20180130,20220412,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20220412,,MD,CA,CA,2022,Q2,Elderly
1445851811,14458518,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,11,F,,20220404.0,20180130,20220412,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20220412,,MD,CA,CA,2022,Q2,Elderly
1445851811,14458518,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,11,F,,20220404.0,20180130,20220412,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20220412,,MD,CA,CA,2022,Q2,Elderly
1445851811,14458518,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,11,F,,20220404.0,20180130,20220412,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20220412,,MD,CA,CA,2022,Q2,Elderly
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Hypertrophy,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Blood creatinine decreased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Hepatosplenomegaly,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Gastrointestinal haemorrhage,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Inflammatory marker increased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Arthritis,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Adverse drug reaction,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Glycosylated haemoglobin increased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Blood uric acid decreased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Varices oesophageal,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Joint effusion,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Nausea,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Psoriasis,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Red blood cell sedimentation rate increased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Pain in extremity,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Non-alcoholic fatty liver,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Arthralgia,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Haemoglobin decreased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Liver disorder,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Joint swelling,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
164974092,16497409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, UNK",,,U,,,,,300.0,MG,Tablet,,2022,Q2,Low density lipoprotein increased,,2022,Q2,2,F,20070101.0,20220503.0,20190628,20220507,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20220507,,HP,CA,CA,2022,Q2,Adult
1656345011,16563450,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,11,F,,20220427.0,20190712,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220511,,MD,CA,CA,2022,Q2,Elderly
1656345011,16563450,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,11,F,,20220427.0,20190712,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220511,,MD,CA,CA,2022,Q2,Elderly
1656345011,16563450,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,11,F,,20220427.0,20190712,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220511,,MD,CA,CA,2022,Q2,Elderly
1656345011,16563450,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,11,F,,20220427.0,20190712,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220511,,MD,CA,CA,2022,Q2,Elderly
1656345011,16563450,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,11,F,,20220427.0,20190712,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220511,,MD,CA,CA,2022,Q2,Elderly
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Bladder disorder,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oropharyngeal pain,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure diastolic abnormal,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Weight fluctuation,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Gastrointestinal disorder,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Muscle tightness,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Peripheral swelling,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Road traffic accident,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Nasal congestion,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Swelling face,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Soft tissue injury,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cough,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Tooth disorder,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure systolic decreased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Constipation,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Respiratory tract congestion,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Disability assessment scale score increased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Medication error,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lower respiratory tract infection,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Headache,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lower respiratory tract congestion,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
167837643,16783764,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Bronchitis,,2022,Q2,3,F,,20220427.0,20190908,20220511,EXP,,CA-AUROBINDO-AUR-APL-2019-058065,AUROBINDO,,46.0,YR,,F,Y,72.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
173667822,17366782,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,205879.0,,,Unknown,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20200101.0,20220504.0,20200204,20220506,EXP,ES-AEMPS-589882,ES-JNJFOC-20200144618,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,,,20220506,,MD,ES,ES,2022,Q2,Adult
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Drug level increased,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Drug interaction,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Gait disturbance,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Drug-induced liver injury,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Laboratory test abnormal,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Drug level above therapeutic,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Rhabdomyolysis,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Muscle disorder,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2022,Q2,Hepatocellular injury,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Drug level increased,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Drug interaction,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Gait disturbance,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Drug-induced liver injury,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Laboratory test abnormal,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Drug level above therapeutic,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Rhabdomyolysis,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Muscle disorder,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
181569286,18156928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 every 1 Days,,,U,,,,,100.0,MG,Tablets,,2022,Q2,Hepatocellular injury,,2022,Q2,6,F,,20220510.0,20200817,20220517,EXP,,CA-Accord-195666,ACCORD,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Ann Intern Med. 2020 Aug 4",76.0,YR,,F,Y,,,20220517,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Malignant mediastinal neoplasm,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Bronchiectasis,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Cough,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Nasal congestion,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Rhinorrhoea,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Intentional product use issue,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Blood immunoglobulin E increased,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
183440424,18344042,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,4,F,,20220606.0,20201005,20220614,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20220614,,MD,CA,CA,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Expired product administered,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Lower respiratory tract infection,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Device infusion issue,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Bladder cancer,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Needle issue,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
187421914,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Infusion site pain,,2022,Q2,4,F,20200916.0,20220523.0,20210114,20220531,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220531,,HP,IE,IE,2022,Q2,Elderly
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Hypoacusis,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Depression,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
191402624,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,4,F,,20220517.0,20210415,20220527,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20220527,,MD,CA,CA,2022,Q2,Adult
1953884812,19538848,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
1953884812,19538848,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,12,F,,20220606.0,20210713,20220609,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220609,,CN,CA,CA,2022,Q2,Elderly
197107656,19710765,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,6,F,,20220404.0,20210817,20220425,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220425,,CN,CA,CA,2022,Q2,Elderly
197107656,19710765,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,6,F,,20220404.0,20210817,20220425,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220425,,CN,CA,CA,2022,Q2,Elderly
197107656,19710765,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,6,F,,20220404.0,20210817,20220425,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220425,,CN,CA,CA,2022,Q2,Elderly
197107656,19710765,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,6,F,,20220404.0,20210817,20220425,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220425,,CN,CA,CA,2022,Q2,Elderly
197107656,19710765,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,6,F,,20220404.0,20210817,20220425,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220425,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200141512,20014151,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,2,F,,20220411.0,20211029,20220413,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20220413,,CN,CA,CA,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Lip oedema,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Cholestasis,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Ulcerative keratitis,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Skin lesion,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,SJS-TEN overlap,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Visual impairment,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Oral candidiasis,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Macule,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Pyrexia,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Blister,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Ocular hyperaemia,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Odynophagia,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Toxic epidermal necrolysis,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200341256,20034125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Stevens-Johnson syndrome,,2022,Q2,6,F,,20220516.0,20211104,20220523,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220523,,MD,PT,PT,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Wheezing,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Full blood count abnormal,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Nasal congestion,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Bronchiectasis,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Cough,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Malignant mediastinal neoplasm,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Rhinorrhoea,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Asthma,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Dyspnoea,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablets,,2022,Q2,Blood immunoglobulin E increased,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ulcerative keratitis,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,SJS-TEN overlap,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Skin lesion,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Stevens-Johnson syndrome,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blister,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oral candidiasis,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Rash macular,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lip oedema,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200704666,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Toxic epidermal necrolysis,,2022,Q2,6,F,,20220509.0,20211115,20220510,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Stevens-Johnson-syndrome-the cease of therapy as the key to the cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Toxic epidermal necrolysis,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,SJS-TEN overlap,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Pyrexia,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Dysphagia,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Rash macular,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Ulcerative keratitis,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Odynophagia,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Oral candidiasis,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Stevens-Johnson syndrome,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Ocular hyperaemia,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Visual impairment,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Lip oedema,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Cholestasis,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Macule,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Blister,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200732886,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,6,F,,20220509.0,20211116,20220510,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220510,,HP,PT,PT,2022,Q2,Elderly
200839473,20083947,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200839473,20083947,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,3,F,,20220330.0,20211118,20220401,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220401,,MD,CA,CA,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Stevens-Johnson syndrome,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Rash macular,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lip oedema,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ulcerative keratitis,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Skin lesion,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cholestasis,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Visual impairment,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blister,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Macule,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Odynophagia,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oral candidiasis,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Toxic epidermal necrolysis,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ocular hyperaemia,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,SJS-TEN overlap,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pyrexia,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
200846357,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,7,F,,20220507.0,20211118,20220520,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220520,,MD,PT,PT,2022,Q2,Elderly
201968824,20196882,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,Tablet,,2022,Q2,Stevens-Johnson syndrome,,2022,Q2,4,F,,20220511.0,20211217,20220514,EXP,,PT-JNJFOC-20211130496,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20220514,,HP,PT,PT,2022,Q2,Elderly
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Limb injury,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Nasal congestion,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Pulpitis dental,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Malaise,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Arthritis,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Pain,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Tooth fracture,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Inflammation,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Rhinorrhoea,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Alopecia,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Myalgia,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Rhinitis allergic,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Off label use,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Product use issue,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Exposure to SARS-CoV-2,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202403343,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,3,F,,20220504.0,20211228,20220511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220511,,HP,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Depression,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202669072,20266907,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Hypoacusis,,2022,Q2,2,F,,20220516.0,20211231,20220523,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220523,,CN,CA,CA,2022,Q2,Adult
202693312,20269331,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,,20220324.0,20220101,20220401,EXP,,JP-JNJFOC-20211206105,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220401,,MD,JP,JP,2022,Q2,Adult
202693312,20269331,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Necrotising oesophagitis,,2022,Q2,2,F,,20220324.0,20220101,20220401,EXP,,JP-JNJFOC-20211206105,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220401,,MD,JP,JP,2022,Q2,Adult
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Erythema multiforme,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Rash pustular,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Febrile neutropenia,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Cellulitis,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Skin disorder,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,15,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,QD,2022,Q2,Skin infection,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Erythema multiforme,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Rash pustular,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Febrile neutropenia,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Cellulitis,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Skin disorder,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
203604486,20360448,16,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, Everyday",,,U,,,,,,,Tablet,QD,2022,Q2,Skin infection,,2022,Q2,6,F,20211208.0,20220519.0,20220121,20220607,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008354,BRISTOL MYERS SQUIBB,,73.0,YR,E,M,Y,53.0,KG,20220608,,MD,JP,JP,2022,Q2,Elderly
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Glycosylated haemoglobin increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,White blood cell count increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Basophil count increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,General physical health deterioration,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Photosensitivity reaction,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hepatitis B surface antibody positive,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Haemoglobin increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lymphocyte percentage increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood triglycerides increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Creatinine urine increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ill-defined disorder,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pain,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood creatinine increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Osteoarthritis,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,COVID-19 pneumonia,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Haematocrit decreased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Back pain,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Basophil percentage increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Influenza,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hypertension,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Product supply issue,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Acute respiratory distress syndrome,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Red blood cell sedimentation rate increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Deformity thorax,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Low density lipoprotein increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Aspartate aminotransferase increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Adjusted calcium increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,High density lipoprotein decreased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Malaise,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lymphadenopathy,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Plantar fasciitis,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Red blood cell count increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Alanine aminotransferase increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Very low density lipoprotein increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Lymphocyte count increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Red cell distribution width increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Platelet count decreased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hypersensitivity,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyslipidaemia,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Neutrophil count increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Eosinophil percentage increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Illness,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ocular hyperaemia,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Protein urine present,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Glomerular filtration rate decreased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
204092397,20409239,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood cholesterol increased,,2022,Q2,7,F,20190917.0,20220609.0,20220201,20220611,EXP,,NVSC2021CO168708,NOVARTIS,,53.0,YR,,M,Y,79.0,KG,20220612,,CN,CO,CO,2022,Q2,Adult
205832442,20583244,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablets,,2022,Q2,Hypoglycaemia,,2022,Q2,2,F,20220303.0,20220407.0,20220311,20220411,EXP,,JP-Eisai Medical Research-EC-2022-110401,EISAI,,66.0,YR,E,F,Y,,,20220411,,PH,JP,JP,2022,Q2,Elderly
205933752,20593375,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg,,,,,UNKNOWN,,,,,,,2022,Q2,Blood glucose increased,,2022,Q2,2,F,20220101.0,20220323.0,20220315,20220401,EXP,,JP-NOVOPROD-898588,NOVO NORDISK,,9.0,DEC,,F,Y,,,20220401,,MD,JP,JP,2022,Q2,Child
205933752,20593375,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg,,,,,UNKNOWN,,,,,,,2022,Q2,Dehydration,,2022,Q2,2,F,20220101.0,20220323.0,20220315,20220401,EXP,,JP-NOVOPROD-898588,NOVO NORDISK,,9.0,DEC,,F,Y,,,20220401,,MD,JP,JP,2022,Q2,Child
205933752,20593375,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg,,,,,UNKNOWN,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,2,F,20220101.0,20220323.0,20220315,20220401,EXP,,JP-NOVOPROD-898588,NOVO NORDISK,,9.0,DEC,,F,Y,,,20220401,,MD,JP,JP,2022,Q2,Child
206218082,20621808,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD, 6 months or more",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,,20220420.0,20220322,20220426,EXP,,NVSJ2022JP004764,NOVARTIS,,46.0,YR,,M,Y,65.3,KG,20220426,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Protein urine,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Ageusia,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Oedema peripheral,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Pyrexia,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,COVID-19,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206244613,20624461,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,U,,,,,100.0,MG,,QD,2022,Q2,Dyspnoea,,2022,Q2,3,F,20210622.0,20220511.0,20220322,20220515,EXP,,NVSJ2021JP020638,NOVARTIS,,57.0,YR,,M,Y,80.0,KG,20220516,,MD,JP,JP,2022,Q2,Adult
206295932,20629593,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q2,Immune-mediated renal disorder,,2022,Q2,2,F,20200821.0,20220509.0,20220323,20220516,EXP,,JP-009507513-2203JPN002008J,MERCK,,71.0,YR,,M,Y,59.0,KG,20220516,,MD,JP,JP,2022,Q2,Elderly
206523663,20652366,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",8300.0,MG,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Ketosis,,2022,Q2,3,F,20211130.0,20220427.0,20220330,20220508,EXP,,JP-JNJFOC-20220358416,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220509,,MD,JP,JP,2022,Q2,Adult
206523663,20652366,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",8300.0,MG,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Postoperative wound complication,,2022,Q2,3,F,20211130.0,20220427.0,20220330,20220508,EXP,,JP-JNJFOC-20220358416,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220509,,MD,JP,JP,2022,Q2,Adult
206873791,20687379,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1504.16666,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Tremor,,2022,Q2,1,I,20211109.0,20220405.0,20220408,20220408,EXP,GB-MHRA-TPP6137974C2400306YC1636463072444,GB-JNJFOC-20220407465,JOHNSON AND JOHNSON,,60.0,YR,A,M,Y,154.0,KG,20220408,,HP,GB,GB,2022,Q2,Adult
206873791,20687379,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1504.16666,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Dysuria,,2022,Q2,1,I,20211109.0,20220405.0,20220408,20220408,EXP,GB-MHRA-TPP6137974C2400306YC1636463072444,GB-JNJFOC-20220407465,JOHNSON AND JOHNSON,,60.0,YR,A,M,Y,154.0,KG,20220408,,HP,GB,GB,2022,Q2,Adult
206873791,20687379,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1504.16666,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Confusional state,,2022,Q2,1,I,20211109.0,20220405.0,20220408,20220408,EXP,GB-MHRA-TPP6137974C2400306YC1636463072444,GB-JNJFOC-20220407465,JOHNSON AND JOHNSON,,60.0,YR,A,M,Y,154.0,KG,20220408,,HP,GB,GB,2022,Q2,Adult
206873791,20687379,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1504.16666,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Throat tightness,,2022,Q2,1,I,20211109.0,20220405.0,20220408,20220408,EXP,GB-MHRA-TPP6137974C2400306YC1636463072444,GB-JNJFOC-20220407465,JOHNSON AND JOHNSON,,60.0,YR,A,M,Y,154.0,KG,20220408,,HP,GB,GB,2022,Q2,Adult
206873791,20687379,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,1504.16666,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Respiratory rate decreased,,2022,Q2,1,I,20211109.0,20220405.0,20220408,20220408,EXP,GB-MHRA-TPP6137974C2400306YC1636463072444,GB-JNJFOC-20220407465,JOHNSON AND JOHNSON,,60.0,YR,A,M,Y,154.0,KG,20220408,,HP,GB,GB,2022,Q2,Adult
206923641,20692364,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,,,,,,100.0,MG,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,20211221.0,20220406.0,20220409,20220409,EXP,,JP-009507513-2204JPN000719J,MERCK,,48.0,YR,,F,Y,52.0,KG,20220409,,PH,JP,JP,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Renal impairment,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Left ventricular hypertrophy,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Cardiac failure congestive,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Dyspnoea,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Multiple drug therapy,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Left atrial enlargement,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Oedema,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
206956864,20695686,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, QD",,,Y,,,,,100.0,NG,,QD,2022,Q2,Pneumothorax,,2022,Q2,4,F,20200201.0,20220505.0,20220411,20220511,EXP,,TW-SA-2022SA121833,SANOFI AVENTIS,,60.0,YR,A,M,Y,80.0,KG,20220511,,MD,TW,TW,2022,Q2,Adult
207022382,20702238,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, 1x/day",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Pneumothorax,,2022,Q2,2,F,20200201.0,20220408.0,20220412,20220420,EXP,,TW-PFIZER INC-202200532661,PFIZER,"Lin, C.. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220420,,MD,TW,TW,2022,Q2,Adult
207022382,20702238,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, 1x/day",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Renal impairment,,2022,Q2,2,F,20200201.0,20220408.0,20220412,20220420,EXP,,TW-PFIZER INC-202200532661,PFIZER,"Lin, C.. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220420,,MD,TW,TW,2022,Q2,Adult
207022382,20702238,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, 1x/day",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Cardiac failure congestive,,2022,Q2,2,F,20200201.0,20220408.0,20220412,20220420,EXP,,TW-PFIZER INC-202200532661,PFIZER,"Lin, C.. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220420,,MD,TW,TW,2022,Q2,Adult
207022382,20702238,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ng, 1x/day",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,2,F,20200201.0,20220408.0,20220412,20220420,EXP,,TW-PFIZER INC-202200532661,PFIZER,"Lin, C.. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220420,,MD,TW,TW,2022,Q2,Adult
207028752,20702875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Hypernatraemia,,2022,Q2,2,F,,20220418.0,20220412,20220426,EXP,,JP-JNJFOC-20220421561,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20220426,,MD,JP,JP,2022,Q2,Elderly
207028752,20702875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Dehydration,,2022,Q2,2,F,,20220418.0,20220412,20220426,EXP,,JP-JNJFOC-20220421561,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20220426,,MD,JP,JP,2022,Q2,Elderly
207028752,20702875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Rhabdomyolysis,,2022,Q2,2,F,,20220418.0,20220412,20220426,EXP,,JP-JNJFOC-20220421561,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20220426,,MD,JP,JP,2022,Q2,Elderly
207028752,20702875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Cardiac failure acute,,2022,Q2,2,F,,20220418.0,20220412,20220426,EXP,,JP-JNJFOC-20220421561,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20220426,,MD,JP,JP,2022,Q2,Elderly
207028752,20702875,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,,20220418.0,20220412,20220426,EXP,,JP-JNJFOC-20220421561,JOHNSON AND JOHNSON,,80.0,YR,E,M,Y,,,20220426,,MD,JP,JP,2022,Q2,Elderly
207038951,20703895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,,20220405.0,20220413,20220413,EXP,,US-JNJFOC-20220415036,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,,,20220413,,HP,US,US,2022,Q2,Adult
207046612,20704661,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 dosage form,,,Y,,,,,100.0,NG,Tablet,,2022,Q2,Discomfort,,2022,Q2,2,F,20200201.0,20220415.0,20220413,20220429,EXP,,TW-Accord-260210,ACCORD,"Yao CA, Chen YC, Lai CY, Lin CH. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73.",60.0,YR,,M,Y,80.0,KG,20220429,,MD,TW,TW,2022,Q2,Adult
207046612,20704661,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 dosage form,,,Y,,,,,100.0,NG,Tablet,,2022,Q2,Cardiac failure congestive,,2022,Q2,2,F,20200201.0,20220415.0,20220413,20220429,EXP,,TW-Accord-260210,ACCORD,"Yao CA, Chen YC, Lai CY, Lin CH. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73.",60.0,YR,,M,Y,80.0,KG,20220429,,MD,TW,TW,2022,Q2,Adult
207046612,20704661,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 dosage form,,,Y,,,,,100.0,NG,Tablet,,2022,Q2,Hydronephrosis,,2022,Q2,2,F,20200201.0,20220415.0,20220413,20220429,EXP,,TW-Accord-260210,ACCORD,"Yao CA, Chen YC, Lai CY, Lin CH. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73.",60.0,YR,,M,Y,80.0,KG,20220429,,MD,TW,TW,2022,Q2,Adult
207046612,20704661,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 dosage form,,,Y,,,,,100.0,NG,Tablet,,2022,Q2,Pneumothorax,,2022,Q2,2,F,20200201.0,20220415.0,20220413,20220429,EXP,,TW-Accord-260210,ACCORD,"Yao CA, Chen YC, Lai CY, Lin CH. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73.",60.0,YR,,M,Y,80.0,KG,20220429,,MD,TW,TW,2022,Q2,Adult
207046612,20704661,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 dosage form,,,Y,,,,,100.0,NG,Tablet,,2022,Q2,Renal impairment,,2022,Q2,2,F,20200201.0,20220415.0,20220413,20220429,EXP,,TW-Accord-260210,ACCORD,"Yao CA, Chen YC, Lai CY, Lin CH. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73.",60.0,YR,,M,Y,80.0,KG,20220429,,MD,TW,TW,2022,Q2,Adult
207083372,20708337,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Nausea,,2022,Q2,2,F,20220411.0,20220428.0,20220414,20220509,EXP,,NVSJ2022JP006054,NOVARTIS,,62.0,YR,,M,Y,,,20220509,,PH,JP,JP,2022,Q2,Adult
207083372,20708337,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Palpitations,,2022,Q2,2,F,20220411.0,20220428.0,20220414,20220509,EXP,,NVSJ2022JP006054,NOVARTIS,,62.0,YR,,M,Y,,,20220509,,PH,JP,JP,2022,Q2,Adult
207083372,20708337,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,20220411.0,20220428.0,20220414,20220509,EXP,,NVSJ2022JP006054,NOVARTIS,,62.0,YR,,M,Y,,,20220509,,PH,JP,JP,2022,Q2,Adult
207083372,20708337,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,2,F,20220411.0,20220428.0,20220414,20220509,EXP,,NVSJ2022JP006054,NOVARTIS,,62.0,YR,,M,Y,,,20220509,,PH,JP,JP,2022,Q2,Adult
207095141,20709514,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,U,,,,100.0,NG,,QD,2022,Q2,Renal failure,,2022,Q2,1,I,,20220406.0,20220414,20220414,EXP,,TW-MYLANLABS-2022M1027166,MYLAN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM 2022;15(2):68-73.",60.0,YR,,M,Y,,,20220414,,MD,TW,TW,2022,Q2,Adult
207095141,20709514,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,U,,,,100.0,NG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,1,I,,20220406.0,20220414,20220414,EXP,,TW-MYLANLABS-2022M1027166,MYLAN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM 2022;15(2):68-73.",60.0,YR,,M,Y,,,20220414,,MD,TW,TW,2022,Q2,Adult
207095141,20709514,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,U,,,,100.0,NG,,QD,2022,Q2,Pneumonia,,2022,Q2,1,I,,20220406.0,20220414,20220414,EXP,,TW-MYLANLABS-2022M1027166,MYLAN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM 2022;15(2):68-73.",60.0,YR,,M,Y,,,20220414,,MD,TW,TW,2022,Q2,Adult
207095141,20709514,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,U,,,,100.0,NG,,QD,2022,Q2,Cardiac failure congestive,,2022,Q2,1,I,,20220406.0,20220414,20220414,EXP,,TW-MYLANLABS-2022M1027166,MYLAN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM 2022;15(2):68-73.",60.0,YR,,M,Y,,,20220414,,MD,TW,TW,2022,Q2,Adult
207095141,20709514,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,U,,,,100.0,NG,,QD,2022,Q2,Pleural effusion,,2022,Q2,1,I,,20220406.0,20220414,20220414,EXP,,TW-MYLANLABS-2022M1027166,MYLAN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM 2022;15(2):68-73.",60.0,YR,,M,Y,,,20220414,,MD,TW,TW,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hypoacusis,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207106061,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220405.0,20220414,20220414,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Hypoacusis,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207111561,20711156,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Depression,,2022,Q2,1,I,,20220411.0,20220414,20220414,EXP,,CA-BAUSCH-BL-2022-009084,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220414,,CN,CA,CA,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Renal impairment,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Cardiac failure congestive,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Hydronephrosis,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Nephropathy toxic,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Pneumonia,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Pleural effusion,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207189131,20718913,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 nanogram/per day,,,,,,,,100.0,NG,,,2022,Q2,Renal failure,,2022,Q2,1,I,,20220406.0,20220418,20220418,EXP,,TW-STRIDES ARCOLAB LIMITED-2022SP003860,STRIDES,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220418,,MD,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Cardiac failure congestive,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Nephropathy toxic,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Pneumonia,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Renal failure,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Renal impairment,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207242201,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q2,Pleural effusion,,2022,Q2,1,I,,20220406.0,20220419,20220419,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220419,,HP,TW,TW,2022,Q2,Adult
207252671,20725267,18,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027120,TEVA,,76.0,YR,E,F,Y,,,20220419,,HP,CA,CA,2022,Q2,Elderly
207252671,20725267,18,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027120,TEVA,,76.0,YR,E,F,Y,,,20220419,,HP,CA,CA,2022,Q2,Elderly
207252671,20725267,18,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027120,TEVA,,76.0,YR,E,F,Y,,,20220419,,HP,CA,CA,2022,Q2,Elderly
207252671,20725267,18,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027120,TEVA,,76.0,YR,E,F,Y,,,20220419,,HP,CA,CA,2022,Q2,Elderly
207252671,20725267,18,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,,20220411.0,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027120,TEVA,,76.0,YR,E,F,Y,,,20220419,,HP,CA,CA,2022,Q2,Elderly
207331782,20733178,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, Daily",,,Y,,,,,100.0,NG,,,2022,Q2,Hydronephrosis,,2022,Q2,2,F,20200220.0,20220420.0,20220421,20220620,EXP,,TW-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-333866,RANBAXY,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. IJCEM. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220620,,HP,TW,TW,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Cough,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Lower respiratory tract infection,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Road traffic accident,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Nasal congestion,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Headache,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Blood pressure diastolic abnormal,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Peripheral swelling,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Medication error,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Lower respiratory tract congestion,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Disability assessment scale score increased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Bladder disorder,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Tooth disorder,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Swelling face,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Bronchitis,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Gastrointestinal disorder,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Soft tissue injury,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Muscle tightness,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Oropharyngeal pain,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Weight fluctuation,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Blood pressure systolic decreased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207336482,20733648,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Constipation,,2022,Q2,2,F,,20220524.0,20220421,20220531,EXP,,CA-APOTEX-2022AP006141,APOTEX,,46.0,YR,,F,Y,89.0,KG,20220531,,HP,CA,CA,2022,Q2,Adult
207378292,20737829,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Encephalitis,,2022,Q2,2,F,20220101.0,20220426.0,20220422,20220509,EXP,,JP-NOVOPROD-909977,NOVO NORDISK,,52.0,YR,,M,Y,81.1,KG,20220509,,MD,JP,JP,2022,Q2,Adult
207378292,20737829,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,2,F,20220101.0,20220426.0,20220422,20220509,EXP,,JP-NOVOPROD-909977,NOVO NORDISK,,52.0,YR,,M,Y,81.1,KG,20220509,,MD,JP,JP,2022,Q2,Adult
207378292,20737829,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20220101.0,20220426.0,20220422,20220509,EXP,,JP-NOVOPROD-909977,NOVO NORDISK,,52.0,YR,,M,Y,81.1,KG,20220509,,MD,JP,JP,2022,Q2,Adult
207378292,20737829,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Weight decreased,,2022,Q2,2,F,20220101.0,20220426.0,20220422,20220509,EXP,,JP-NOVOPROD-909977,NOVO NORDISK,,52.0,YR,,M,Y,81.1,KG,20220509,,MD,JP,JP,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Gastrointestinal disorder,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Oropharyngeal pain,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Lower respiratory tract infection,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Cough,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Constipation,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure systolic decreased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Bronchitis,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Soft tissue injury,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Muscle tightness,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Peripheral swelling,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Medication error,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Lower respiratory tract congestion,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Road traffic accident,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Bladder disorder,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Tooth disorder,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Swelling face,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Disability assessment scale score increased,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Weight fluctuation,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Nasal congestion,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic abnormal,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207385091,20738509,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220418.0,20220422,20220422,EXP,,CA-BAUSCH-BL-2022-009542,BAUSCH AND LOMB,,46.0,YR,,F,Y,,,20220422,,CN,CA,CA,2022,Q2,Adult
207413172,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,2,F,,20220411.0,20220422,20220426,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220426,,CN,CA,CA,2022,Q2,Elderly
207413172,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,2,F,,20220411.0,20220422,20220426,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220426,,CN,CA,CA,2022,Q2,Elderly
207413172,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,2,F,,20220411.0,20220422,20220426,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220426,,CN,CA,CA,2022,Q2,Elderly
207413172,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,2,F,,20220411.0,20220422,20220426,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220426,,CN,CA,CA,2022,Q2,Elderly
207413172,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,,20220411.0,20220422,20220426,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220426,,CN,CA,CA,2022,Q2,Elderly
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Off label use,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Weight increased,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Infusion site extravasation,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Carpal tunnel syndrome,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207481991,20748199,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q2,Intentional product use issue,,2022,Q2,1,I,,20220420.0,20220426,20220426,EXP,,CA-JNJFOC-20220445603,JOHNSON AND JOHNSON,,63.0,YR,A,F,Y,92.0,KG,20220426,,HP,CA,CA,2022,Q2,Adult
207551561,20755156,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220225.0,20220421.0,20220427,20220427,EXP,GB-MHRA-MIDB-61f0c4b8-947a-4cfb-9c83-3abf52bf927a,GB-NOVOPROD-911814,NOVO NORDISK,,59.0,YR,,F,Y,,,20220427,,PH,GB,GB,2022,Q2,Adult
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Heart rate increased,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Contusion,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Hypotension,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure increased,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Vascular stenosis,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Lower respiratory tract infection,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Nodule,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Hypothyroidism,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Steroid diabetes,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Finger deformity,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fibromyalgia,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Kidney infection,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Intercepted medication error,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Cystitis,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic abnormal,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Pain,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Breast disorder,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Urinary tract infection,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Intentional product use issue,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207555031,20755503,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fall,,2022,Q2,1,I,,20220420.0,20220427,20220427,EXP,,CA-ROCHE-3080457,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220427,,HP,CA,,2022,Q2,Elderly
207562451,20756245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,300.0,MG,,QD,2022,Q2,Femur fracture,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,300.0,MG,,QD,2022,Q2,Limb injury,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,300.0,MG,,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,300.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,300.0,MG,,QD,2022,Q2,Fall,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Cardiac failure congestive,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Hydronephrosis,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Oedema,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Renal impairment,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207634642,20763464,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 ng once a day,,,Y,,,,,100.0,NG,,,2022,Q2,Pleural effusion,,2022,Q2,2,F,20200220.0,20220502.0,20220428,20220503,EXP,,TW-DEXPHARM-20220610,DEXCEL,"Yao C-A; Chen Y-C; Lai C-Y; Lin C-H.  Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine 2022, V15, P68-73",60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207740923,20774092,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Hepatic function abnormal,,2022,Q2,3,F,20220418.0,20220602.0,20220502,20220610,EXP,,JP-NOVOPROD-912555,NOVO NORDISK,,73.0,YR,,M,Y,67.0,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
207740923,20774092,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,,QD,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,3,F,20220418.0,20220602.0,20220502,20220610,EXP,,JP-NOVOPROD-912555,NOVO NORDISK,,73.0,YR,,M,Y,67.0,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Pleural effusion,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Renal failure,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Pneumothorax,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Renal impairment,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207776751,20777675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Cardiac failure congestive,,2022,Q2,1,I,,20220419.0,20220503,20220503,EXP,,TW-MICRO LABS LIMITED-ML2022-01783,MICRO LABS,,60.0,YR,A,M,Y,,,20220503,,HP,TW,,2022,Q2,Adult
207840091,20784009,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Renal impairment,,2022,Q2,1,I,20200228.0,20220421.0,20220504,20220504,EXP,,TW-SCIEGENP-2022SCLIT00347,SCIEGEN,"Yao C-A, et al.Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review.International Journal of Clinical and Experimental Medicine.2022;15 (2):68-73",60.0,YR,A,M,Y,,,20220504,,MD,TW,TW,2022,Q2,Adult
207840091,20784009,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,100.0,NG,,QD,2022,Q2,Nephropathy toxic,,2022,Q2,1,I,20200228.0,20220421.0,20220504,20220504,EXP,,TW-SCIEGENP-2022SCLIT00347,SCIEGEN,"Yao C-A, et al.Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review.International Journal of Clinical and Experimental Medicine.2022;15 (2):68-73",60.0,YR,A,M,Y,,,20220504,,MD,TW,TW,2022,Q2,Adult
207934832,20793483,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,unknown,,,100.0,MG,Tablet,QD,2022,Q2,Pemphigoid,,2022,Q2,2,F,20220401.0,20220603.0,20220506,20220614,EXP,,JP-NOVOPROD-914055,NOVO NORDISK,,72.0,YR,,F,Y,56.8,KG,20220614,,MD,JP,JP,2022,Q2,Elderly
208295651,20829565,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,,20210614.0,20220513,20220513,EXP,,JP-OTSUKA-2021_020773,OTSUKA,,71.0,YR,,F,Y,,,20220513,,MD,JP,JP,2022,Q2,Elderly
208295651,20829565,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Renal impairment,,2022,Q2,1,I,,20210614.0,20220513,20220513,EXP,,JP-OTSUKA-2021_020773,OTSUKA,,71.0,YR,,F,Y,,,20220513,,MD,JP,JP,2022,Q2,Elderly
208295651,20829565,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, qd",,,,,,,,100.0,MG,,QD,2022,Q2,Underdose,,2022,Q2,1,I,,20210614.0,20220513,20220513,EXP,,JP-OTSUKA-2021_020773,OTSUKA,,71.0,YR,,F,Y,,,20220513,,MD,JP,JP,2022,Q2,Elderly
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208314411,20831441,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4392422-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208315911,20831591,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220510.0,20220516,20220516,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Adult
208331582,20833158,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, daily",,,,,,,,100.0,MG,,QD,2022,Q2,Pulmonary embolism,,2022,Q2,2,F,20220429.0,20220516.0,20220516,20220519,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202205004231,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20220519,,CN,JP,JP,2022,Q2,Elderly
208359221,20835922,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,150 mg/1000 mg tablets,,,Y,,,,204353.0,,,Film-coated tablet,,2022,Q2,Anal abscess,,2022,Q2,1,I,20220125.0,20220513.0,20220516,20220516,EXP,ES-AEMPS-1180332,ES-JNJFOC-20220529225,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,94.5,KG,20220517,,HP,ES,ES,2022,Q2,Elderly
208359221,20835922,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,150 mg/1000 mg tablets,,,Y,,,,204353.0,,,Film-coated tablet,,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20220125.0,20220513.0,20220516,20220516,EXP,ES-AEMPS-1180332,ES-JNJFOC-20220529225,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,94.5,KG,20220517,,HP,ES,ES,2022,Q2,Elderly
208364341,20836434,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Chest pain,,2022,Q2,1,I,20220101.0,20220508.0,20220517,20220517,EXP,,CN-009507513-2205CHN003137,MERCK,,48.0,YR,,M,Y,76.0,KG,20220517,,HP,CN,CN,2022,Q2,Adult
208364341,20836434,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Rash pruritic,,2022,Q2,1,I,20220101.0,20220508.0,20220517,20220517,EXP,,CN-009507513-2205CHN003137,MERCK,,48.0,YR,,M,Y,76.0,KG,20220517,,HP,CN,CN,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Flank pain,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Decreased appetite,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Muscle spasms,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Rhabdomyolysis,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Blood creatine increased,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208375801,20837580,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablets,,2022,Q2,Blood creatine phosphokinase increased,,2022,Q2,1,I,,20220507.0,20220517,20220517,EXP,CA-MHPD-000948322,CA-Accord-263290,ACCORD,,61.0,YR,,F,Y,79.0,KG,20220517,,HP,CA,CA,2022,Q2,Adult
208442001,20844200,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Malaise,,2022,Q2,1,I,,20220511.0,20220518,20220518,EXP,,JP-JNJFOC-20220533834,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,,,20220518,,MD,JP,JP,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Synovitis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Gastrointestinal infection,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Bone cyst,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Joint ankylosis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Nausea,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Skin injury,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Upper respiratory tract infection,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Drug hypersensitivity,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pain,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Transaminases increased,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Arthropathy,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hypertension,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,C-reactive protein abnormal,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Localised infection,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Osteolysis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Rheumatoid arthritis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Infection,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hand deformity,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Diabetes mellitus,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Drug intolerance,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hepatic steatosis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Treatment failure,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyspepsia,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hepatic fibrosis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Joint swelling,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Hepatic cirrhosis,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Psoriatic arthropathy,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Abdominal discomfort,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pruritus,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Drug-induced liver injury,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208442763,20844276,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Bone erosion,,2022,Q2,3,F,,20220516.0,20220518,20220524,EXP,,NVSC2022CA110853,NOVARTIS,,61.0,YR,,M,Y,,,20220524,,HP,CA,CA,2022,Q2,Adult
208451221,20845122,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q2,Balanoposthitis,,2022,Q2,1,I,,20220504.0,20220518,20220518,EXP,,CZ-EMD Serono-9319868,EMD SERONO INC,Unknown. Is the refusal of injection treatment only relative Or how a simple injection of dulaglutide can significantly affect diabetes control. CASE REPORTS IN DIABETOLOGY.. 2022;20(1):24-26.,72.0,YR,E,M,Y,,,20220518,,MD,CZ,,2022,Q2,Elderly
208451221,20845122,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q2,Diabetic neuropathy,,2022,Q2,1,I,,20220504.0,20220518,20220518,EXP,,CZ-EMD Serono-9319868,EMD SERONO INC,Unknown. Is the refusal of injection treatment only relative Or how a simple injection of dulaglutide can significantly affect diabetes control. CASE REPORTS IN DIABETOLOGY.. 2022;20(1):24-26.,72.0,YR,E,M,Y,,,20220518,,MD,CZ,,2022,Q2,Elderly
208451221,20845122,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q2,Diabetic nephropathy,,2022,Q2,1,I,,20220504.0,20220518,20220518,EXP,,CZ-EMD Serono-9319868,EMD SERONO INC,Unknown. Is the refusal of injection treatment only relative Or how a simple injection of dulaglutide can significantly affect diabetes control. CASE REPORTS IN DIABETOLOGY.. 2022;20(1):24-26.,72.0,YR,E,M,Y,,,20220518,,MD,CZ,,2022,Q2,Elderly
208451221,20845122,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,1,I,,20220504.0,20220518,20220518,EXP,,CZ-EMD Serono-9319868,EMD SERONO INC,Unknown. Is the refusal of injection treatment only relative Or how a simple injection of dulaglutide can significantly affect diabetes control. CASE REPORTS IN DIABETOLOGY.. 2022;20(1):24-26.,72.0,YR,E,M,Y,,,20220518,,MD,CZ,,2022,Q2,Elderly
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Swelling face,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Bronchitis,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Road traffic accident,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Lower respiratory tract congestion,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Disability assessment scale score increased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Peripheral swelling,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Lower respiratory tract infection,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Muscle tightness,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cough,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure fluctuation,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Nasal congestion,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Oropharyngeal pain,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight fluctuation,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure systolic decreased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Tooth disorder,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Constipation,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Soft tissue injury,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic abnormal,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Gastrointestinal disorder,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Medication error,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Nasopharyngitis,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208479861,20847986,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Bladder disorder,,2022,Q2,1,I,,20220510.0,20220519,20220519,EXP,,CA-ROCHE-3094623,ROCHE,,46.0,YR,,F,Y,,,20220519,,HP,CA,,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208487061,20848706,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220511.0,20220519,20220519,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20220519,,HP,CA,CA,2022,Q2,Adult
208559421,20855942,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 milligram, qd",,,,U,,,,300.0,MG,,QD,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220511.0,20220520,20220520,EXP,,US-MYLANLABS-2022M1036713,MYLAN,"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. J-Clin-Transl-Endocrinol-Case-Rep 2022;23:100109.",35.0,YR,,F,Y,,,20220520,,HP,US,US,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208585791,20858579,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220512.0,20220522,20220522,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-041967,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20220522,,CN,CA,CA,2022,Q2,Adult
208588312,20858831,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,204042.0,300.0,MG,Tablet,,2022,Q2,Intentional product misuse,,2022,Q2,2,F,20211219.0,20220525.0,20220522,20220531,EXP,IT-MINISAL02-868217,IT-JNJFOC-20220538654,JOHNSON AND JOHNSON,,44.0,YR,A,F,Y,75.0,KG,20220531,,MD,IT,IT,2022,Q2,Adult
208588312,20858831,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,204042.0,300.0,MG,Tablet,,2022,Q2,Coma,,2022,Q2,2,F,20211219.0,20220525.0,20220522,20220531,EXP,IT-MINISAL02-868217,IT-JNJFOC-20220538654,JOHNSON AND JOHNSON,,44.0,YR,A,F,Y,75.0,KG,20220531,,MD,IT,IT,2022,Q2,Adult
208588312,20858831,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,204042.0,300.0,MG,Tablet,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20211219.0,20220525.0,20220522,20220531,EXP,IT-MINISAL02-868217,IT-JNJFOC-20220538654,JOHNSON AND JOHNSON,,44.0,YR,A,F,Y,75.0,KG,20220531,,MD,IT,IT,2022,Q2,Adult
208588312,20858831,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,UNKNOWN,,204042.0,300.0,MG,Tablet,,2022,Q2,Drug abuse,,2022,Q2,2,F,20211219.0,20220525.0,20220522,20220531,EXP,IT-MINISAL02-868217,IT-JNJFOC-20220538654,JOHNSON AND JOHNSON,,44.0,YR,A,F,Y,75.0,KG,20220531,,MD,IT,IT,2022,Q2,Adult
208652981,20865298,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, qd",,,D,,Unknown,,,,,,QD,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220511.0,20220524,20220524,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-07363,LUPIN,"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. Journal of Clinical and Translational Endocrinology: Case Reports. 2022;23(2022):1-3",35.0,YR,,F,Y,,,20220524,,HP,US,US,2022,Q2,Adult
208735621,20873562,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220518.0,20220525,20220525,EXP,,US-MYLANLABS-2022M1038788,MYLAN,"Hayes C, Stezzi M, Gelin L, Perilli G. Abstract #1182972: Euglycemic PEA. Endocr-Pract 2022;28 (Suppl.)(5):S36 abstr. 1182972.",51.0,YR,,F,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208753181,20875318,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 qd(Preferably Before Breakfast),,,,,UNKNOWN,,,,,,,2022,Q2,Hallucination,,2022,Q2,1,I,20220517.0,20220519.0,20220526,20220526,EXP,GB-MHRA-ADR 26934312,GB-NOVOPROD-920198,NOVO NORDISK,,69.0,YR,,F,Y,139.0,KG,20220526,,HP,GB,GB,2022,Q2,Elderly
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Pain,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Infection,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208800281,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220523.0,20220526,20220526,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20220526,,HP,CA,CA,2022,Q2,Adult
208844861,20884486,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, daily (in morning)",,,Y,U,,,,300.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,1,I,,20220516.0,20220527,20220527,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202205006231,ELI LILLY AND CO,,43.0,YR,,M,Y,,,20220527,,CN,GB,GB,2022,Q2,Adult
208844861,20884486,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, daily (in morning)",,,Y,U,,,,300.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220516.0,20220527,20220527,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202205006231,ELI LILLY AND CO,,43.0,YR,,M,Y,,,20220527,,CN,GB,GB,2022,Q2,Adult
208844861,20884486,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, daily (in morning)",,,Y,U,,,,300.0,MG,,QD,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220516.0,20220527,20220527,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202205006231,ELI LILLY AND CO,,43.0,YR,,M,Y,,,20220527,,CN,GB,GB,2022,Q2,Adult
208846281,20884628,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,Tablet,QD,2022,Q2,Peripheral swelling,,2022,Q2,1,I,20220401.0,20220523.0,20220527,20220527,PER,,US-JNJFOC-20220548151,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,64.468,KG,20220527,,CN,US,US,2022,Q2,Elderly
208846281,20884628,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,Tablet,QD,2022,Q2,Glycosuria,,2022,Q2,1,I,20220401.0,20220523.0,20220527,20220527,PER,,US-JNJFOC-20220548151,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,64.468,KG,20220527,,CN,US,US,2022,Q2,Elderly
208846281,20884628,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,Tablet,QD,2022,Q2,Urinary tract infection bacterial,,2022,Q2,1,I,20220401.0,20220523.0,20220527,20220527,PER,,US-JNJFOC-20220548151,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,64.468,KG,20220527,,CN,US,US,2022,Q2,Elderly
208893661,20889366,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220425.0,20220525.0,20220530,20220530,EXP,IT-MINISAL02-869284,IT-JNJFOC-20220556242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,85.0,KG,20220530,,MD,IT,IT,2022,Q2,Elderly
208894702,20889470,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, qd",,,,,,,,300.0,MG,,QD,2022,Q2,Angina pectoris,,2022,Q2,2,F,,20220529.0,20220530,20220608,EXP,,BR-NOVOPROD-920828,NOVO NORDISK,,55.0,YR,,M,Y,109.0,KG,20220608,,MD,BR,BR,2022,Q2,Adult
208894702,20889470,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, qd",,,,,,,,300.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,2,F,,20220529.0,20220530,20220608,EXP,,BR-NOVOPROD-920828,NOVO NORDISK,,55.0,YR,,M,Y,109.0,KG,20220608,,MD,BR,BR,2022,Q2,Adult
208894702,20889470,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, qd",,,,,,,,300.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,2,F,,20220529.0,20220530,20220608,EXP,,BR-NOVOPROD-920828,NOVO NORDISK,,55.0,YR,,M,Y,109.0,KG,20220608,,MD,BR,BR,2022,Q2,Adult
208894702,20889470,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, qd",,,,,,,,300.0,MG,,QD,2022,Q2,Constipation,,2022,Q2,2,F,,20220529.0,20220530,20220608,EXP,,BR-NOVOPROD-920828,NOVO NORDISK,,55.0,YR,,M,Y,109.0,KG,20220608,,MD,BR,BR,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208924651,20892465,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220516.0,20220531,20220531,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20220531,,HP,CA,CA,2022,Q2,Adult
208991931,20899193,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,1,I,,20220524.0,20220601,20220601,EXP,CA-MHPD-E2B_04003495,CA-Accord-265082,ACCORD,,76.0,YR,E,F,Y,,,20220601,,CN,CA,CA,2022,Q2,Elderly
208991931,20899193,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,,20220524.0,20220601,20220601,EXP,CA-MHPD-E2B_04003495,CA-Accord-265082,ACCORD,,76.0,YR,E,F,Y,,,20220601,,CN,CA,CA,2022,Q2,Elderly
208991931,20899193,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,,20220524.0,20220601,20220601,EXP,CA-MHPD-E2B_04003495,CA-Accord-265082,ACCORD,,76.0,YR,E,F,Y,,,20220601,,CN,CA,CA,2022,Q2,Elderly
208991931,20899193,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220524.0,20220601,20220601,EXP,CA-MHPD-E2B_04003495,CA-Accord-265082,ACCORD,,76.0,YR,E,F,Y,,,20220601,,CN,CA,CA,2022,Q2,Elderly
208991931,20899193,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,1,I,,20220524.0,20220601,20220601,EXP,CA-MHPD-E2B_04003495,CA-Accord-265082,ACCORD,,76.0,YR,E,F,Y,,,20220601,,CN,CA,CA,2022,Q2,Elderly
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209025231,20902523,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220520.0,20220601,20220601,EXP,,CA-UCBSA-2022029813,UCB,,61.0,YR,,M,Y,,,20220601,,HP,CA,CA,2022,Q2,Adult
209059952,20905995,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 Milligram Daily;,,,Y,,,,,300.0,MG,,QD,2022,Q2,Fanconi syndrome,,2022,Q2,2,F,,20220607.0,20220602,20220616,EXP,,US-TEVA-2022-US-2041213,TEVA,"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. J-Clin-Transl-Endocrinol-Case-Rep 2022;23:100109.",35.0,YR,A,F,Y,,,20220616,,HP,US,US,2022,Q2,Adult
209059952,20905995,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 Milligram Daily;,,,Y,,,,,300.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,2,F,,20220607.0,20220602,20220616,EXP,,US-TEVA-2022-US-2041213,TEVA,"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. J-Clin-Transl-Endocrinol-Case-Rep 2022;23:100109.",35.0,YR,A,F,Y,,,20220616,,HP,US,US,2022,Q2,Adult
209059952,20905995,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,300 Milligram Daily;,,,Y,,,,,300.0,MG,,QD,2022,Q2,Drug ineffective,,2022,Q2,2,F,,20220607.0,20220602,20220616,EXP,,US-TEVA-2022-US-2041213,TEVA,"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. J-Clin-Transl-Endocrinol-Case-Rep 2022;23:100109.",35.0,YR,A,F,Y,,,20220616,,HP,US,US,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209085621,20908562,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220523.0,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041372,TEVA,,61.0,YR,A,M,Y,,,20220603,,HP,CA,CA,2022,Q2,Adult
209250611,20925061,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,1,I,20220531.0,20220603.0,20220607,20220607,PER,,US-PFIZER INC-202200797680,PFIZER,,67.0,YR,,M,Y,,,20220607,,MD,US,US,2022,Q2,Elderly
209250611,20925061,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Disease recurrence,,2022,Q2,1,I,20220531.0,20220603.0,20220607,20220607,PER,,US-PFIZER INC-202200797680,PFIZER,,67.0,YR,,M,Y,,,20220607,,MD,US,US,2022,Q2,Elderly
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Hypoacusis,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Depression,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209251031,20925103,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,1,I,,20220530.0,20220607,20220607,EXP,,CA-TEVA-2021-CA-1994804,TEVA,,51.0,YR,A,F,Y,,,20220607,,HP,CA,CA,2022,Q2,Adult
209355712,20935571,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043574,TEVA,"Hayes C, Stezzi M, Gelin L, Perilli G. Abstract #1182972: Euglycemic PEA. Endocr-Pract 2022;28 (Suppl.)(5):S36 abstr. 1182972.",51.0,YR,A,F,Y,,,20220625,,HP,US,US,2022,Q2,Adult
209355712,20935571,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Encephalopathy,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043574,TEVA,"Hayes C, Stezzi M, Gelin L, Perilli G. Abstract #1182972: Euglycemic PEA. Endocr-Pract 2022;28 (Suppl.)(5):S36 abstr. 1182972.",51.0,YR,A,F,Y,,,20220625,,HP,US,US,2022,Q2,Adult
209355712,20935571,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Cardiac arrest,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043574,TEVA,"Hayes C, Stezzi M, Gelin L, Perilli G. Abstract #1182972: Euglycemic PEA. Endocr-Pract 2022;28 (Suppl.)(5):S36 abstr. 1182972.",51.0,YR,A,F,Y,,,20220625,,HP,US,US,2022,Q2,Adult
209355712,20935571,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043574,TEVA,"Hayes C, Stezzi M, Gelin L, Perilli G. Abstract #1182972: Euglycemic PEA. Endocr-Pract 2022;28 (Suppl.)(5):S36 abstr. 1182972.",51.0,YR,A,F,Y,,,20220625,,HP,US,US,2022,Q2,Adult
209422711,20942271,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,Unknown,,,100.0,MG,Tablet,QD,2022,Q2,Cerebral haemorrhage,,2022,Q2,1,I,20220520.0,20220602.0,20220610,20220610,EXP,,JP-NOVOPROD-925893,NOVO NORDISK,,82.0,YR,,M,Y,,,20220610,,MD,JP,JP,2022,Q2,Elderly
209476371,20947637,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,,,Tablet,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220531.0,20220611,20220611,EXP,,US-JNJFOC-20220610374,JOHNSON AND JOHNSON,,46.0,YR,A,M,Y,,,20220611,,HP,US,US,2022,Q2,Adult
209476371,20947637,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,,,Tablet,,2022,Q2,Off label use,,2022,Q2,1,I,,20220531.0,20220611,20220611,EXP,,US-JNJFOC-20220610374,JOHNSON AND JOHNSON,,46.0,YR,A,M,Y,,,20220611,,HP,US,US,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209534321,20953432,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220608.0,20220613,20220613,EXP,,CA-ROCHE-3113965,ROCHE,,61.0,YR,,M,Y,,,20220614,,HP,CA,,2022,Q2,Adult
209610851,20961085,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,CA-MHPD-E2B_04208803,CA-Accord-266192,ACCORD,,64.0,YR,,M,Y,110.0,KG,20220615,,HP,CA,CA,2022,Q2,Adult
209610851,20961085,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,,2022,Q2,Blood creatinine increased,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,CA-MHPD-E2B_04208803,CA-Accord-266192,ACCORD,,64.0,YR,,M,Y,110.0,KG,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone cyst,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Nausea,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint swelling,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Upper respiratory tract infection,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Red blood cell sedimentation rate abnormal,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Osteolysis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic fibrosis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Anti-cyclic citrullinated peptide antibody positive,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect decreased,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic cirrhosis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug hypersensitivity,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Skin injury,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Synovitis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Infection,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Diabetes mellitus,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hand deformity,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Arthropathy,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Localised infection,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hypertension,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Gastrointestinal infection,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Psoriatic arthropathy,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Drug-induced liver injury,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Alanine aminotransferase abnormal,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Rheumatoid arthritis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,C-reactive protein abnormal,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Joint ankylosis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Transaminases increased,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Dyspepsia,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Bone erosion,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pain,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Pruritus,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209633331,20963333,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,,20220510.0,20220615,20220615,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20220615,,HP,CA,CA,2022,Q2,Adult
209670131,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,U,,,,,300.0,MG,Tablet,,2022,Q2,Off label use,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209670131,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,U,,,,,300.0,MG,Tablet,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209670131,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,U,,,,,300.0,MG,Tablet,,2022,Q2,Product prescribing error,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209670131,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,U,,,,,100.0,MG,Tablet,,2022,Q2,Off label use,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209670131,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,U,,,,,100.0,MG,Tablet,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209670131,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,U,,,,,100.0,MG,Tablet,,2022,Q2,Product prescribing error,,2022,Q2,1,I,,20220607.0,20220616,20220616,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,unk. unk. unk. unk;unk:unk,17.0,YR,T,M,Y,,,20220616,,HP,CA,CA,2022,Q2,Youth
209730881,20973088,18,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Daily",,,,,,,,,,,,2022,Q2,Electrocardiogram QT prolonged,,2022,Q2,1,I,,20220603.0,20220617,20220617,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-341012,RANBAXY,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;Mar 17; 58:1-7(438)",69.0,YR,,M,Y,,,20220617,,HP,US,US,2022,Q2,Elderly
209730881,20973088,18,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Daily",,,,,,,,,,,,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220603.0,20220617,20220617,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-341012,RANBAXY,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;Mar 17; 58:1-7(438)",69.0,YR,,M,Y,,,20220617,,HP,US,US,2022,Q2,Elderly
209730881,20973088,18,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 dosage form, Daily",,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220603.0,20220617,20220617,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-341012,RANBAXY,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;Mar 17; 58:1-7(438)",69.0,YR,,M,Y,,,20220617,,HP,US,US,2022,Q2,Elderly
209790581,20979058,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diarrhoea,,2022,Q2,1,I,20220606.0,20220609.0,20220619,20220619,EXP,,GB-JNJFOC-20220637143,JOHNSON AND JOHNSON,,67.0,YR,E,F,Y,,,20220620,,HP,GB,GB,2022,Q2,Elderly
209790581,20979058,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Medication error,,2022,Q2,1,I,20220606.0,20220609.0,20220619,20220619,EXP,,GB-JNJFOC-20220637143,JOHNSON AND JOHNSON,,67.0,YR,E,F,Y,,,20220620,,HP,GB,GB,2022,Q2,Elderly
209790581,20979058,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220606.0,20220609.0,20220619,20220619,EXP,,GB-JNJFOC-20220637143,JOHNSON AND JOHNSON,,67.0,YR,E,F,Y,,,20220620,,HP,GB,GB,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Blood immunoglobulin E increased,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Cough,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Rhinorrhoea,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Bronchiectasis,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Malignant mediastinal neoplasm,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Nasal congestion,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798261,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Intentional product use issue,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,HP,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Blood immunoglobulin E increased,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Rhinorrhoea,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Nasal congestion,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Cough,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Malignant mediastinal neoplasm,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Wheezing,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Asthma,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Bronchiectasis,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209798331,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q2,Intentional product use issue,,2022,Q2,1,I,,20220613.0,20220620,20220620,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20220620,,MD,CA,CA,2022,Q2,Elderly
209817201,20981720,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220611.0,20220615.0,20220620,20220620,EXP,GB-MHRA-MIDB-5066969e-16c7-4f13-b73d-2aaed8ae812c,GB-JNJFOC-20220636821,JOHNSON AND JOHNSON,,59.0,YR,A,M,Y,,,20220620,,PH,GB,GB,2022,Q2,Adult
210048881,21004888,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,,20220616.0,20220624,20220624,EXP,,CA-AstraZeneca-2022A225441,ASTRAZENECA,,76.0,YR,,F,Y,,,20220624,,MD,CA,,2022,Q2,Elderly
210048881,21004888,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Asthma,,2022,Q2,1,I,,20220616.0,20220624,20220624,EXP,,CA-AstraZeneca-2022A225441,ASTRAZENECA,,76.0,YR,,F,Y,,,20220624,,MD,CA,,2022,Q2,Elderly
210048881,21004888,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,,20220616.0,20220624,20220624,EXP,,CA-AstraZeneca-2022A225441,ASTRAZENECA,,76.0,YR,,F,Y,,,20220624,,MD,CA,,2022,Q2,Elderly
210048881,21004888,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220616.0,20220624,20220624,EXP,,CA-AstraZeneca-2022A225441,ASTRAZENECA,,76.0,YR,,F,Y,,,20220624,,MD,CA,,2022,Q2,Elderly
210048881,21004888,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,1,I,,20220616.0,20220624,20220624,EXP,,CA-AstraZeneca-2022A225441,ASTRAZENECA,,76.0,YR,,F,Y,,,20220624,,MD,CA,,2022,Q2,Elderly
210082131,21008213,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,unknown,,,,,,,2022,Q2,Death,,2022,Q2,1,I,20220614.0,20220616.0,20220627,20220627,EXP,GB-MHRA-ADR 27018515,GB-NOVOPROD-929477,NOVO NORDISK,,68.0,YR,,M,Y,123.0,KG,20220627,,MD,GB,GB,2022,Q2,Elderly
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Hepatic fibrosis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Osteolysis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Nausea,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Arthropathy,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein abnormal,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Bone cyst,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein abnormal,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Psoriatic arthropathy,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase increased,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Drug-induced liver injury,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Transaminases increased,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal infection,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Joint swelling,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect incomplete,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Hand deformity,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Drug ineffective,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Red blood cell sedimentation rate abnormal,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Infection,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Rheumatoid arthritis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase abnormal,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Upper respiratory tract infection,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Anti-cyclic citrullinated peptide antibody positive,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Pain,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Hepatic steatosis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Hypertension,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Diarrhoea,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Synovitis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect decreased,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Abdominal discomfort,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein increased,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Liver disorder,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Skin injury,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Dyspepsia,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Bone erosion,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Pruritus,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Therapeutic response decreased,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Localised infection,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Drug hypersensitivity,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Drug intolerance,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Arthralgia,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Joint ankylosis,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1231249415,12312494,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Treatment failure,,2022,Q3,15,F,20090209.0,20220628.0,20160428,20220705,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20220704,,HP,CA,CA,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Transaminases increased,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic steatosis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Abdominal discomfort,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Upper respiratory tract infection,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Arthralgia,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Rheumatoid arthritis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Pain,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Joint swelling,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic fibrosis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hypertension,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug intolerance,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Localised infection,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Pruritus,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Skin injury,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Bone erosion,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Diarrhoea,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein increased,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Treatment failure,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Psoriatic arthropathy,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein abnormal,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase increased,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Synovitis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hand deformity,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Liver disorder,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase abnormal,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect decreased,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug hypersensitivity,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug-induced liver injury,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Bone cyst,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Osteolysis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Red blood cell sedimentation rate abnormal,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Arthropathy,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect incomplete,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Therapeutic response decreased,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Joint ankylosis,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Infection,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Dyspepsia,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Anti-cyclic citrullinated peptide antibody positive,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug ineffective,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Nausea,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
1307079912,13070799,102,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal infection,,2022,Q3,12,F,20090209.0,20220705.0,20161229,20220711,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,50.0,YR,A,M,Y,,,20220711,,MD,CA,,2022,Q3,Adult
147511828,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, UNKNOWN",,,D,,,,,300.0,MG,,,2022,Q3,Prescribed overdose,,2022,Q3,8,F,20170602.0,20220627.0,20180412,20220629,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20220629,,MD,CA,CA,2022,Q3,Adult
147511828,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, UNKNOWN",,,D,,,,,300.0,MG,,,2022,Q3,Psoriasis,,2022,Q3,8,F,20170602.0,20220627.0,20180412,20220629,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20220629,,MD,CA,CA,2022,Q3,Adult
147511828,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, UNKNOWN",,,D,,,,,300.0,MG,,,2022,Q3,Cardiac failure acute,,2022,Q3,8,F,20170602.0,20220627.0,20180412,20220629,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20220629,,MD,CA,CA,2022,Q3,Adult
147511828,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 mg, UNKNOWN",,,D,,,,,300.0,MG,,,2022,Q3,Cellulitis,,2022,Q3,8,F,20170602.0,20220627.0,20180412,20220629,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20220629,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Bone erosion,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect incomplete,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Bone cyst,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Arthralgia,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase abnormal,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Upper respiratory tract infection,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Drug-induced liver injury,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Pruritus,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,C-reactive protein abnormal,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Diarrhoea,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Localised infection,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Hypertension,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Liver disorder,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Synovitis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Joint ankylosis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Abdominal discomfort,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Product use issue,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect decreased,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Infection,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Osteolysis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Hepatic steatosis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Drug hypersensitivity,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal infection,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Skin injury,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Therapeutic response decreased,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Drug ineffective,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,C-reactive protein increased,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Psoriatic arthropathy,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Rheumatoid arthritis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase increased,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Transaminases increased,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Treatment failure,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Dyspepsia,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Joint swelling,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Arthropathy,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Anti-cyclic citrullinated peptide antibody positive,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Hepatic fibrosis,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Red blood cell sedimentation rate abnormal,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Hand deformity,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Pain,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Drug intolerance,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Off label use,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1556724814,15567248,85,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q3,Nausea,,2022,Q3,14,F,20090209.0,20220628.0,20181030,20220707,EXP,,CA-PFIZER INC-2016181292,PFIZER,,50.0,YR,,M,Y,,,20220707,,MD,CA,CA,2022,Q3,Adult
1656345012,16563450,72,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,72,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,72,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,72,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,72,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,73,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,73,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,73,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,73,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,73,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,74,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,74,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,74,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,74,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,74,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,75,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,75,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,75,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,75,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,75,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,76,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,76,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,76,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,76,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,76,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,77,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,77,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,77,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,77,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,77,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,78,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,78,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,78,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,78,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,78,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,79,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,79,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,79,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,79,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
1656345012,16563450,79,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,12,F,,20220721.0,20190712,20220804,EXP,,CA-AUROBINDO-AUR-APL-2019-038508,AUROBINDO,,76.0,YR,,F,Y,,,20220804,,MD,CA,CA,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Abscess limb,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Renal tubular necrosis,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urosepsis,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Anal abscess,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Sepsis syndrome,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Rectal abscess,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Scrotal abscess,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Genital abscess,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Depression,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Organ failure,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Perirectal abscess,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
168915275,16891527,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fournier's gangrene,,2022,Q3,5,F,20151121.0,20220823.0,20191007,20220829,EXP,,US-AstraZeneca-2019SF40914,ASTRAZENECA,,23720.0,DY,,M,Y,72.1,KG,20220829,,LW,US,,2022,Q3,Elderly
172697326,17269732,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Gait disturbance,,2022,Q3,6,F,20200103.0,20220629.0,20200114,20220726,EXP,,JP-ABBVIE-20P-087-3231624-00,ABBVIE,,67.0,YR,,M,Y,68.0,KG,20220726,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
172697326,17269732,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Fall,,2022,Q3,6,F,20200103.0,20220629.0,20200114,20220726,EXP,,JP-ABBVIE-20P-087-3231624-00,ABBVIE,,67.0,YR,,M,Y,68.0,KG,20220726,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
172697326,17269732,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Pain,,2022,Q3,6,F,20200103.0,20220629.0,20200114,20220726,EXP,,JP-ABBVIE-20P-087-3231624-00,ABBVIE,,67.0,YR,,M,Y,68.0,KG,20220726,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Blood cholesterol abnormal,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Back pain,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Off label use,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Ligament sprain,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Blood growth hormone increased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Infectious mononucleosis,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Heart rate decreased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Drug resistance,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Nasal congestion,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Heart rate increased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Laryngitis bacterial,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Cortisol decreased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Sinusitis,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Abdominal pain,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Drug ineffective for unapproved indication,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Blood pressure increased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Groin abscess,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Body temperature decreased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Facial pain,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Insulin-like growth factor increased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Movement disorder,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179322652,17932265,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 dosage form, QD (1 every 1 Days)",,,U,,,,,,,Tablet,QD,2022,Q3,Headache,,2022,Q3,2,F,,20220726.0,20200623,20220731,EXP,,NVSC2020CA172766,NOVARTIS,,27.0,YR,,F,Y,,,20220801,,CN,CA,CA,2022,Q3,Young Adult
179366137,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,7,F,,20220711.0,20200624,20220716,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,E,F,Y,,,20220716,,CN,CA,CA,2022,Q3,Elderly
179366137,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,7,F,,20220711.0,20200624,20220716,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,E,F,Y,,,20220716,,CN,CA,CA,2022,Q3,Elderly
179366137,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,7,F,,20220711.0,20200624,20220716,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,E,F,Y,,,20220716,,CN,CA,CA,2022,Q3,Elderly
179366137,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,7,F,,20220711.0,20200624,20220716,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,E,F,Y,,,20220716,,CN,CA,CA,2022,Q3,Elderly
179366137,17936613,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,7,F,,20220711.0,20200624,20220716,EXP,000736566,CA-Accord-185852,ACCORD,,76.0,YR,E,F,Y,,,20220716,,CN,CA,CA,2022,Q3,Elderly
180874094,18087409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",27900.0,MG,,,,,,100.0,MG,Tablet,QD,2022,Q3,Subdural haematoma,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",27900.0,MG,,,,,,100.0,MG,Tablet,QD,2022,Q3,Fall,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",27900.0,MG,,,,,,100.0,MG,Tablet,QD,2022,Q3,Cardiac failure chronic,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",27900.0,MG,,,,,,100.0,MG,Tablet,QD,2022,Q3,Ventricular tachycardia,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,27900.0,MG,,,,,,,,Tablet,,2022,Q3,Subdural haematoma,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,27900.0,MG,,,,,,,,Tablet,,2022,Q3,Fall,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,27900.0,MG,,,,,,,,Tablet,,2022,Q3,Cardiac failure chronic,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
180874094,18087409,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,27900.0,MG,,,,,,,,Tablet,,2022,Q3,Ventricular tachycardia,,2022,Q3,4,F,20200727.0,20220713.0,20200729,20220715,EXP,,JP-PFIZER INC-2020286557,PFIZER,,80.0,YR,,M,Y,59.8,KG,20220715,,MD,JP,JP,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Lower respiratory tract infection,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Device infusion issue,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Expired product administered,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Needle issue,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Bladder cancer,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Infusion site pain,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Illness,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
187421915,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,,,,,,100.0,MG,,QD,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,5,F,20200916.0,20220826.0,20210114,20220902,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20220902,,CN,IE,IE,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Fibromyalgia,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Kidney infection,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Drug ineffective,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypertension,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Nasopharyngitis,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypotension,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Intentional product use issue,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure fluctuation,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Lower respiratory tract infection,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Rheumatoid arthritis,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Contusion,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Steroid diabetes,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure increased,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Nodule,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypothyroidism,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Arthralgia,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Fall,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Breast disorder,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Cystitis,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Pain,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Heart rate increased,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Finger deformity,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Vascular stenosis,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Oxygen saturation decreased,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Intercepted medication error,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
188950022,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Urinary tract infection,,2022,Q3,2,F,,20210208.0,20210215,20220811,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220811,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Steroid diabetes,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Nodule,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Contusion,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Heart rate increased,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Rheumatoid arthritis,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Kidney infection,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Cystitis,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Fibromyalgia,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Vascular stenosis,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Breast disorder,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypothyroidism,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Pain,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Intercepted medication error,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Lower respiratory tract infection,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Finger deformity,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Intentional product use issue,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Blood pressure increased,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Fall,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
189236273,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,3,F,,20210208.0,20210222,20220816,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
1902563535,19025635,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,42,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,42,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,42,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,42,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
1902563535,19025635,42,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,35,F,,20220912.0,20210318,20220926,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20220926,,CN,CA,CA,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Rheumatoid arthritis,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Contusion,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Kidney infection,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Breast disorder,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Heart rate increased,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Intercepted medication error,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Fibromyalgia,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Steroid diabetes,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure increased,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Pain,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Lower respiratory tract infection,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Finger deformity,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypothyroidism,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Vascular stenosis,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Cystitis,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Intentional product use issue,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Nodule,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
194978042,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Fall,,2022,Q3,2,F,,20220722.0,20210706,20220726,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220726,,HP,CA,,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
198157984,19815798,39,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,4,F,,20220829.0,20210910,20220908,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20220908,,CN,CA,CA,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Skin lesion,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Lip oedema,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Macule,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Cholestasis,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Odynophagia,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Dysphagia,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Visual impairment,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Oral candidiasis,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,SJS-TEN overlap,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Toxic epidermal necrolysis,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Blister,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Ocular hyperaemia,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Ulcerative keratitis,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200341257,20034125,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Stevens-Johnson syndrome,,2022,Q3,7,F,,20220905.0,20211104,20220908,EXP,,PT-MYLANLABS-2021M1080475,MYLAN,"Gama L, Duarte J, Santos e Silva A, et al. P n? 1058 Stevens-Johnson Syndrome ? the cessation of therapy as the key to the cure.. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20220908,,MD,PT,PT,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Lip oedema,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Toxic epidermal necrolysis,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Ocular hyperaemia,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Macule,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Skin lesion,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Cholestasis,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Stevens-Johnson syndrome,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Oral candidiasis,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Blister,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Ulcerative keratitis,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Dysphagia,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,SJS-TEN overlap,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Visual impairment,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Odynophagia,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200732888,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2022,Q3,Pyrexia,,2022,Q3,8,F,,20220808.0,20211116,20220812,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20220812,,HP,PT,PT,2022,Q3,Elderly
200821084,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q3,Vascular stent thrombosis,,2022,Q3,4,F,,20220809.0,20211117,20220810,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220810,,MD,JP,JP,2022,Q3,Child
200821084,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal haemorrhage,,2022,Q3,4,F,,20220809.0,20211117,20220810,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220810,,MD,JP,JP,2022,Q3,Child
200821084,20082108,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100mg/day,,,,,,,,,,Tablet,,2022,Q3,Disseminated intravascular coagulation,,2022,Q3,4,F,,20220809.0,20211117,20220810,EXP,,JP-DAIICHI SANKYO EUROPE GMBH-DSJ-2021-137429,DAIICHI,"Nakano M, Yoshiga T, Yamaji K, Ishimatsu T, Ishizaki Y, Sasaki M, et al.. A case of a patient with a high risk of haemorrhage and thrombus who developed subacute stent thrombosis after discontinuation of aspirin due to haemorrhage of digestive tract. 33rd Met of Jpn Assoc of CVIT Kyushu/Okinawa Chapter-6th Winter Case Study Met-. 2022;20",8.0,DEC,,M,Y,58.0,KG,20220810,,MD,JP,JP,2022,Q3,Child
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Toxic epidermal necrolysis,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Visual impairment,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Lip oedema,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Cholestasis,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Skin lesion,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Dysphagia,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Ulcerative keratitis,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Oral candidiasis,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Macule,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Rash macular,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Odynophagia,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Stevens-Johnson syndrome,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Blister,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,SJS-TEN overlap,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
200846359,20084635,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Ocular hyperaemia,,2022,Q3,9,F,,20220804.0,20211118,20220818,EXP,,PT-AUROBINDO-AUR-APL-2021-045646,AUROBINDO,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H.. S?ndrome de Stevens-Johnson ? o cessar da terap?utica(S?ndrome Stevens-Johnson - the cessation of therapy as the key to cure). Congresso Nacional de Medicina Interna. 2021;1058",79.0,YR,,F,Y,,,20220818,,MD,PT,PT,2022,Q3,Elderly
201374335,20137433,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,,,,,,100.0,MG,UNK,,2022,Q3,Pneumonia aspiration,,2022,Q3,5,F,20201214.0,20220822.0,20211201,20220824,EXP,,JP-ABBVIE-21P-087-4181504-00,ABBVIE,,65.0,YR,,M,Y,90.0,KG,20220824,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
201374335,20137433,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,,,,,,100.0,MG,UNK,,2022,Q3,Oesophageal varices haemorrhage,,2022,Q3,5,F,20201214.0,20220822.0,20211201,20220824,EXP,,JP-ABBVIE-21P-087-4181504-00,ABBVIE,,65.0,YR,,M,Y,90.0,KG,20220824,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
201374335,20137433,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,,,,,,100.0,MG,UNK,,2022,Q3,Hepatic cirrhosis,,2022,Q3,5,F,20201214.0,20220822.0,20211201,20220824,EXP,,JP-ABBVIE-21P-087-4181504-00,ABBVIE,,65.0,YR,,M,Y,90.0,KG,20220824,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Swelling face,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Soft tissue injury,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Sinus congestion,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Weight fluctuation,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Muscle tightness,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Gastrointestinal disorder,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure systolic decreased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Peripheral swelling,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Cough,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Constipation,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Weight increased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Bladder disorder,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Tooth disorder,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Bronchitis,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Lower respiratory tract infection,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Oropharyngeal pain,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Disability assessment scale score increased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Medication error,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Lower respiratory tract congestion,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Road traffic accident,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Abdominal pain upper,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nasal congestion,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure decreased,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
201507303,20150730,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,3,F,,20220921.0,20211206,20220926,EXP,,CA-BAUSCH-BL-2021-039633,BAUSCH AND LOMB,,46.0,YR,,F,Y,89.0,KG,20220926,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Arthritis,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Tooth fracture,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Rhinorrhoea,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Off label use,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Joint injury,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Alopecia,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Nervousness,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Inflammation,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,COVID-19,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Pain,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Immunosuppression,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Fall,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Exposure to SARS-CoV-2,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Product use issue,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Pulpitis dental,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Gait disturbance,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Nasal congestion,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Limb injury,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Rhinitis allergic,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Malaise,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Discomfort,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
202403344,20240334,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Myalgia,,2022,Q3,4,F,,20220901.0,20211228,20220912,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20220912,,HP,CA,CA,2022,Q3,Adult
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Off label use,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204906962,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,2,F,,20220819.0,20220218,20220823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
204950912,20495091,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,2,F,,20220719.0,20220221,20220726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-024149,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20220726,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086836,20508683,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,6,F,,20220726.0,20220223,20220804,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220804,,MD,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Off label use,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205086843,20508684,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,3,F,,20220819.0,20220223,20220825,EXP,,CA-PFIZER INC-202200299943,PFIZER,,73.0,YR,,F,Y,101.0,KG,20220825,,HP,CA,CA,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Overdose,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
205109366,20510936,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,6,F,,20220801.0,20220224,20220805,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20220805,,MD,CA,,2022,Q3,Elderly
206437964,20643796,9,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Aspiration,,2022,Q3,4,F,20220320.0,20220822.0,20220328,20220831,EXP,,JP-009507513-2203JPN002840J,MERCK,,88.0,YR,,M,Y,,,20220831,,MD,JP,JP,2022,Q3,Elderly
206437964,20643796,9,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Loss of consciousness,,2022,Q3,4,F,20220320.0,20220822.0,20220328,20220831,EXP,,JP-009507513-2203JPN002840J,MERCK,,88.0,YR,,M,Y,,,20220831,,MD,JP,JP,2022,Q3,Elderly
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Renal impairment,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Nephropathy toxic,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Hydronephrosis,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Pneumonia,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Cardiac failure congestive,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Pleural effusion,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207242202,20724220,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 nanogram, qd",,,Y,,Unknown,,,100.0,NG,,QD,2022,Q3,Renal failure,,2022,Q3,2,F,,20220902.0,20220419,20220913,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2022-05698,LUPIN,"Yao C-A, Chen Y-C, Lai C-Y, Lin C-H. Case Report Eefooton adjuvant therapy for diabetic nephropathy, heart failure, and pulmonary effusion: a case report and literature review. International Journal of Clinical and Experimental Medicine. 2022;15(2):68-73",60.0,YR,,M,Y,,,20220913,,HP,TW,TW,2022,Q3,Adult
207413173,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,3,F,,20220801.0,20220422,20220808,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220808,,CN,CA,CA,2022,Q3,Elderly
207413173,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,3,F,,20220801.0,20220422,20220808,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220808,,CN,CA,CA,2022,Q3,Elderly
207413173,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,3,F,,20220801.0,20220422,20220808,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220808,,CN,CA,CA,2022,Q3,Elderly
207413173,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,3,F,,20220801.0,20220422,20220808,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220808,,CN,CA,CA,2022,Q3,Elderly
207413173,20741317,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,3,F,,20220801.0,20220422,20220808,EXP,,CA-PFIZER INC-202200604078,PFIZER,,76.0,YR,,F,Y,,,20220808,,CN,CA,CA,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Adrenal insufficiency,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Blood pressure decreased,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Pyrexia,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Tubulointerstitial nephritis,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Renal impairment,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Adrenocortical insufficiency acute,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Adrenocorticotropic hormone deficiency,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Cortisol decreased,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Malaise,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
208723092,20872309,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,,,,,,,,,,,Tablet,QD,2022,Q3,Decreased appetite,,2022,Q3,2,F,20220405.0,20220804.0,20220525,20220812,EXP,,JP-EMD Serono-9314301,EMD SERONO INC,,70.0,YR,E,M,Y,,,20220812,,MD,JP,,2022,Q3,Elderly
209572443,20957244,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, daily",,,U,,,,,100.0,MG,,QD,2022,Q3,Hypernatraemia,,2022,Q3,3,F,20220401.0,20220816.0,20220614,20220822,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202206002093,ELI LILLY AND CO,,78.0,YR,,M,Y,,,20220822,,CN,JP,JP,2022,Q3,Elderly
209572443,20957244,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, daily",,,U,,,,,100.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,3,F,20220401.0,20220816.0,20220614,20220822,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202206002093,ELI LILLY AND CO,,78.0,YR,,M,Y,,,20220822,,CN,JP,JP,2022,Q3,Elderly
209572443,20957244,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, daily",,,U,,,,,100.0,MG,,QD,2022,Q3,Diabetes mellitus inadequate control,,2022,Q3,3,F,20220401.0,20220816.0,20220614,20220822,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202206002093,ELI LILLY AND CO,,78.0,YR,,M,Y,,,20220822,,CN,JP,JP,2022,Q3,Elderly
209572443,20957244,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, daily",,,U,,,,,100.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,3,F,20220401.0,20220816.0,20220614,20220822,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202206002093,ELI LILLY AND CO,,78.0,YR,,M,Y,,,20220822,,CN,JP,JP,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Restless legs syndrome,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Dizziness,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Blood pressure decreased,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Depression,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Sedation,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209654323,20965432,11,C,"METFORMIN 1000 mg, CANAGLIFLOZIN 150 mg",,2,,,,,,,UNKNOWN,,,,,,,2022,Q3,Fatigue,,2022,Q3,3,F,,20220705.0,20220616,20220713,PER,,US-drreddys-LIT/USA/22/0151100,DR REDDYS,"Amundson C, Knight R, Ybarra G, Turgeon J, Bingham J. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. Medicina (Kaunas). 2022;58(3):1-7. doi:10.3390/medicina58030438",69.0,YR,E,M,Y,,,20220713,,PH,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Restless legs syndrome,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Sedation,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Depression,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Drug level increased,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209665803,20966580,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Blood pressure decreased,,2022,Q3,3,F,,20220913.0,20220616,20220918,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-08623,LUPIN,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: A case report. Medicina (Kaunas). 2022;58(3):1-7",69.0,YR,,M,Y,,,20220918,,HP,US,US,2022,Q3,Elderly
209722982,20972298,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Metformin 1 g/Canagliflozin 50 mg,,,D,,,,204353.0,,,Tablet,Q12H,2022,Q3,Fournier's gangrene,,2022,Q3,2,F,20190901.0,20220607.0,20220616,20220701,EXP,,ES-JNJFOC-20220620103,JOHNSON AND JOHNSON,,84.0,YR,E,F,Y,,,20220701,,HP,ES,ES,2022,Q3,Elderly
210250072,21025007,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Blood pressure increased,,2022,Q3,2,F,20211002.0,20220715.0,20220629,20220720,EXP,,NVSJ2022JP093041,NOVARTIS,,38.0,YR,,F,Y,,,20220721,,MD,JP,JP,2022,Q3,Adult
210250072,21025007,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,2,F,20211002.0,20220715.0,20220629,20220720,EXP,,NVSJ2022JP093041,NOVARTIS,,38.0,YR,,F,Y,,,20220721,,MD,JP,JP,2022,Q3,Adult
210250072,21025007,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,2,F,20211002.0,20220715.0,20220629,20220720,EXP,,NVSJ2022JP093041,NOVARTIS,,38.0,YR,,F,Y,,,20220721,,MD,JP,JP,2022,Q3,Adult
210250072,21025007,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Ovarian cancer,,2022,Q3,2,F,20211002.0,20220715.0,20220629,20220720,EXP,,NVSJ2022JP093041,NOVARTIS,,38.0,YR,,F,Y,,,20220721,,MD,JP,JP,2022,Q3,Adult
210250072,21025007,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Dyslipidaemia,,2022,Q3,2,F,20211002.0,20220715.0,20220629,20220720,EXP,,NVSJ2022JP093041,NOVARTIS,,38.0,YR,,F,Y,,,20220721,,MD,JP,JP,2022,Q3,Adult
210342121,21034212,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Acquired haemophilia,,2022,Q3,1,I,20220502.0,20220628.0,20220701,20220701,EXP,,JP-SA-2022SA248441,SANOFI AVENTIS,,69.0,YR,E,F,Y,52.1,KG,20220701,,PH,JP,JP,2022,Q3,Elderly
210361702,21036170,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,at 100 mg/day gradually increased to 300 mg/day,,,U,,,,,100.0,MG,,,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,2,F,,20220706.0,20220701,20220712,EXP,,CA-BAUSCH-BL-2022-016780,BAUSCH AND LOMB,"Shamchuk A, Doulla M, Jetha M. Possible association between diabetic ketoacidosis and use of a sodium-glucose co-transporter 2 inhibitor in a 17-year-old man with type 2 diabetes. CMAJ. 2021 SEP 07;193:E1746-49. doi:10.1503/cmaj.202627-f",17.0,YR,,M,Y,,,20220712,,MD,CA,CA,2022,Q3,Youth
210361702,21036170,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,at 100 mg/day gradually increased to 300 mg/day,,,U,,,,,100.0,MG,,,2022,Q3,Treatment noncompliance,,2022,Q3,2,F,,20220706.0,20220701,20220712,EXP,,CA-BAUSCH-BL-2022-016780,BAUSCH AND LOMB,"Shamchuk A, Doulla M, Jetha M. Possible association between diabetic ketoacidosis and use of a sodium-glucose co-transporter 2 inhibitor in a 17-year-old man with type 2 diabetes. CMAJ. 2021 SEP 07;193:E1746-49. doi:10.1503/cmaj.202627-f",17.0,YR,,M,Y,,,20220712,,MD,CA,CA,2022,Q3,Youth
210361702,21036170,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,at 100 mg/day gradually increased to 300 mg/day,,,U,,,,,300.0,MG,,,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,2,F,,20220706.0,20220701,20220712,EXP,,CA-BAUSCH-BL-2022-016780,BAUSCH AND LOMB,"Shamchuk A, Doulla M, Jetha M. Possible association between diabetic ketoacidosis and use of a sodium-glucose co-transporter 2 inhibitor in a 17-year-old man with type 2 diabetes. CMAJ. 2021 SEP 07;193:E1746-49. doi:10.1503/cmaj.202627-f",17.0,YR,,M,Y,,,20220712,,MD,CA,CA,2022,Q3,Youth
210361702,21036170,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,at 100 mg/day gradually increased to 300 mg/day,,,U,,,,,300.0,MG,,,2022,Q3,Treatment noncompliance,,2022,Q3,2,F,,20220706.0,20220701,20220712,EXP,,CA-BAUSCH-BL-2022-016780,BAUSCH AND LOMB,"Shamchuk A, Doulla M, Jetha M. Possible association between diabetic ketoacidosis and use of a sodium-glucose co-transporter 2 inhibitor in a 17-year-old man with type 2 diabetes. CMAJ. 2021 SEP 07;193:E1746-49. doi:10.1503/cmaj.202627-f",17.0,YR,,M,Y,,,20220712,,MD,CA,CA,2022,Q3,Youth
210501351,21050135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,QD,2022,Q3,Fall,,2022,Q3,1,I,20220101.0,20220628.0,20220706,20220706,EXP,,US-JNJFOC-20220660833,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,99.88,KG,20220707,,CN,US,US,2022,Q3,Elderly
210501351,21050135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,QD,2022,Q3,Upper limb fracture,,2022,Q3,1,I,20220101.0,20220628.0,20220706,20220706,EXP,,US-JNJFOC-20220660833,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,99.88,KG,20220707,,CN,US,US,2022,Q3,Elderly
210501351,21050135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,QD,2022,Q3,Toe amputation,,2022,Q3,1,I,20220101.0,20220628.0,20220706,20220706,EXP,,US-JNJFOC-20220660833,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,99.88,KG,20220707,,CN,US,US,2022,Q3,Elderly
210501351,21050135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,QD,2022,Q3,Gangrene,,2022,Q3,1,I,20220101.0,20220628.0,20220706,20220706,EXP,,US-JNJFOC-20220660833,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,99.88,KG,20220707,,CN,US,US,2022,Q3,Elderly
210501351,21050135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,QD,2022,Q3,Foot fracture,,2022,Q3,1,I,20220101.0,20220628.0,20220706,20220706,EXP,,US-JNJFOC-20220660833,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,99.88,KG,20220707,,CN,US,US,2022,Q3,Elderly
210563171,21056317,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Photosensitivity reaction,,2022,Q3,1,I,20220620.0,20220628.0,20220708,20220708,EXP,,GB-AUROBINDO-AUR-APL-2022-024214,AUROBINDO,,39.0,YR,,F,Y,129.0,KG,20220708,,CN,GB,GB,2022,Q3,Adult
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210605811,21060581,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220629.0,20220708,20220708,EXP,,CA-TEVA-2022-CA-2051648,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220708,,HP,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210613861,21061386,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220629.0,20220709,20220709,EXP,,CA-TEVA-2022-CA-2051641,TEVA,,73.0,YR,E,F,Y,101.0,KG,20220709,,MD,CA,CA,2022,Q3,Elderly
210709691,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220704.0,20220712,20220712,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20220712,,MD,CA,,2022,Q3,Elderly
210709691,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220704.0,20220712,20220712,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20220712,,MD,CA,,2022,Q3,Elderly
210709691,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220704.0,20220712,20220712,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20220712,,MD,CA,,2022,Q3,Elderly
210709691,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220704.0,20220712,20220712,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20220712,,MD,CA,,2022,Q3,Elderly
210709691,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220704.0,20220712,20220712,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20220712,,MD,CA,,2022,Q3,Elderly
210725571,21072557,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20191028.0,20220712,20220712,EXP,,CA-BAUSCH-BL-2022-016523,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20220712,,HP,CA,CA,2022,Q3,Adult
210725571,21072557,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Post streptococcal glomerulonephritis,,2022,Q3,1,I,,20191028.0,20220712,20220712,EXP,,CA-BAUSCH-BL-2022-016523,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20220712,,HP,CA,CA,2022,Q3,Adult
210725571,21072557,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Extradural abscess,,2022,Q3,1,I,,20191028.0,20220712,20220712,EXP,,CA-BAUSCH-BL-2022-016523,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20220712,,HP,CA,CA,2022,Q3,Adult
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Restless legs syndrome,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Blood pressure decreased,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Long QT syndrome,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Depression,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Sedation,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210816881,21081688,16,C,METFORMIN/CANAGLIFLOZIN,,2,Unknown,,,,U,,,,,,,UNK,,2022,Q3,Fatigue,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-TORRENT-00011929,TORRENT,,69.0,YR,E,M,Y,,,20220714,,PH,US,US,2022,Q3,Elderly
210818041,21081804,2,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Tendon rupture,,2022,Q3,1,I,20220406.0,20220706.0,20220714,20220714,EXP,,ES-AstraZeneca-2022A207451,ASTRAZENECA,,20476.0,DY,,M,Y,112.0,KG,20220714,,PH,ES,,2022,Q3,Elderly
210818041,21081804,2,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Injection site swelling,,2022,Q3,1,I,20220406.0,20220706.0,20220714,20220714,EXP,,ES-AstraZeneca-2022A207451,ASTRAZENECA,,20476.0,DY,,M,Y,112.0,KG,20220714,,PH,ES,,2022,Q3,Elderly
210821071,21082107,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Asthma,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-JNJFOC-20220714135,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,,,20220714,,HP,US,US,2022,Q3,Adult
210821071,21082107,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-JNJFOC-20220714135,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,,,20220714,,HP,US,US,2022,Q3,Adult
210821071,21082107,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,U,,,204042.0,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-JNJFOC-20220714135,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,,,20220714,,HP,US,US,2022,Q3,Adult
210821071,21082107,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,U,,,204042.0,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220705.0,20220714,20220714,EXP,,US-JNJFOC-20220714135,JOHNSON AND JOHNSON,,61.0,YR,A,F,Y,,,20220714,,HP,US,US,2022,Q3,Adult
210853022,21085302,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Tonsillectomy,,2022,Q3,2,F,20170215.0,20220721.0,20220714,20220729,EXP,,JP-JNJFOC-20220725228,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20220729,,MD,JP,JP,2022,Q3,Elderly
210853022,21085302,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Off label use,,2022,Q3,2,F,20170215.0,20220721.0,20220714,20220729,EXP,,JP-JNJFOC-20220725228,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20220729,,MD,JP,JP,2022,Q3,Elderly
210853022,21085302,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Glomerular filtration rate decreased,,2022,Q3,2,F,20170215.0,20220721.0,20220714,20220729,EXP,,JP-JNJFOC-20220725228,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20220729,,MD,JP,JP,2022,Q3,Elderly
210888451,21088845,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,,2022,Q3,Cerebral infarction,,2022,Q3,1,I,,20220706.0,20220715,20220715,EXP,,JP-JNJFOC-20220730006,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20220715,,MD,JP,JP,2022,Q3,Elderly
210888451,21088845,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,,2022,Q3,Bacterial infection,,2022,Q3,1,I,,20220706.0,20220715,20220715,EXP,,JP-JNJFOC-20220730006,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20220715,,MD,JP,JP,2022,Q3,Elderly
210888451,21088845,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,Tablet,,2022,Q3,Ketoacidosis,,2022,Q3,1,I,,20220706.0,20220715,20220715,EXP,,JP-JNJFOC-20220730006,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20220715,,MD,JP,JP,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Depression,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Sedation,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Blood pressure decreased,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Dizziness,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Restless legs syndrome,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Long QT syndrome,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210932141,21093214,18,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"1 dosage form, qd",,,D,,,,,,,,QD,2022,Q3,Fatigue,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-CIPLA LTD.-2022US04334,CIPLA,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina (Kaunas). 2022;58(3):438",69.0,YR,,M,Y,,,20220718,,PH,US,US,2022,Q3,Elderly
210999543,21099954,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Polyp,,2022,Q3,3,F,20220601.0,20220808.0,20220719,20220812,EXP,,NVSJ2022JP093985,NOVARTIS,,62.0,YR,,M,Y,,,20220812,,MD,JP,JP,2022,Q3,Adult
211185961,21118596,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,12,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211185961,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220718.0,20220722,20220722,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220722,,HP,CA,CA,2022,Q3,Elderly
211227661,21122766,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,100.0,MG,Tablet,,2022,Q3,Myopathy toxic,,2022,Q3,1,I,,20220715.0,20220723,20220723,EXP,CA-MHPD-E2B_04438537,CA-Accord-270184,ACCORD,,76.0,YR,E,F,Y,,,20220723,,MD,CA,CA,2022,Q3,Elderly
211227661,21122766,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,100.0,MG,Tablet,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220715.0,20220723,20220723,EXP,CA-MHPD-E2B_04438537,CA-Accord-270184,ACCORD,,76.0,YR,E,F,Y,,,20220723,,MD,CA,CA,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Cardiac failure chronic,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Renal ischaemia,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Blood pressure decreased,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Oedema,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Oedema peripheral,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Oliguria,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Renal impairment,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Renal failure,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Hypervolaemia,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211308862,21130886,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q3,Weight increased,,2022,Q3,2,F,20220401.0,20220728.0,20220726,20220803,EXP,,NVSJ2022JP090772,NOVARTIS,,83.0,YR,,M,Y,59.0,KG,20220804,,MD,JP,JP,2022,Q3,Elderly
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Eructation,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Diarrhoea,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Epigastric discomfort,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Abdominal distension,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211335841,21133584,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,50700.0,MG,Y,,146220205,,,300.0,MG,Tablet,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220622.0,20220718.0,20220726,20220726,EXP,,CN-AstraZeneca-2022A262971,ASTRAZENECA,,58.0,YR,,F,Y,52.0,KG,20220726,,MD,CN,,2022,Q3,Adult
211348131,21134813,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Escherichia sepsis,,2022,Q3,1,I,20220114.0,20220722.0,20220727,20220727,EXP,IT-MINISAL02-876568,IT-JNJFOC-20220745913,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,60.0,KG,20220727,,MD,IT,IT,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211371121,21137112,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264844,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Intentional product use issue,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Cough,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211377821,21137782,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,1,I,,20220719.0,20220727,20220727,EXP,,CA-AstraZeneca-2022A264798,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20220727,,MD,CA,,2022,Q3,Elderly
211398402,21139840,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Hepatic function abnormal,,2022,Q3,2,F,20220712.0,20220802.0,20220728,20220808,EXP,,JP-JNJFOC-20220754034,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220808,,MD,JP,JP,2022,Q3,Child
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Nasopharyngitis,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Kidney infection,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Oxygen saturation decreased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Cystitis,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Heart rate increased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Lower respiratory tract infection,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure increased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Arthralgia,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Vascular stenosis,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Breast disorder,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Rheumatoid arthritis,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Fibromyalgia,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Steroid diabetes,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Hypothyroidism,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Intercepted medication error,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Contusion,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Finger deformity,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Nodule,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Pain,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211423041,21142304,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Fall,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-079384,BRISTOL MYERS SQUIBB,,67.0,YR,E,F,Y,69.0,KG,20220728,,CN,CA,CA,2022,Q3,Elderly
211439481,21143948,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,CA-MHPD-E2B_04580989,CA-Accord-271102,ACCORD,,48.0,YR,A,F,Y,,,20220728,,HP,CA,CA,2022,Q3,Adult
211439481,21143948,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Abdominal pain,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,CA-MHPD-E2B_04580989,CA-Accord-271102,ACCORD,,48.0,YR,A,F,Y,,,20220728,,HP,CA,CA,2022,Q3,Adult
211439481,21143948,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Haematochezia,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,CA-MHPD-E2B_04580989,CA-Accord-271102,ACCORD,,48.0,YR,A,F,Y,,,20220728,,HP,CA,CA,2022,Q3,Adult
211439481,21143948,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Therapeutic response shortened,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,CA-MHPD-E2B_04580989,CA-Accord-271102,ACCORD,,48.0,YR,A,F,Y,,,20220728,,HP,CA,CA,2022,Q3,Adult
211439481,21143948,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220722.0,20220728,20220728,EXP,CA-MHPD-E2B_04580989,CA-Accord-271102,ACCORD,,48.0,YR,A,F,Y,,,20220728,,HP,CA,CA,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Nausea,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Urine abnormality,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Abnormal faeces,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Renal impairment,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Proteinuria,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Dysuria,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211455531,21145553,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,,,Tablet,,2022,Q3,Pollakiuria,,2022,Q3,1,I,20200101.0,20220727.0,20220729,20220729,EXP,DK-DKMA-ADR 27084589,DK-JNJFOC-20220757351,JOHNSON AND JOHNSON,,59.0,YR,A,F,Y,,,20220729,,LW,DK,DK,2022,Q3,Adult
211456221,21145622,10,C,VOKANAMET [CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE],,2,,UNK,,,,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,20220702.0,20220722.0,20220729,20220729,EXP,IT-MINISAL02-875455,IT-009507513-2207ITA007248,MERCK,,50.0,YR,,F,Y,,,20220729,,MD,IT,IT,2022,Q3,Adult
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fall,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure increased,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Vascular stenosis,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Kidney infection,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Intercepted medication error,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hypothyroidism,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Cystitis,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Contusion,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nodule,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Lower respiratory tract infection,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Finger deformity,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Heart rate increased,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fibromyalgia,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Steroid diabetes,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Breast disorder,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Rheumatoid arthritis,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211466541,21146654,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Pain,,2022,Q3,1,I,,20220722.0,20220729,20220729,EXP,,CA-ROCHE-3145972,ROCHE,,67.0,YR,,F,Y,69.0,KG,20220729,,HP,CA,,2022,Q3,Elderly
211561951,21156195,5,C,CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE,,1,,,,,,,,,,,,,,2022,Q3,Exposure during pregnancy,,2022,Q3,1,I,20211201.0,20220722.0,20220801,20220801,EXP,,CH-JNJFOC-20211132313,JOHNSON AND JOHNSON,,35.0,YR,A,F,Y,,,20220801,,MD,CH,CH,2022,Q3,Adult
211561951,21156195,5,C,CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE,,1,,,,,,,,,,,,,,2022,Q3,Abortion spontaneous,,2022,Q3,1,I,20211201.0,20220722.0,20220801,20220801,EXP,,CH-JNJFOC-20211132313,JOHNSON AND JOHNSON,,35.0,YR,A,F,Y,,,20220801,,MD,CH,CH,2022,Q3,Adult
211577342,21157734,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,22,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,22,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,22,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,22,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211577342,21157734,22,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,2,F,,20220802.0,20220801,20220804,EXP,,CA-PFIZER INC-202201018350,PFIZER,,76.0,YR,,F,Y,,,20220804,,HP,CA,CA,2022,Q3,Elderly
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Depression,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211604103,21160410,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,3,F,,20220829.0,20220802,20220912,EXP,CA-MHPD-E2B_04528744,CA-Accord-271138,ACCORD,,51.0,YR,A,F,Y,,,20220912,,HP,CA,CA,2022,Q3,Adult
211635702,21163570,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,204042.0,,,Tablet,,2022,Q3,Dialysis,,2022,Q3,2,F,,20220804.0,20220802,20220811,EXP,,JP-JNJFOC-20220802794,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20220811,,PH,JP,JP,2022,Q3,Adult
211635762,21163576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Diabetic complication neurological,,2022,Q3,2,F,,20220808.0,20220802,20220817,EXP,,JP-JNJFOC-20220802793,JOHNSON AND JOHNSON,,39.0,YR,A,F,Y,,,20220817,,MD,JP,JP,2022,Q3,Adult
211635762,21163576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Retinopathy proliferative,,2022,Q3,2,F,,20220808.0,20220802,20220817,EXP,,JP-JNJFOC-20220802793,JOHNSON AND JOHNSON,,39.0,YR,A,F,Y,,,20220817,,MD,JP,JP,2022,Q3,Adult
211635762,21163576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Nephropathy,,2022,Q3,2,F,,20220808.0,20220802,20220817,EXP,,JP-JNJFOC-20220802793,JOHNSON AND JOHNSON,,39.0,YR,A,F,Y,,,20220817,,MD,JP,JP,2022,Q3,Adult
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Platelet count decreased,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Respiratory failure,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Hyperglycaemia,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Pneumonia,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Immune-mediated lung disease,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211689672,21168967,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,0.1,GM,Tablet,QD,2022,Q3,Dyspnoea,,2022,Q3,2,F,20220513.0,20220809.0,20220803,20220813,EXP,,CN-ROCHE-3097820,ROCHE,,68.0,YR,,M,Y,58.0,KG,20220814,,MD,CN,,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Multiple drug therapy,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211771511,21177151,19,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,"UNK UNK, qd ( 150 mg/1000 mg)",,,D,,,,,,,,,2022,Q3,Sedation,,2022,Q3,1,I,,20220603.0,20220805,20220805,PER,,US-APOTEX-2022AP008868,APOTEX,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for ResistantMajor Depressive Disorder: A Case Report. Medicina. 2022;58 (3):438",69.0,YR,,M,Y,,,20220805,,HP,US,US,2022,Q3,Elderly
211819248,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q3,Acute kidney injury,,2022,Q3,8,F,20220729.0,20220916.0,20220807,20220922,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20220922,,MD,TW,,2022,Q3,Elderly
211819248,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q3,Pneumonia,,2022,Q3,8,F,20220729.0,20220916.0,20220807,20220922,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20220922,,MD,TW,,2022,Q3,Elderly
211819248,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q3,Hyperglycaemia,,2022,Q3,8,F,20220729.0,20220916.0,20220807,20220922,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20220922,,MD,TW,,2022,Q3,Elderly
211819248,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q3,Acute kidney injury,,2022,Q3,8,F,20220729.0,20220916.0,20220807,20220922,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20220922,,MD,TW,,2022,Q3,Elderly
211838361,21183836,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,,20220729.0,20220808,20220808,EXP,,IN-ROCHE-3131563,ROCHE,,56.0,YR,,F,Y,,,20220808,,CN,IN,,2022,Q3,Adult
211838361,21183836,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Dehydration,,2022,Q3,1,I,,20220729.0,20220808,20220808,EXP,,IN-ROCHE-3131563,ROCHE,,56.0,YR,,F,Y,,,20220808,,CN,IN,,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Off label use,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Arthralgia,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Intentional product use issue,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Infusion site extravasation,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Carpal tunnel syndrome,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211910141,21191014,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220731.0,20220809,20220809,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-19073,SAMSUNG BIOEPIS,,63.0,YR,A,F,Y,92.0,KG,20220809,,HP,CA,CA,2022,Q3,Adult
211982471,21198247,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220802.0,20220811,20220811,EXP,,IN-JNJFOC-20220807237,JOHNSON AND JOHNSON,,45.0,YR,A,F,Y,,,20220811,,,COUNTRY NOT SPECIFIED,IN,2022,Q3,Adult
212008621,21200862,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220802.0,20220811,20220811,EXP,,IN-EMD Serono-9341878,EMD SERONO INC,"Vadi S, Bajpe S, Kulkarni N. Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels, and Recalcitrant Metabolic Acidosis Requiring Rescue Hemodialysis in a Patient of COVID-19 Infection.. Indian Journal of Critical Care Medicine. 2022 JUN 01;26 (6):752-754. doi:10.5005/jp-journals-10071-24257",45.0,YR,A,F,Y,,,20220811,,HP,IN,,2022,Q3,Adult
212012792,21201279,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd, HS",,,,,,,,100.0,MG,,QD,2022,Q3,Hypoglycaemia,,2022,Q3,2,F,20190104.0,20220906.0,20220811,20220915,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005977,AEGERION,,12.0,YR,,F,Y,42.8,KG,20220915,,HP,US,US,2022,Q3,Child
212012792,21201279,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd, HS",,,,,,,,100.0,MG,,QD,2022,Q3,Treatment noncompliance,,2022,Q3,2,F,20190104.0,20220906.0,20220811,20220915,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005977,AEGERION,,12.0,YR,,F,Y,42.8,KG,20220915,,HP,US,US,2022,Q3,Child
212039781,21203978,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,Tablet,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220808.0,20220810.0,20220811,20220811,EXP,,GB-JNJFOC-20220822832,JOHNSON AND JOHNSON,,62.0,YR,A,M,Y,74.0,KG,20220812,,HP,GB,GB,2022,Q3,Adult
212046752,21204675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,2,F,,20220808.0,20220812,20220819,EXP,,CA-BAUSCH-BL-2022-019855,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220819,,CN,CA,CA,2022,Q3,Elderly
212046752,21204675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,2,F,,20220808.0,20220812,20220819,EXP,,CA-BAUSCH-BL-2022-019855,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220819,,CN,CA,CA,2022,Q3,Elderly
212046752,21204675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,2,F,,20220808.0,20220812,20220819,EXP,,CA-BAUSCH-BL-2022-019855,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220819,,CN,CA,CA,2022,Q3,Elderly
212046752,21204675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,2,F,,20220808.0,20220812,20220819,EXP,,CA-BAUSCH-BL-2022-019855,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220819,,CN,CA,CA,2022,Q3,Elderly
212046752,21204675,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,2,F,,20220808.0,20220812,20220819,EXP,,CA-BAUSCH-BL-2022-019855,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20220819,,CN,CA,CA,2022,Q3,Elderly
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein abnormal,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug hypersensitivity,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect decreased,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Osteolysis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal infection,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hand deformity,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Rheumatoid arthritis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Pain,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Psoriatic arthropathy,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug intolerance,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Bone erosion,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Treatment failure,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Upper respiratory tract infection,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic steatosis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Therapeutic product effect incomplete,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Joint swelling,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Drug-induced liver injury,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Joint ankylosis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Localised infection,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,C-reactive protein increased,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Anti-cyclic citrullinated peptide antibody positive,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Skin injury,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Infection,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Pruritus,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Red blood cell sedimentation rate abnormal,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Abdominal discomfort,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Synovitis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Arthropathy,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Arthralgia,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Hepatic fibrosis,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Transaminases increased,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Bone cyst,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Dyspepsia,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Nausea,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212061471,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q3,Alanine aminotransferase abnormal,,2022,Q3,1,I,,20220730.0,20220812,20220812,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20220812,,HP,CA,CA,2022,Q3,Adult
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Obesity,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Renal failure,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Productive cough,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212086211,21208621,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,100.0,MG,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220808.0,20220812,20220812,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186572",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,128.0,KG,20220812,,HP,CA,CA,2022,Q3,Elderly
212087762,21208776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Perineal abscess,,2022,Q3,2,F,,20220829.0,20220812,20220902,EXP,,JP-JNJFOC-20220825607,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220902,,MD,JP,JP,2022,Q3,Child
212087772,21208777,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,Tablet,,2022,Q3,Glomerular filtration rate abnormal,,2022,Q3,2,F,,20220826.0,20220812,20220902,EXP,,JP-JNJFOC-20220825606,JOHNSON AND JOHNSON,,84.0,YR,E,,Y,,,20220902,,PH,JP,JP,2022,Q3,Elderly
212094243,21209424,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,150.0,MG,Tablet,,2022,Q3,Coronary artery disease,,2022,Q3,3,F,20220731.0,20220908.0,20220813,20220916,EXP,,PL-JNJFOC-20220810171,JOHNSON AND JOHNSON,,64.0,YR,A,F,Y,93.0,KG,20220916,,MD,PL,PL,2022,Q3,Adult
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Obesity,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Renal failure,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Productive cough,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212147981,21214798,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220812.0,20220816,20220816,EXP,,CA-BAUSCH-BL-2022-020150,BAUSCH AND LOMB,,70.0,YR,,M,Y,128.0,KG,20220816,,HP,CA,CA,2022,Q3,Elderly
212233381,21223338,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, 50mg/1g twice a day",,,Y,U,,,,,,Tablet,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220814.0,20220817,20220817,EXP,,GB-MYLANLABS-2022M1086800,MYLAN,,54.0,YR,,,Y,,,20220817,,HP,GB,GB,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212243712,21224371,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,2,F,,20220812.0,20220817,20220819,EXP,,CA-BAUSCH-BL-2022-020141,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212256251,21225625,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Headache,,2022,Q3,1,I,20220812.0,20220816.0,20220818,20220818,PER,,US-JNJFOC-20220833240,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,64.014,KG,20220818,,CN,US,US,2022,Q3,Elderly
212256251,21225625,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,COVID-19,,2022,Q3,1,I,20220812.0,20220816.0,20220818,20220818,PER,,US-JNJFOC-20220833240,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,64.014,KG,20220818,,CN,US,US,2022,Q3,Elderly
212268871,21226887,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-TAKEDA-2022TUS056526,TAKEDA,,76.0,YR,,F,Y,,,20220818,,CN,CA,CA,2022,Q3,Elderly
212268871,21226887,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-TAKEDA-2022TUS056526,TAKEDA,,76.0,YR,,F,Y,,,20220818,,CN,CA,CA,2022,Q3,Elderly
212268871,21226887,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-TAKEDA-2022TUS056526,TAKEDA,,76.0,YR,,F,Y,,,20220818,,CN,CA,CA,2022,Q3,Elderly
212268871,21226887,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-TAKEDA-2022TUS056526,TAKEDA,,76.0,YR,,F,Y,,,20220818,,CN,CA,CA,2022,Q3,Elderly
212268871,21226887,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-TAKEDA-2022TUS056526,TAKEDA,,76.0,YR,,F,Y,,,20220818,,CN,CA,CA,2022,Q3,Elderly
212272741,21227274,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,,2022,Q3,Tooth disorder,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-ROCHE-3160731,ROCHE,,52.0,YR,,F,Y,108.0,KG,20220818,,HP,CA,,2022,Q3,Adult
212272741,21227274,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,,2022,Q3,Gastrointestinal disorder,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-ROCHE-3160731,ROCHE,,52.0,YR,,F,Y,108.0,KG,20220818,,HP,CA,,2022,Q3,Adult
212272741,21227274,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,,2022,Q3,Polypectomy,,2022,Q3,1,I,,20220812.0,20220818,20220818,EXP,,CA-ROCHE-3160731,ROCHE,,52.0,YR,,F,Y,108.0,KG,20220818,,HP,CA,,2022,Q3,Adult
212275571,21227557,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",800.0,MG,N,,,,204042.0,100.0,MG,Tablet,QD,2022,Q3,Liver disorder,,2022,Q3,1,I,20220808.0,20220810.0,20220818,20220818,EXP,,JP-JNJFOC-20220834389,JOHNSON AND JOHNSON,,9.0,DEC,E,F,Y,,,20220818,,MD,JP,JP,2022,Q3,Child
212303301,21230330,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2022,Q3,Pneumonia,,2022,Q3,1,I,,20220809.0,20220818,20220818,EXP,,JP-009507513-2208JPN006233,MERCK,,6.0,DEC,,M,Y,,,20220818,,MD,JP,JP,2022,Q3,Child
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212316171,21231617,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220809.0,20220819,20220819,EXP,,CA-AUROBINDO-AUR-APL-2022-032512,AUROBINDO,,51.0,YR,,F,Y,,,20220819,,HP,CA,CA,2022,Q3,Adult
212317191,21231719,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,50mg/1g twice a day,,,Y,U,,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220814.0,20220819,20220819,EXP,,GB-EMD Serono-E2B_90088740,EMD SERONO INC,,54.0,YR,A,,Y,,,20220819,,HP,GB,,2022,Q3,Adult
212321811,21232181,2,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,1.0 COMP BEFORE BREAKFAST AND DINNER; 60 tablets,,,,,,,,,,Film-coated tablet,,2022,Q3,Renal disorder,,2022,Q3,1,I,20220802.0,20220816.0,20220819,20220819,EXP,ES-AEMPS-1243626,ES-009507513-2208ESP006440,MERCK,,68.0,YR,,M,Y,,,20220819,,PH,ES,ES,2022,Q3,Elderly
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346081,21234608,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032499,AUROBINDO,,51.0,YR,,F,Y,,,20220820,,CN,CA,CA,2022,Q3,Adult
212346561,21234656,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032517,AUROBINDO,,79.0,YR,,F,Y,,,20220820,,HP,CA,CA,2022,Q3,Elderly
212346561,21234656,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032517,AUROBINDO,,79.0,YR,,F,Y,,,20220820,,HP,CA,CA,2022,Q3,Elderly
212346561,21234656,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032517,AUROBINDO,,79.0,YR,,F,Y,,,20220820,,HP,CA,CA,2022,Q3,Elderly
212346561,21234656,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032517,AUROBINDO,,79.0,YR,,F,Y,,,20220820,,HP,CA,CA,2022,Q3,Elderly
212346561,21234656,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220809.0,20220820,20220820,EXP,,CA-AUROBINDO-AUR-APL-2022-032517,AUROBINDO,,79.0,YR,,F,Y,,,20220820,,HP,CA,CA,2022,Q3,Elderly
212368961,21236896,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,unk,,,,,,,2022,Q3,Fall,,2022,Q3,1,I,20220720.0,20220809.0,20220822,20220822,EXP,,JP-NOVOPROD-949626,NOVO NORDISK,,74.0,YR,,M,Y,,,20220822,,MD,JP,JP,2022,Q3,Elderly
212368961,21236896,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,unk,,,,,,,2022,Q3,Death,,2022,Q3,1,I,20220720.0,20220809.0,20220822,20220822,EXP,,JP-NOVOPROD-949626,NOVO NORDISK,,74.0,YR,,M,Y,,,20220822,,MD,JP,JP,2022,Q3,Elderly
212384871,21238487,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220812.0,20220822,20220822,EXP,,CA-PFIZER INC-202201074914,PFIZER,,76.0,YR,,F,Y,,,20220822,,CN,CA,CA,2022,Q3,Elderly
212384871,21238487,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220812.0,20220822,20220822,EXP,,CA-PFIZER INC-202201074914,PFIZER,,76.0,YR,,F,Y,,,20220822,,CN,CA,CA,2022,Q3,Elderly
212384871,21238487,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220812.0,20220822,20220822,EXP,,CA-PFIZER INC-202201074914,PFIZER,,76.0,YR,,F,Y,,,20220822,,CN,CA,CA,2022,Q3,Elderly
212384871,21238487,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220812.0,20220822,20220822,EXP,,CA-PFIZER INC-202201074914,PFIZER,,76.0,YR,,F,Y,,,20220822,,CN,CA,CA,2022,Q3,Elderly
212384871,21238487,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,Unknown,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220812.0,20220822,20220822,EXP,,CA-PFIZER INC-202201074914,PFIZER,,76.0,YR,,F,Y,,,20220822,,CN,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Obesity,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Productive cough,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Renal failure,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212416481,21241648,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032429,AUROBINDO,,70.0,YR,,M,Y,128.0,KG,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212421011,21242101,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220809.0,20220823,20220823,EXP,,CA-AUROBINDO-AUR-APL-2022-032496,AUROBINDO,,76.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
212449121,21244912,80,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,80,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,80,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,80,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,80,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,81,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,81,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,81,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,81,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,81,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,112,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,unk,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,112,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,unk,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,112,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,unk,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,112,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,unk,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,112,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,unk,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,113,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,113,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,113,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,113,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212449121,21244912,113,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220816.0,20220823,20220823,EXP,,CA-ORGANON-O2206CAN002029,ORGANON,,76.0,YR,,F,Y,,,20220823,,MD,CA,CA,2022,Q3,Elderly
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Sinus tachycardia,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Lactic acidosis,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Fluid intake reduced,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Blood ketone body increased,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Acidosis,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212455351,21245535,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q3,Malaise,,2022,Q3,1,I,20220624.0,20220817.0,20220824,20220824,EXP,,NVSJ2022JP096057,NOVARTIS,,51.0,YR,,M,Y,,,20220824,,MD,JP,JP,2022,Q3,Adult
212463731,21246373,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"50mg/1g, Two Times a Day",,,Y,U,,,,,,,BID,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220814.0,20220824,20220824,EXP,,GB-AUROBINDO-AUR-APL-2022-033115,AUROBINDO,,54.0,YR,,,Y,,,20220824,,HP,GB,GB,2022,Q3,Adult
212577811,21257781,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220816.0,20220826,20220826,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2022-10539,LUPIN,"Vadi S, Bajpe S, Kulkarni N. Diabetic Ketoacidosis with lower-than-anticipated glucose Levels, and recalcitrant metabolic acidosis requiring rescue hemodialysis in a patient of COVID-19 infection. Indian Journal of Critical Care Medicine. 2022;26(6):752-754",45.0,YR,,F,Y,,,20220826,,HP,IN,IN,2022,Q3,Adult
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Sedation,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Drug level increased,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Blood pressure decreased,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Restless legs syndrome,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Depression,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212590701,21259070,20,C,CANAGLIFLOZIN;METFORMIN,,1,Unknown,1 dosage form per day,,,D,,,,,,,,,2022,Q3,Off label use,,2022,Q3,1,I,,20220705.0,20220826,20220826,PER,US-MLMSERVICE-20220616-3622677-1,US-STRIDES ARCOLAB LIMITED-2022SP006948,STRIDES,"Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM.. Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.. Medicina-Kaunas. 2022;58(3):438",69.0,YR,,M,Y,,,20220826,,PH,US,US,2022,Q3,Elderly
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Soft tissue injury,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Road traffic accident,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Weight fluctuation,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Disability assessment scale score increased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Cough,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Abdominal pain upper,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Nasal congestion,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Bronchitis,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Lower respiratory tract congestion,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Peripheral swelling,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Nasopharyngitis,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Bladder disorder,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Oropharyngeal pain,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Sinus congestion,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Medication error,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Muscle tightness,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Constipation,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Gastrointestinal disorder,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Swelling face,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Lower respiratory tract infection,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure systolic decreased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Tooth disorder,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212675281,21267528,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220826.0,20220829,20220829,EXP,CA-MHPD-E2B_04997247,CA-Accord-275794,ACCORD,,46.0,YR,A,F,Y,,,20220829,,HP,CA,CA,2022,Q3,Adult
212690671,21269067,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220816.0,20220830,20220830,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352194,RANBAXY,"Vadi S, Bajpe S, Kulkarni N. Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels, and Recalcitrant Metabolic Acidosis Requiring Rescue Hemodialysis in a Patient of COVID-19 Infection. Indian J Crit Care Med. 2022;26(6):752-754",45.0,YR,,F,Y,,,20220830,,HP,IN,IN,2022,Q3,Adult
212690671,21269067,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220816.0,20220830,20220830,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352194,RANBAXY,"Vadi S, Bajpe S, Kulkarni N. Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels, and Recalcitrant Metabolic Acidosis Requiring Rescue Hemodialysis in a Patient of COVID-19 Infection. Indian J Crit Care Med. 2022;26(6):752-754",45.0,YR,,F,Y,,,20220830,,HP,IN,IN,2022,Q3,Adult
212726851,21272685,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220823.0,20220830,20220830,EXP,,CA-AstraZeneca-2022A298012,ASTRAZENECA,,76.0,YR,,F,Y,,,20220831,,MD,CA,,2022,Q3,Elderly
212726851,21272685,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220823.0,20220830,20220830,EXP,,CA-AstraZeneca-2022A298012,ASTRAZENECA,,76.0,YR,,F,Y,,,20220831,,MD,CA,,2022,Q3,Elderly
212726851,21272685,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220823.0,20220830,20220830,EXP,,CA-AstraZeneca-2022A298012,ASTRAZENECA,,76.0,YR,,F,Y,,,20220831,,MD,CA,,2022,Q3,Elderly
212726851,21272685,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220823.0,20220830,20220830,EXP,,CA-AstraZeneca-2022A298012,ASTRAZENECA,,76.0,YR,,F,Y,,,20220831,,MD,CA,,2022,Q3,Elderly
212726851,21272685,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220823.0,20220830,20220830,EXP,,CA-AstraZeneca-2022A298012,ASTRAZENECA,,76.0,YR,,F,Y,,,20220831,,MD,CA,,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Productive cough,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Obesity,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Renal failure,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
212921401,21292140,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220824.0,20220904,20220904,EXP,,CA-SANOFI US-2022SA356329,SANOFI AVENTIS,,70.0,YR,E,M,Y,128.0,KG,20220905,,HP,CA,CA,2022,Q3,Elderly
213102711,21310271,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,Unknown,,,,,UNK,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220831.0,20220909,20220909,EXP,,IN-GRANULES-IN-2022GRALIT00218,GRANULES INDIA,"Sonali Vadi.Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels, and Recalcitrant Metabolic Acidosis Requiring Rescue Hemodialysis in a Patient of COVID-19 Infection.Indian journal of critical care medicine.JUN-2022;26:752-754",45.0,YR,A,F,Y,,,20220909,,HP,IN,IN,2022,Q3,Adult
213164811,21316481,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,,,,,,100.0,MG,UNK,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,20180725.0,20220901.0,20220910,20220910,EXP,,JP-ABBVIE-22P-087-4533465-00,ABBVIE,,34.0,YR,,M,Y,70.3,KG,20220909,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Young Adult
213211162,21321116,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,U,,,204042.0,100.0,MG,Tablet,,2022,Q3,Thyroiditis subacute,,2022,Q3,2,F,,20220912.0,20220912,20220921,EXP,,JP-JNJFOC-20220917047,JOHNSON AND JOHNSON,"Kinoshita, Miyu; Azuma, Koichiro; Yanagawa, Tatsuo.A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis.Journal of Clinical and Translational Endocrinology: Case Reports.2022;25",55.0,YR,A,M,Y,,,20220921,,MD,JP,JP,2022,Q3,Adult
213211162,21321116,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,U,,,204042.0,100.0,MG,Tablet,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,2,F,,20220912.0,20220912,20220921,EXP,,JP-JNJFOC-20220917047,JOHNSON AND JOHNSON,"Kinoshita, Miyu; Azuma, Koichiro; Yanagawa, Tatsuo.A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis.Journal of Clinical and Translational Endocrinology: Case Reports.2022;25",55.0,YR,A,M,Y,,,20220921,,MD,JP,JP,2022,Q3,Adult
213245341,21324534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,Tablet,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20211004.0,20220912,20220912,EXP,,JP-JNJFOC-20210912426,JOHNSON AND JOHNSON,,75.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213286661,21328666,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-AstraZeneca-2022A308823,ASTRAZENECA,,51.0,YR,,F,Y,,,20220913,,MD,CA,,2022,Q3,Adult
213302841,21330284,2,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Uterine spasm,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-BAYER-2022A124708,BAYER,,35.0,YR,A,F,Y,141.0,KG,20220913,,HP,CA,CA,2022,Q3,Adult
213302841,21330284,2,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Urticaria,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-BAYER-2022A124708,BAYER,,35.0,YR,A,F,Y,141.0,KG,20220913,,HP,CA,CA,2022,Q3,Adult
213302841,21330284,2,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Haemorrhage,,2022,Q3,1,I,,20220905.0,20220913,20220913,EXP,,CA-BAYER-2022A124708,BAYER,,35.0,YR,A,F,Y,141.0,KG,20220913,,HP,CA,CA,2022,Q3,Adult
213311191,21331119,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,Tablet,,2022,Q3,Heat illness,,2022,Q3,1,I,,20220905.0,20220914,20220914,EXP,,JP-JNJFOC-20220925165,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220914,,MD,JP,JP,2022,Q3,Adult
213311191,21331119,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,Tablet,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220905.0,20220914,20220914,EXP,,JP-JNJFOC-20220925165,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20220914,,MD,JP,JP,2022,Q3,Adult
213410291,21341029,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,Unknown,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220905.0,20220916,20220916,EXP,,IN-EPICPHARMA-IN-2022EPCLIT01300,EPIC PHARM,"Vadi S.Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels, and Recalcitrant Metabolic Acidosis Requiring Rescue Hemodialysis in a Patient of COVID-19 Infection.Indian journal of critical care medicine.JUN-2022;26:752-754",45.0,YR,A,F,Y,,,20220916,,HP,IN,IN,2022,Q3,Adult
213538421,21353842,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,CA-TEVA-2022-CA-2073937,TEVA,,78.0,YR,E,F,Y,,,20220920,,CN,CA,CA,2022,Q3,Elderly
213538421,21353842,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,,,2022,Q3,Asthma,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,CA-TEVA-2022-CA-2073937,TEVA,,78.0,YR,E,F,Y,,,20220920,,CN,CA,CA,2022,Q3,Elderly
213538421,21353842,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,,,2022,Q3,Full blood count abnormal,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,CA-TEVA-2022-CA-2073937,TEVA,,78.0,YR,E,F,Y,,,20220920,,CN,CA,CA,2022,Q3,Elderly
213538421,21353842,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,CA-TEVA-2022-CA-2073937,TEVA,,78.0,YR,E,F,Y,,,20220920,,CN,CA,CA,2022,Q3,Elderly
213538421,21353842,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,CA-TEVA-2022-CA-2073937,TEVA,,78.0,YR,E,F,Y,,,20220920,,CN,CA,CA,2022,Q3,Elderly
213653421,21365342,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,Unknown,,2022,Q3,Death,,2022,Q3,1,I,20220918.0,20220921.0,20220922,20220922,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-109812,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,100.0,KG,20220922,,HP,CA,CA,2022,Q3,Elderly
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Hypoacusis,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Sleep disorder due to a general medical condition,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Wheezing,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Asthma,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213756431,21375643,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,,,Tablet,,2022,Q3,Loss of personal independence in daily activities,,2022,Q3,1,I,,20220916.0,20220926,20220926,EXP,,CA-TEVA-2022-CA-2075477,TEVA,,51.0,YR,A,F,Y,,,20220926,,HP,CA,CA,2022,Q3,Adult
213806711,21380671,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 mg, qd",,,Y,,,,,100.0,MG,,QD,2022,Q3,Hypokalaemia,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213806711,21380671,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 mg, qd",,,Y,,,,,100.0,MG,,QD,2022,Q3,Intestinal obstruction,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213806711,21380671,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 mg, qd",,,Y,,,,,100.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213806711,21380671,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK (resumed),,,Y,,,,,,,,,2022,Q3,Hypokalaemia,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213806711,21380671,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK (resumed),,,Y,,,,,,,,,2022,Q3,Intestinal obstruction,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213806711,21380671,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK (resumed),,,Y,,,,,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220914.0,20220927,20220927,EXP,,CN-NOVOPROD-959810,NOVO NORDISK,Hong Bo Wei Lihong. A case of euglycemic diabetic ketoacidosis induced by canagliflozin. Zhejiang Medicine Journal. 44(12),39.0,YR,,M,Y,,,20220927,,HP,CN,CN,2022,Q3,Adult
213850361,21385036,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 milligram, unk",,,U,,,,,100.0,MG,,,2022,Q3,Treatment noncompliance,,2022,Q3,1,I,,20220914.0,20220928,20220928,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-355972,RANBAXY,"Kinoshita M, Azuma K, Yanagawa T.. A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis. J Clin Transl Endocrinol Case Rep. 2022;25:100124",55.0,YR,,M,Y,,,20220928,,HP,JP,JP,2022,Q3,Adult
213850361,21385036,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 milligram, unk",,,U,,,,,100.0,MG,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220914.0,20220928,20220928,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-355972,RANBAXY,"Kinoshita M, Azuma K, Yanagawa T.. A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis. J Clin Transl Endocrinol Case Rep. 2022;25:100124",55.0,YR,,M,Y,,,20220928,,HP,JP,JP,2022,Q3,Adult
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Productive cough,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Renal failure,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Obesity,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213913111,21391311,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,U,,,,,100.0,MG,,,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220921.0,20220929,20220929,EXP,,CA-JNJFOC-20220425229,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,128.0,KG,20220929,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Productive cough,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Deep vein thrombosis,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Lung disorder,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Mycobacterial infection,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Renal failure,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Bronchiectasis,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Obesity,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Pulmonary embolism,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Multiple allergies,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Asthma-chronic obstructive pulmonary disease overlap syndrome,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
213965421,21396542,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,CA-TEVA-2022-CA-2076924,TEVA,,70.0,YR,E,M,Y,128.0,KG,20220930,,HP,CA,CA,2022,Q3,Elderly
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Therapeutic response decreased,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Liver disorder,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
1231249417,12312494,90,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,17,F,20090209.0,20221220.0,20160428,20221227,PER,,CA-AMGEN-CANSP2016039095,AMGEN,,57.0,YR,A,M,Y,,,20221227,,HP,CA,CA,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Liver disorder,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic response decreased,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Product use issue,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
123262568,12326256,52,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,8,F,,20221121.0,20160503,20221123,EXP,,CA-ROCHE-1750136,ROCHE,,50.0,YR,,M,Y,,,20221123,,HP,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Liver disorder,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic response decreased,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
1307079914,13070799,111,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,14,F,20090209.0,20221227.0,20161229,20221230,EXP,,CA-Orion Corporation ORION PHARMA-TREX2016-2790,ORION,,57.0,YR,A,M,Y,,,20221230,,MD,CA,,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Product use issue,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Liver disorder,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Joint space narrowing,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Therapeutic response decreased,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
131226566,13122656,70,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,6,F,20060101.0,20221128.0,20170117,20221206,EXP,,CA-SA-2016SA086812,SANOFI AVENTIS,,50.0,YR,A,M,Y,,,20221206,,MD,CA,CA,2022,Q4,Adult
1445851814,14458518,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,40,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
1445851814,14458518,41,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,14,F,,20221014.0,20180130,20221021,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20221021,,MD,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,45,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,46,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
155469666,15546966,47,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221218.0,20181024,20221226,EXP,,CA-TEVA-2018-CA-967835,TEVA,,76.0,YR,E,F,Y,,,20221226,,CN,CA,CA,2022,Q4,Elderly
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Liver disorder,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Therapeutic response decreased,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Product use issue,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
1556724816,15567248,92,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Unit=Not Available),,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,16,F,20090209.0,20221220.0,20181030,20221229,EXP,,CA-PFIZER INC-2016181292,PFIZER,,57.0,YR,,M,Y,,,20221229,,MD,CA,CA,2022,Q4,Adult
169390672,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Extradural abscess,,2022,Q4,2,F,,20221124.0,20191020,20221128,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-108533",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20221128,,HP,CA,CA,2022,Q4,Adult
169390672,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Post streptococcal glomerulonephritis,,2022,Q4,2,F,,20221124.0,20191020,20221128,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-108533",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20221128,,HP,CA,CA,2022,Q4,Adult
169390672,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221124.0,20191020,20221128,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-108533",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20221128,,HP,CA,CA,2022,Q4,Adult
1719352811,17193528,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,104,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,104,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,104,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,104,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,104,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,125,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,125,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,125,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,125,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,125,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,126,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,126,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,126,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,126,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,126,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,127,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,127,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,127,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,127,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
1719352811,17193528,127,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,11,F,,20221226.0,20191223,20221230,EXP,,CA-BAUSCH-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,CN,CA,CA,2022,Q4,Elderly
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Eyelid infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Musculoskeletal pain,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Fungal infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Pain in extremity,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Neuralgia,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Ear disorder,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Influenza,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Sepsis,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Viral infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Neck pain,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Sinusitis,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Therapeutic response shortened,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Malaise,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Ear infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Blood pressure systolic increased,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Bronchitis,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Tympanic membrane perforation,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Weight increased,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Constipation,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Urinary tract infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Polyp,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Paranasal cyst,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Hypotension,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Tinnitus,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Kidney infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Localised infection,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
172368295,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Cough,,2022,Q4,5,F,,20221010.0,20200106,20221020,EXP,,CA-PFIZER INC-2019561414,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Incorrect dose administered,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Blood pressure systolic increased,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Weight increased,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Intentional product use issue,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Off label use,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Blood pressure diastolic decreased,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Blood pressure increased,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Weight decreased,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
176941417,17694141,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,300.0,MG,,QD,2022,Q4,Anal fistula,,2022,Q4,7,F,,20221214.0,20200422,20221221,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-13473,SAMSUNG BIOEPIS,,62.0,YR,A,M,Y,106.0,KG,20221221,,MD,CA,CA,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Malaise,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Blood pressure systolic increased,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Heart rate increased,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Weight increased,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Ear disorder,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Constipation,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Influenza,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Paranasal cyst,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic response shortened,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Viral infection,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Neuralgia,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Polyp,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Sinusitis,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Ear infection,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hypotension,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Tinnitus,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal pain,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bronchitis,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pain in extremity,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Eyelid infection,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Tympanic membrane perforation,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Weight decreased,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Neck pain,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
179072093,17907209,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,3,F,,20221124.0,20200617,20221125,EXP,,CA-ROCHE-2619589,ROCHE,,60.0,YR,,F,Y,120.0,KG,20221125,,HP,CA,,2022,Q4,Adult
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Drug-induced liver injury,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Musculoskeletal toxicity,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Rhabdomyolysis,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Hepatocellular injury,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Drug interaction,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
182236163,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd",,,Y,,Unknown,,,100.0,MG,,QD,2022,Q4,Toxicity to various agents,,2022,Q4,3,F,,20221027.0,20200902,20221108,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,"Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of internal medicine. 2020;1-2",76.0,YR,,F,Y,,,20221108,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
183440426,18344042,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,6,F,,20221014.0,20201005,20221020,EXP,,CA-APOTEX-2020AP018847,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221020,,MD,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Blood pressure diastolic decreased,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Blood pressure diastolic abnormal,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Contusion,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Vascular stenosis,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Finger deformity,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Hypothyroidism,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Steroid diabetes,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Kidney infection,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Intentional product use issue,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Fall,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Cystitis,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Nodule,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Intercepted medication error,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Lower respiratory tract infection,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Urinary tract infection,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Oxygen saturation decreased,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Fibromyalgia,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Breast disorder,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Blood pressure fluctuation,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Nasopharyngitis,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189236274,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,4,F,,20221220.0,20210222,20221228,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Diabetes mellitus,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Abdominal discomfort,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Pain,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Rheumatoid arthritis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Arthralgia,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,C-reactive protein increased,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Joint ankylosis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Psoriatic arthropathy,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Bone erosion,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Arthropathy,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Drug hypersensitivity,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Liver disorder,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Diarrhoea,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Osteolysis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Upper respiratory tract infection,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Treatment failure,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Infection,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Hand deformity,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Drug ineffective,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Therapeutic response decreased,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Localised infection,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,C-reactive protein abnormal,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Hepatic cirrhosis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Drug intolerance,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Pruritus,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Transaminases increased,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Synovitis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Skin injury,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Hepatic steatosis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Gastrointestinal infection,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Joint swelling,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Drug-induced liver injury,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Hypertension,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Hepatic fibrosis,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Nausea,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Bone cyst,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
189687093,18968709,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Unknown,,2022,Q4,Dyspepsia,,2022,Q4,3,F,,20221129.0,20210304,20221204,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-019463,BRISTOL MYERS SQUIBB,,50.0,YR,A,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Adult
1901242930,19012429,117,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,117,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,117,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,117,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,117,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,118,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,118,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,118,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,118,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,118,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,119,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,119,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,119,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,119,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,119,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,120,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Tablet),,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,120,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Tablet),,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,120,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Tablet),,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,120,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Tablet),,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1901242930,19012429,120,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK(Tablet),,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,30,F,,20221010.0,20210315,20221022,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20221022,,MD,CA,CA,2022,Q4,Elderly
1902563536,19025635,124,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,124,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,124,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,124,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,124,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,125,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,125,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,125,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,125,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,125,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,126,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,126,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,126,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,126,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,126,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,127,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,127,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,127,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,127,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,127,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,128,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,128,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,U,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,128,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,128,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,U,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
1902563536,19025635,128,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK (tablet),,,U,U,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,36,F,,20221021.0,20210318,20221101,EXP,,CA-PFIZER INC-2021284310,MYLAN,,76.0,YR,,F,Y,,,20221101,,CN,CA,CA,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Debridement,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Perineal pain,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Fournier's gangrene,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Genital lesion,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Testicular pain,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Depression,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Emotional distress,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Proctalgia,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Scrotal swelling,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Scrotal gangrene,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Stress,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anal abscess,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Genital abscess,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rectal abscess,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
190796515,19079651,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Sepsis,,2022,Q4,5,F,20161101.0,20221123.0,20210331,20221201,EXP,,US-AstraZeneca-2021A231660,ASTRAZENECA,,665.0,MON,,M,Y,102.1,KG,20221201,,LW,US,,2022,Q4,Elderly
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Injection site mass,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Infusion site swelling,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Injection site pain,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Injection site oedema,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Anal abscess,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Device infusion issue,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194071393,19407139,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Injection site swelling,,2022,Q4,3,F,20210201.0,20221103.0,20210611,20221110,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,109.0,KG,20221110,,CN,CA,CA,2022,Q4,Adult
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Kidney infection,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Blood pressure diastolic decreased,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Blood pressure diastolic abnormal,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Nasopharyngitis,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Intercepted medication error,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Oxygen saturation decreased,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Cystitis,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Fibromyalgia,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Intentional product use issue,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Hypothyroidism,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Urinary tract infection,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Steroid diabetes,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Lower respiratory tract infection,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Fall,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Finger deformity,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Blood pressure fluctuation,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Contusion,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Breast disorder,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Nodule,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Vascular stenosis,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
194978043,19497804,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,3,F,,20221214.0,20210706,20221220,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20221220,,HP,CA,,2022,Q4,Elderly
195312366,19531236,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,6,F,,20221011.0,20210713,20221019,EXP,,CA-AstraZeneca-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221019,,MD,CA,,2022,Q4,Elderly
195312366,19531236,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,6,F,,20221011.0,20210713,20221019,EXP,,CA-AstraZeneca-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221019,,MD,CA,,2022,Q4,Elderly
195312366,19531236,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,6,F,,20221011.0,20210713,20221019,EXP,,CA-AstraZeneca-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221019,,MD,CA,,2022,Q4,Elderly
195312366,19531236,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,6,F,,20221011.0,20210713,20221019,EXP,,CA-AstraZeneca-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221019,,MD,CA,,2022,Q4,Elderly
195312366,19531236,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,6,F,,20221011.0,20210713,20221019,EXP,,CA-AstraZeneca-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221019,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
199768402,19976840,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221227.0,20211020,20221229,EXP,,CA-AstraZeneca-2021A770473,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,,2022,Q4,Elderly
200242293,20024229,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q4,Takayasu's arteritis,,2022,Q4,3,F,20200916.0,20221012.0,20211102,20221020,PER,,JP-AMGEN-JPNSP2021169299,AMGEN,"Noritsugu Morita, Ippei Yasuda, Moe Yagi, Naomi Suda, Kiyotaka Yamada, Keiko Morita, et al.. Aortitis after administration of pegfilgrastim during preoperative chemotherapy for ovarian cancer. The 49th Ann. Mtg. of the Hokuriku Soc. of Obstet. Gynecol.. 2021;22",76.0,YR,E,F,Y,,,20221019,,PH,JP,JP,2022,Q4,Elderly
203682093,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Tinea pedis,,2022,Q4,3,F,20201015.0,20220922.0,20220124,20221002,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221003,,CN,JP,JP,2022,Q4,Elderly
203682093,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Gastric cancer,,2022,Q4,3,F,20201015.0,20220922.0,20220124,20221002,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221003,,CN,JP,JP,2022,Q4,Elderly
203682093,20368209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",35300.0,MG,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Chronic gastritis,,2022,Q4,3,F,20201015.0,20220922.0,20220124,20221002,EXP,,JP-JNJFOC-20211124197,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221003,,CN,JP,JP,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anxiety,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anhedonia,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Emotional distress,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone demineralisation,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Gait disturbance,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone density decreased,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204676422,20467642,96,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone pain,,2022,Q4,2,F,,20221109.0,20220214,20221117,PER,,US-GILEAD-2022-0569212,GILEAD,,69.0,YR,E,M,Y,78.005,KG,20221116,,LW,US,US,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
204906963,20490696,39,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221206.0,20220218,20221221,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-023168,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221221,,HP,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086838,20508683,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,8,F,,20221018.0,20220223,20221031,EXP,,CA-PFIZER INC-202200308664,PFIZER,,73.0,YR,,F,Y,101.0,KG,20221031,,MD,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205086849,20508684,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,9,F,,20221206.0,20220223,20221228,EXP,,CA-PFIZER INC-202200299943,MYLAN,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Overdose,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Overdose,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205109367,20510936,26,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,7,F,,20221028.0,20220224,20221102,EXP,,CA-Orion Corporation ORION PHARMA-22_00017678,ORION,,73.0,YR,E,F,Y,101.0,KG,20221102,,MD,CA,,2022,Q4,Elderly
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Crohn's disease,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Visual impairment,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Ocular discomfort,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,COVID-19,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Inappropriate schedule of product administration,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Abdominal pain,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Intentional product use issue,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
205710092,20571009,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,2,F,,20221123.0,20220309,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-05496,SAMSUNG BIOEPIS,,48.0,YR,A,F,Y,88.0,KG,20221201,,HP,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Sleep disorder due to a general medical condition,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Loss of personal independence in daily activities,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Depression,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207106064,20710606,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hypoacusis,,2022,Q4,4,F,,20221012.0,20220414,20221020,EXP,,CA-PFIZER INC-202200545955,PFIZER,,51.0,YR,,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
207635866,20763586,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,Y,,,,,,,,,2022,Q4,Dry mouth,,2022,Q4,6,F,20220218.0,20221003.0,20220428,20221012,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202204010648,ELI LILLY AND CO,,67.0,YR,,M,Y,59.0,KG,20221012,,CN,JP,JP,2022,Q4,Elderly
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208315912,20831591,46,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221017.0,20220516,20221029,EXP,,CA-ABBVIE-22K-028-4391508-00,ABBVIE,,61.0,YR,,M,Y,,,20221029,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208487062,20848706,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221017.0,20220519,20221025,EXP,,CA-APOTEX-2022AP007942,APOTEX,,61.0,YR,,M,Y,,,20221025,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Infection,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208800282,20880028,27,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221208.0,20220526,20221209,EXP,,CA-BAYER-2022A073828,BAYER,,61.0,YR,A,M,Y,,,20221209,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
208924652,20892465,40,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221128.0,20220531,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018520,AUROBINDO,,61.0,YR,,M,Y,,,20221212,,HP,CA,CA,2022,Q4,Adult
209106384,20910638,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Anaphylactic reaction,,2022,Q4,4,F,20220425.0,20221108.0,20220603,20221109,EXP,,JP-BAYER-2022A066783,BAYER,,31.0,YR,A,M,Y,136.4,KG,20221109,,MD,JP,JP,2022,Q4,Young Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209633333,20963333,45,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,3,F,,20221110.0,20220615,20221124,EXP,,CA-TEVA-2022-CA-2041498,TEVA,,61.0,YR,A,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Adult
209670132,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,Y,,,,,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209670132,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,Y,,,,,300.0,MG,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209670132,20967013,4,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,300 mg,,,Y,,,,,300.0,MG,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209670132,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209670132,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209670132,20967013,5,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,100 mg,,,Y,,,,,100.0,MG,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221222.0,20220616,20221228,EXP,,CA-SA-2022SA213299,SANOFI AVENTIS,Unknown. Unknown. Unknown. Unk;Unknown:Unknown,17.0,YR,T,M,Y,,,20221228,,HP,CA,CA,2022,Q4,Youth
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798262,20979826,22,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,2,F,,20221226.0,20220620,20221228,EXP,,CA-BAUSCH-BL-2022-015056,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221228,,HP,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bronchiectasis,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Intentional product use issue,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nasal congestion,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Asthma,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Wheezing,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rhinorrhoea,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
209798333,20979833,23,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cough,,2022,Q4,3,F,,20221226.0,20220620,20221229,EXP,,CA-BAUSCH-BL-2022-015054,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
210674052,21067405,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 milligram,,,U,,,,,300.0,MG,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210674052,21067405,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 milligram,,,U,,,,,300.0,MG,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210674052,21067405,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 milligram,,,U,,,,,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210674052,21067405,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,,,,,100.0,MG,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210674052,21067405,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,,,,,100.0,MG,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210674052,21067405,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 milligram,,,U,,,,,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221202.0,20220712,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-024802,AUROBINDO,"Shamchuk A, Doulla M, Jetha M.. Association possible entre l^acidocetose diabetique et l^utilisation d^un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabete de type 2.. CMAJCanadianMedicalAssociationJournal. 2021;193:E1746-E1749",17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
210709692,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221121.0,20220712,20221129,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
210709692,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221121.0,20220712,20221129,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
210709692,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221121.0,20220712,20221129,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
210709692,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221121.0,20220712,20221129,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
210709692,21070969,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221121.0,20220712,20221129,EXP,,CA-AstraZeneca-2022A245163,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
210711282,21071128,150,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,150,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,150,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,150,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,150,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,151,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,151,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,151,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,151,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,151,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,152,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,152,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,152,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,152,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,152,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,153,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,153,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,153,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,153,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,153,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,154,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,154,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,154,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,154,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,154,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,155,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,155,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,155,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,155,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,155,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,156,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,156,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,156,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,156,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,156,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,157,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,157,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,157,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,157,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,157,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,158,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,158,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,158,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,158,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,158,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,159,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,159,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,159,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,159,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,159,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,160,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,160,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,160,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,160,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,160,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,161,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,161,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,161,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,161,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,161,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,162,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,162,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,162,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,162,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,162,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,163,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,163,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,163,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,163,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,163,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,164,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,164,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,164,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,164,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,164,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,165,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,165,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,165,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,165,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,165,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,196,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,196,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,196,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,196,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210711282,21071128,196,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221219.0,20220712,20221227,EXP,,CA-AstraZeneca-2020SF11610,ASTRAZENECA,,76.0,YR,,F,Y,,,20221227,,MD,CA,,2022,Q4,Elderly
210999545,21099954,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, QD",,,,,,,,100.0,MG,,QD,2022,Q4,Rectal cancer,,2022,Q4,5,F,20220422.0,20221128.0,20220719,20221204,EXP,,NVSJ2022JP093985,NOVARTIS,,72.0,YR,,M,Y,64.0,KG,20221205,,MD,JP,JP,2022,Q4,Elderly
211185964,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211185964,21118596,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,4,F,,20221226.0,20220722,20221230,EXP,,CA-BAUSCH-BL-2022-018257,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221230,,HP,CA,CA,2022,Q4,Elderly
211672974,21167297,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablets,QD,2022,Q4,IgA nephropathy,,2022,Q4,4,F,20220117.0,20221109.0,20220803,20221117,EXP,,JP-JNJFOC-20220804627,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20221117,,MD,JP,JP,2022,Q4,Elderly
211672974,21167297,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablets,QD,2022,Q4,Protein urine,,2022,Q4,4,F,20220117.0,20221109.0,20220803,20221117,EXP,,JP-JNJFOC-20220804627,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20221117,,MD,JP,JP,2022,Q4,Elderly
211672974,21167297,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablets,QD,2022,Q4,Urinary occult blood,,2022,Q4,4,F,20220117.0,20221109.0,20220803,20221117,EXP,,JP-JNJFOC-20220804627,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20221117,,MD,JP,JP,2022,Q4,Elderly
2118192411,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,11,F,20220729.0,20221219.0,20220807,20221221,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20221221,,MD,TW,,2022,Q4,Elderly
2118192411,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,11,F,20220729.0,20221219.0,20220807,20221221,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20221221,,MD,TW,,2022,Q4,Elderly
2118192411,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Hyperglycaemia,,2022,Q4,11,F,20220729.0,20221219.0,20220807,20221221,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20221221,,MD,TW,,2022,Q4,Elderly
2118192411,21181924,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Pneumonia,,2022,Q4,11,F,20220729.0,20221219.0,20220807,20221221,EXP,,TW-ROCHE-3152629,ROCHE,,68.0,YR,,M,Y,,,20221221,,MD,TW,,2022,Q4,Elderly
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212061472,21206147,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221029.0,20220812,20221109,EXP,CA-MHPD-E2B_05106720,CA-Accord-272475,ACCORD,,61.0,YR,A,M,Y,,,20221109,,HP,CA,CA,2022,Q4,Adult
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Oral candidiasis,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Blister,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Visual impairment,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Odynophagia,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Pyrexia,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Lip oedema,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Toxic epidermal necrolysis,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Cholestasis,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Dysphagia,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Skin lesion,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Stevens-Johnson syndrome,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,SJS-TEN overlap,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Ocular hyperaemia,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Macule,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Dysphagia,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212082352,21208235,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Ulcerative keratitis,,2022,Q4,2,F,,20221017.0,20220812,20221026,EXP,,PT-BAXTER-2022BAX016925,BAXTER,,79.0,YR,,F,Y,,,20221025,,HP,PT,PT,2022,Q4,Elderly
212087764,21208776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",70600.0,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Perineal abscess,,2022,Q4,4,F,20220723.0,20221110.0,20220812,20221116,EXP,,JP-JNJFOC-20220825607,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Child
2124017511,21240175,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Tablets,,2022,Q4,Cholangitis sclerosing,Cholangitis sclerosing,2022,Q4,11,F,20220721.0,20221129.0,20220822,20221206,PER,,JP-Eisai Medical Research-EC-2022-121674,EISAI,,63.0,YR,A,M,Y,75.0,KG,20221206,,MD,JP,,2022,Q4,Adult
2124017511,21240175,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Tablets,,2022,Q4,Stomatitis,Stomatitis,2022,Q4,11,F,20220721.0,20221129.0,20220822,20221206,PER,,JP-Eisai Medical Research-EC-2022-121674,EISAI,,63.0,YR,A,M,Y,75.0,KG,20221206,,MD,JP,,2022,Q4,Adult
2124017511,21240175,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Tablets,,2022,Q4,Colitis,,2022,Q4,11,F,20220721.0,20221129.0,20220822,20221206,PER,,JP-Eisai Medical Research-EC-2022-121674,EISAI,,63.0,YR,A,M,Y,75.0,KG,20221206,,MD,JP,,2022,Q4,Adult
2124017511,21240175,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Tablets,,2022,Q4,Dehydration,,2022,Q4,11,F,20220721.0,20221129.0,20220822,20221206,PER,,JP-Eisai Medical Research-EC-2022-121674,EISAI,,63.0,YR,A,M,Y,75.0,KG,20221206,,MD,JP,,2022,Q4,Adult
213164812,21316481,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,,,,,,100.0,MG,UNK,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,20180725.0,20221209.0,20220910,20221214,EXP,,JP-ABBVIE-22P-087-4533465-00,ABBVIE,,34.0,YR,,M,Y,,,20221214,,MD,JP,JP,2022,Q4,Young Adult
213653422,21365342,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,Unknown,,2022,Q4,Death,,2022,Q4,2,F,20220918.0,20221128.0,20220922,20221128,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-109812,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,100.0,KG,20221129,,HP,CA,CA,2022,Q4,Elderly
213656622,21365662,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",23072.64,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Septic shock,,2022,Q4,2,F,20220808.0,20220928.0,20220922,20221007,EXP,,JP-JNJFOC-20220855757,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20221007,,MD,JP,JP,2022,Q4,Elderly
213656622,21365662,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",23072.64,MG,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Urinary tract infection,,2022,Q4,2,F,20220808.0,20220928.0,20220922,20221007,EXP,,JP-JNJFOC-20220855757,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20221007,,MD,JP,JP,2022,Q4,Elderly
213797463,21379746,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
213797463,21379746,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20220927,20221109,EXP,,NVSC2022CA214707,NOVARTIS,,76.0,YR,,F,Y,,,20221109,,HP,CA,CA,2022,Q4,Elderly
214110831,21411083,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20220927.0,20221005,20221005,EXP,,US-EMD Serono-9355439,EMD SERONO INC,"Fuhrman G, McCabe D, Strollo B. Euglycemic Diabetic Ketoacidosis in the Surgical Patient.. American Surgeon.. 2020 JAN 01;0(0):1-4. doi:10.1177/0003134820956352",49.0,YR,A,F,Y,,,20221005,,MD,US,,2022,Q4,Adult
214112601,21411260,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20220927.0,20221005,20221005,EXP,,US-EMD Serono-9355570,EMD SERONO INC,"Fuhrman G, McCabe D, Strollo B. Euglycemic Diabetic Ketoacidosis in the Surgical Patient.. American Surgeon.. 2020 JAN 01;0(0):1-4. doi:10.1177/0003134820956352",65.0,YR,E,F,Y,,,20221005,,MD,US,,2022,Q4,Elderly
214147353,21414735,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,24,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,25,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,28,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,29,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,30,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,31,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,32,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,33,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Asthma,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214147353,21414735,34,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,"UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,UNK",,,,,Film-coated tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,3,F,,20221103.0,20221006,20221110,EXP,,CA-ROCHE-3188997,ROCHE,,76.0,YR,,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Elderly
214194971,21419497,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Rectal haemorrhage,,2022,Q4,1,I,20220907.0,20221002.0,20221006,20221006,EXP,,GB-MYLANLABS-2022M1110704,MYLAN,,49.0,YR,,F,Y,95.0,KG,20221006,,PH,GB,GB,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Eating disorder,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Gastrointestinal perforation,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Aspartate aminotransferase increased,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Blood glucose increased,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Duodenal ulcer,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Alanine aminotransferase increased,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Nausea,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Abdominal pain upper,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214229513,21422951,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, 1x/day",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Blood triglycerides increased,,2022,Q4,3,F,20220802.0,20221130.0,20221007,20221205,EXP,,JP-PFIZER INC-PV202200076789,PFIZER,,60.0,YR,,M,Y,87.0,KG,20221205,,PH,JP,JP,2022,Q4,Adult
214384611,21438461,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Rectal haemorrhage,,2022,Q4,1,I,20220907.0,20221002.0,20221011,20221011,EXP,GB-MHRA-ADR 27350417,GB-ORGANON-O2210GBR000010,ORGANON,,49.0,YR,,F,Y,95.0,KG,20221011,,PH,GB,GB,2022,Q4,Adult
214440011,21444001,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q4,Postoperative wound infection,,2022,Q4,1,I,,20221005.0,20221012,20221012,EXP,,CA-JNJFOC-20221013012,JOHNSON AND JOHNSON,,64.0,YR,A,F,Y,,,20221010,,HP,CA,CA,2022,Q4,Adult
214440011,21444001,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2022,Q4,Surgery,,2022,Q4,1,I,,20221005.0,20221012,20221012,EXP,,CA-JNJFOC-20221013012,JOHNSON AND JOHNSON,,64.0,YR,A,F,Y,,,20221010,,HP,CA,CA,2022,Q4,Adult
214488711,21448871,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,US-JNJFOC-20221016009,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20221013,,MD,US,US,2022,Q4,Elderly
214494931,21449493,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Rectal haemorrhage,,2022,Q4,1,I,20220907.0,20221002.0,20221013,20221013,EXP,,GB-AUROBINDO-AUR-APL-2022-041767,AUROBINDO,,49.0,YR,,F,Y,95.0,KG,20221013,,PH,GB,GB,2022,Q4,Adult
214499291,21449929,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,US-JNJFOC-20221012673,JOHNSON AND JOHNSON,,49.0,YR,A,F,Y,,,20221013,,MD,US,US,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,Depression,,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,Diabetes mellitus,,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,Suicidal ideation,,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,"Hallucination, auditory",,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,Product prescribing error,,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214516953,21451695,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 milligram, qd,in the morning",,,,,,,,100.0,MG,,QD,2022,Q4,Anxiety,,2022,Q4,3,F,,20221019.0,20221013,20221129,EXP,,CA-MYLANLABS-2022M1113512,MYLAN,"Raphael C, Agid O.. When No Treatment Is the Treatment: Mental Illness-Related Case Report.. Canadian Journal of Hospital Pharmacy. 2022;(1):58-61",56.0,YR,,M,Y,,,20221129,,PH,CA,CA,2022,Q4,Adult
214522021,21452202,28,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 mg,,,,,,,,,,,,2022,Q4,Pemphigus,,2022,Q4,1,I,20220721.0,20221005.0,20221013,20221013,EXP,,JP-AstraZeneca-2022A267148,ASTRAZENECA,,65.0,YR,,M,Y,53.0,KG,20221013,,MD,JP,,2022,Q4,Elderly
214531341,21453134,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,JP-JNJFOC-20221024045,JOHNSON AND JOHNSON,"Fujiyoshi H, Yama S, Takasu Y, Yasuhiko M, Nishiura A, Tanaka S, et al. 133 A case of euglycemic ketoacidosis after removal of an anterior mediastinal tumor. The 237th Kinki Regional Meeting of The Japanese Society of Internal Medicine. 2022.9 10",30.0,YR,A,M,Y,,,20221013,,MD,JP,JP,2022,Q4,Young Adult
214531341,21453134,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,Tablet,,2022,Q4,Benign mediastinal neoplasm,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,JP-JNJFOC-20221024045,JOHNSON AND JOHNSON,"Fujiyoshi H, Yama S, Takasu Y, Yasuhiko M, Nishiura A, Tanaka S, et al. 133 A case of euglycemic ketoacidosis after removal of an anterior mediastinal tumor. The 237th Kinki Regional Meeting of The Japanese Society of Internal Medicine. 2022.9 10",30.0,YR,A,M,Y,,,20221013,,MD,JP,JP,2022,Q4,Young Adult
214543671,21454367,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221010.0,20221013,20221013,EXP,,CA-BAUSCH-BL-2022-023419,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221014,,MD,CA,CA,2022,Q4,Elderly
214543671,21454367,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221010.0,20221013,20221013,EXP,,CA-BAUSCH-BL-2022-023419,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221014,,MD,CA,CA,2022,Q4,Elderly
214543671,21454367,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221010.0,20221013,20221013,EXP,,CA-BAUSCH-BL-2022-023419,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221014,,MD,CA,CA,2022,Q4,Elderly
214543671,21454367,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,,20221010.0,20221013,20221013,EXP,,CA-BAUSCH-BL-2022-023419,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221014,,MD,CA,CA,2022,Q4,Elderly
214543671,21454367,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221010.0,20221013,20221013,EXP,,CA-BAUSCH-BL-2022-023419,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221014,,MD,CA,CA,2022,Q4,Elderly
214578591,21457859,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,D,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Pleural mesothelioma,,2022,Q4,1,I,20211101.0,20221006.0,20221014,20221014,EXP,,JP-JNJFOC-20221025840,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20221014,,MD,JP,JP,2022,Q4,Child
214651251,21465125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05571878,CA-NOVOPROD-968464,NOVO NORDISK,,41.0,YR,,F,Y,,,20221017,,CN,CA,CA,2022,Q4,Adult
214651251,21465125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05571878,CA-NOVOPROD-968464,NOVO NORDISK,,41.0,YR,,F,Y,,,20221017,,CN,CA,CA,2022,Q4,Adult
214651251,21465125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Joint injury,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05571878,CA-NOVOPROD-968464,NOVO NORDISK,,41.0,YR,,F,Y,,,20221017,,CN,CA,CA,2022,Q4,Adult
214651251,21465125,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Fall,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05571878,CA-NOVOPROD-968464,NOVO NORDISK,,41.0,YR,,F,Y,,,20221017,,CN,CA,CA,2022,Q4,Adult
214755672,21475567,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 mg qAM,,,,,,,,,,,,2022,Q4,No adverse event,,2022,Q4,2,F,,20221021.0,20221019,20221103,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-359290,RANBAXY,"Raphael C, Agid O. When No Treatment Is the Treatment: Mental Illness related case report. Can J Hosp Pharm. 2022;75(1):58-61",56.0,YR,,M,Y,,,20221104,,PH,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214864962,21486496,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221110.0,20221020,20221124,EXP,,CA-TEVA-2022-CA-2818072,TEVA,,61.0,YR,A,M,Y,,,20221124,,MD,CA,CA,2022,Q4,Adult
214870082,21487008,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Rectal cancer,,2022,Q4,2,F,,20221024.0,20221020,20221103,EXP,,JP-JNJFOC-20221039159,JOHNSON AND JOHNSON,"Ashidachi K, Daikashiwa H, Ashidachi K, Tsutaho A, Ueno M, Fukushima M, et al. P1 A case of Fournier^s gangrene which developed during bevacizumab combination chemotherapy while on -5 SGLT2 inhibitors. Journal of the Japan Society of Coloproctology. The 77th Annual Meeting of Japan Society of Coloproctology 2022.9.; 2022.10.14, 15; 75: 9: A 206",7.0,DEC,E,M,Y,,,20221103,,MD,JP,JP,2022,Q4,Child
214870082,21487008,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Fournier's gangrene,,2022,Q4,2,F,,20221024.0,20221020,20221103,EXP,,JP-JNJFOC-20221039159,JOHNSON AND JOHNSON,"Ashidachi K, Daikashiwa H, Ashidachi K, Tsutaho A, Ueno M, Fukushima M, et al. P1 A case of Fournier^s gangrene which developed during bevacizumab combination chemotherapy while on -5 SGLT2 inhibitors. Journal of the Japan Society of Coloproctology. The 77th Annual Meeting of Japan Society of Coloproctology 2022.9.; 2022.10.14, 15; 75: 9: A 206",7.0,DEC,E,M,Y,,,20221103,,MD,JP,JP,2022,Q4,Child
215012152,21501215,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,UNKNOWN,,,,,Tablet,,2022,Q4,Portosplenomesenteric venous thrombosis,,2022,Q4,2,F,20221017.0,20221128.0,20221025,20221201,EXP,,JP-ROCHE-3206240,ROCHE,,68.0,YR,,M,Y,64.3,KG,20221201,,MD,JP,JP,2022,Q4,Elderly
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Neuralgia,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Neck pain,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Ear infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Viral infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Kidney infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Tinnitus,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Influenza,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Paranasal cyst,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Ear disorder,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Localised infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Pain in extremity,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Therapeutic response shortened,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Cough,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Bronchitis,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Sinusitis,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Sepsis,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Blood pressure systolic increased,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Malaise,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Polyp,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Musculoskeletal pain,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Urinary tract infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Eyelid infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Fungal infection,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215020271,21502027,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Tympanic membrane perforation,,2022,Q4,1,I,,20221010.0,20221025,20221025,EXP,,CA-MYLANLABS-2022M1117379,MYLAN,,61.0,YR,,F,Y,122.0,KG,20221025,,HP,CA,CA,2022,Q4,Adult
215052931,21505293,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,150/1000 mg,,,Y,,,,204353.0,,,Tablet,Q12H,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20210723.0,20221020.0,20221026,20221026,EXP,CH-SM-2022-19855,CH-JNJFOC-20221039676,JOHNSON AND JOHNSON,,58.0,YR,A,F,Y,60.0,KG,20221026,,PH,CH,CH,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Transaminases increased,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Localised infection,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Treatment failure,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Joint swelling,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug-induced liver injury,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic fibrosis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pruritus,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Joint ankylosis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Synovitis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone erosion,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthropathy,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Osteolysis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein abnormal,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Infection,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug hypersensitivity,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Gastrointestinal infection,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone cyst,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein increased,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Skin injury,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hand deformity,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Psoriatic arthropathy,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Upper respiratory tract infection,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215217752,21521775,32,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dyspepsia,,2022,Q4,2,F,,20221123.0,20221028,20221124,EXP,,CA-ROCHE-3205507,ROCHE,,61.0,YR,,M,Y,,,20221124,,HP,CA,,2022,Q4,Adult
215257462,21525746,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Off label use,,2022,Q4,2,F,20211201.0,20221031.0,20221031,20221104,EXP,,JP-TAKEDA-2022TJP076264,TAKEDA,,46.0,YR,,F,Y,,,20221104,,MD,JP,JP,2022,Q4,Adult
215257462,21525746,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Oedema peripheral,,2022,Q4,2,F,20211201.0,20221031.0,20221031,20221104,EXP,,JP-TAKEDA-2022TJP076264,TAKEDA,,46.0,YR,,F,Y,,,20221104,,MD,JP,JP,2022,Q4,Adult
215257462,21525746,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Cardiac failure,,2022,Q4,2,F,20211201.0,20221031.0,20221031,20221104,EXP,,JP-TAKEDA-2022TJP076264,TAKEDA,,46.0,YR,,F,Y,,,20221104,,MD,JP,JP,2022,Q4,Adult
215257462,21525746,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,,100.0,MG,Tablet,QD,2022,Q4,Weight increased,,2022,Q4,2,F,20211201.0,20221031.0,20221031,20221104,EXP,,JP-TAKEDA-2022TJP076264,TAKEDA,,46.0,YR,,F,Y,,,20221104,,MD,JP,JP,2022,Q4,Adult
215306981,21530698,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,,20221027.0,20221031,20221031,EXP,,CA-BAUSCH-BL-2022-024430,BAUSCH AND LOMB,UNKNOWN. Unspecified article. Unspecified Journal.,17.0,YR,,M,Y,,,20221031,,HP,CA,CA,2022,Q4,Youth
215306981,21530698,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,,20221027.0,20221031,20221031,EXP,,CA-BAUSCH-BL-2022-024430,BAUSCH AND LOMB,UNKNOWN. Unspecified article. Unspecified Journal.,17.0,YR,,M,Y,,,20221031,,HP,CA,CA,2022,Q4,Youth
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hand deformity,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone cyst,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Skin injury,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic steatosis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein increased,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Transaminases increased,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Dyspepsia,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pain,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Gastrointestinal infection,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Localised infection,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Treatment failure,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Arthropathy,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Psoriatic arthropathy,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Synovitis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Rheumatoid arthritis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Pruritus,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diabetes mellitus,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Nausea,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic fibrosis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug-induced liver injury,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint ankylosis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Joint swelling,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,C-reactive protein abnormal,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Osteolysis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic cirrhosis,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Upper respiratory tract infection,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Bone erosion,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Drug intolerance,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215315541,21531554,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hypertension,,2022,Q4,1,I,,20221021.0,20221031,20221031,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-127096,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Adult
215399842,21539984,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,2,F,,20221110.0,20221102,20221116,EXP,,CA-ORGANON-1904CAN003813,ORGANON,,76.0,YR,,F,Y,,,20221116,,MD,CA,CA,2022,Q4,Elderly
215399842,21539984,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,2,F,,20221110.0,20221102,20221116,EXP,,CA-ORGANON-1904CAN003813,ORGANON,,76.0,YR,,F,Y,,,20221116,,MD,CA,CA,2022,Q4,Elderly
215399842,21539984,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221110.0,20221102,20221116,EXP,,CA-ORGANON-1904CAN003813,ORGANON,,76.0,YR,,F,Y,,,20221116,,MD,CA,CA,2022,Q4,Elderly
215399842,21539984,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,2,F,,20221110.0,20221102,20221116,EXP,,CA-ORGANON-1904CAN003813,ORGANON,,76.0,YR,,F,Y,,,20221116,,MD,CA,CA,2022,Q4,Elderly
215399842,21539984,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,2,F,,20221110.0,20221102,20221116,EXP,,CA-ORGANON-1904CAN003813,ORGANON,,76.0,YR,,F,Y,,,20221116,,MD,CA,CA,2022,Q4,Elderly
215428151,21542815,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,Tablet,,2022,Q4,COVID-19,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,PT-JNJFOC-20221056961,JOHNSON AND JOHNSON,,89.0,YR,E,M,Y,,,20221102,,HP,PT,PT,2022,Q4,Elderly
215428151,21542815,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,PT-JNJFOC-20221056961,JOHNSON AND JOHNSON,,89.0,YR,E,M,Y,,,20221102,,HP,PT,PT,2022,Q4,Elderly
215433992,21543399,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,Y,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Hyperglycaemic hyperosmolar nonketotic syndrome,,2022,Q4,2,F,,20221129.0,20221102,20221208,EXP,,JP-JNJFOC-20221102942,JOHNSON AND JOHNSON,,4.0,DEC,A,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Child
215435402,21543540,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,Y,,,,204042.0,100.0,MG,Tablet,,2022,Q4,COVID-19,,2022,Q4,2,F,,20221108.0,20221102,20221118,EXP,,JP-JNJFOC-20221102935,JOHNSON AND JOHNSON,"Numura T, [W27-3 A case of hospital admission with COVID-19 (C19) and DKA while on oral SGLT2 inhibitors/Re-start of SGLT2 inhibitors after treatment/Re-admission with C19 and DKA 2 days after discharge] Diabetic Complications. The 37 Meeting of the Japan Society of Diabetic Complications/The 28th Meeting of the Japanese Society of Ophthalmic Diabetology. 2022.9.20;2022.10.21,22;36:S-1:228",6.0,DEC,A,F,Y,,,20221118,,MD,JP,JP,2022,Q4,Child
215435402,21543540,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,Y,,,,204042.0,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221108.0,20221102,20221118,EXP,,JP-JNJFOC-20221102935,JOHNSON AND JOHNSON,"Numura T, [W27-3 A case of hospital admission with COVID-19 (C19) and DKA while on oral SGLT2 inhibitors/Re-start of SGLT2 inhibitors after treatment/Re-admission with C19 and DKA 2 days after discharge] Diabetic Complications. The 37 Meeting of the Japan Society of Diabetic Complications/The 28th Meeting of the Japanese Society of Ophthalmic Diabetology. 2022.9.20;2022.10.21,22;36:S-1:228",6.0,DEC,A,F,Y,,,20221118,,MD,JP,JP,2022,Q4,Child
215435402,21543540,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,Y,,,,204042.0,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221108.0,20221102,20221118,EXP,,JP-JNJFOC-20221102935,JOHNSON AND JOHNSON,"Numura T, [W27-3 A case of hospital admission with COVID-19 (C19) and DKA while on oral SGLT2 inhibitors/Re-start of SGLT2 inhibitors after treatment/Re-admission with C19 and DKA 2 days after discharge] Diabetic Complications. The 37 Meeting of the Japan Society of Diabetic Complications/The 28th Meeting of the Japanese Society of Ophthalmic Diabetology. 2022.9.20;2022.10.21,22;36:S-1:228",6.0,DEC,A,F,Y,,,20221118,,MD,JP,JP,2022,Q4,Child
215435402,21543540,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,Y,,,,204042.0,100.0,MG,Tablet,,2022,Q4,COVID-19,,2022,Q4,2,F,,20221108.0,20221102,20221118,EXP,,JP-JNJFOC-20221102935,JOHNSON AND JOHNSON,"Numura T, [W27-3 A case of hospital admission with COVID-19 (C19) and DKA while on oral SGLT2 inhibitors/Re-start of SGLT2 inhibitors after treatment/Re-admission with C19 and DKA 2 days after discharge] Diabetic Complications. The 37 Meeting of the Japan Society of Diabetic Complications/The 28th Meeting of the Japanese Society of Ophthalmic Diabetology. 2022.9.20;2022.10.21,22;36:S-1:228",6.0,DEC,A,F,Y,,,20221118,,MD,JP,JP,2022,Q4,Child
215597402,21559740,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,D,,,,,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215597402,21559740,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,D,,,,,100.0,MG,Tablet,,2022,Q4,Treatment noncompliance,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215597402,21559740,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 mg,,,D,,,,,100.0,MG,Tablet,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215597402,21559740,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 mg,,,D,,,,,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215597402,21559740,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 mg,,,D,,,,,300.0,MG,Tablet,,2022,Q4,Treatment noncompliance,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215597402,21559740,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 mg,,,D,,,,,300.0,MG,Tablet,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221202.0,20221107,20221205,EXP,,CA-SA-2022SA447150,SANOFI AVENTIS,,17.0,YR,T,M,Y,,,20221205,,HP,CA,CA,2022,Q4,Youth
215681541,21568154,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2022,Q4,Pancreatic disorder,,2022,Q4,1,I,20221024.0,20221027.0,20221108,20221108,EXP,GB-MHRA-TPP2461208C52638YC1666792122294,GB-ELI_LILLY_AND_COMPANY-GB202210013304,ELI LILLY AND CO,,56.0,YR,,F,Y,107.0,KG,20221108,,CN,GB,GB,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Fall,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Ocular dysmetria,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Depressed level of consciousness,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Hyperglycaemic hyperosmolar nonketotic syndrome,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Encephalopathy,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Facial spasm,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215686422,21568642,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 mg, QD",,,D,,,,,100.0,MG,,QD,2022,Q4,Aphasia,,2022,Q4,2,F,,20221117.0,20221108,20221124,EXP,,NVSJ2022JP100473,NOVARTIS,,64.0,YR,,F,Y,62.3,KG,20221125,,MD,JP,JP,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Vitamin B12 decreased,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Vitamin D decreased,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Liver disorder,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Immune-mediated myositis,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Sensory loss,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Antinuclear antibody,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Muscular weakness,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Blood creatine phosphokinase increased,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Paraesthesia,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Mobility decreased,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215835901,21583590,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Suspected COVID-19,,2022,Q4,1,I,,20221103.0,20221111,20221111,EXP,,CA-APOTEX-2022AP015256,APOTEX,,64.0,YR,,F,Y,72.0,KG,20221111,,CN,CA,CA,2022,Q4,Adult
215847102,21584710,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,N,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,20220415.0,20221109.0,20221111,20221115,EXP,,JP-PFIZER INC-PV202200098748,PFIZER,,49.0,YR,,F,Y,59.0,KG,20221115,,MD,JP,JP,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Mobility decreased,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Suspected COVID-19,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Sensory loss,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Immune-mediated myositis,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Muscular weakness,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Liver disorder,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Paraesthesia,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Blood creatine phosphokinase increased,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Vitamin D decreased,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Antinuclear antibody,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,COVID-19,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215898491,21589849,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Vitamin B12 decreased,,2022,Q4,1,I,,20221101.0,20221114,20221114,EXP,CA-MHPD-E2B_05647434,CA-Accord-285329,ACCORD,,64.0,YR,A,F,Y,72.0,KG,20221114,,CN,CA,CA,2022,Q4,Adult
215903531,21590353,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,Unknown,,,100.0,MG,Tablet,QD,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,20220813.0,20221111.0,20221114,20221114,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202615",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Elderly
215903531,21590353,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,Unknown,,,100.0,MG,Tablet,QD,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,20220813.0,20221111.0,20221114,20221114,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202615",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Elderly
216003341,21600334,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Eye movement disorder,,2022,Q4,1,I,,20221107.0,20221116,20221116,EXP,,PR-JNJFOC-20221121424,JOHNSON AND JOHNSON,,58.0,YR,A,M,Y,,,20221116,,CN,PR,PR,2022,Q4,Adult
216003341,21600334,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221107.0,20221116,20221116,EXP,,PR-JNJFOC-20221121424,JOHNSON AND JOHNSON,,58.0,YR,A,M,Y,,,20221116,,CN,PR,PR,2022,Q4,Adult
216003341,21600334,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221107.0,20221116,20221116,EXP,,PR-JNJFOC-20221121424,JOHNSON AND JOHNSON,,58.0,YR,A,M,Y,,,20221116,,CN,PR,PR,2022,Q4,Adult
216003341,21600334,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,Tablet,,2022,Q4,Heart rate decreased,,2022,Q4,1,I,,20221107.0,20221116,20221116,EXP,,PR-JNJFOC-20221121424,JOHNSON AND JOHNSON,,58.0,YR,A,M,Y,,,20221116,,CN,PR,PR,2022,Q4,Adult
216127121,21612712,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Lactic acidosis,,2022,Q4,1,I,,20221103.0,20221118,20221118,EXP,,AT-ALKEM LABORATORIES LIMITED-AT-ALKEM-2022-12662,ALKEM,"Schwetz V, Eisner F, Schilcher G, Eller K et.al.. Combined metformin associated lactic acidosis and euglycemic ketoacidosis. Wien Klin Wochenschr. 2017;129:646-649",71.0,YR,,M,Y,,,20221118,,HP,AT,AT,2022,Q4,Elderly
216127121,21612712,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221103.0,20221118,20221118,EXP,,AT-ALKEM LABORATORIES LIMITED-AT-ALKEM-2022-12662,ALKEM,"Schwetz V, Eisner F, Schilcher G, Eller K et.al.. Combined metformin associated lactic acidosis and euglycemic ketoacidosis. Wien Klin Wochenschr. 2017;129:646-649",71.0,YR,,M,Y,,,20221118,,HP,AT,AT,2022,Q4,Elderly
216146052,21614605,3,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,"1 dosage form, daily",,,,,,,,,,,QD,2022,Q4,Vomiting,,2022,Q4,2,F,20211225.0,20221125.0,20221118,20221207,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202211006058,ELI LILLY AND CO,,43.0,YR,,F,Y,94.0,KG,20221207,,CN,JP,JP,2022,Q4,Adult
216146052,21614605,3,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,"1 dosage form, daily",,,,,,,,,,,QD,2022,Q4,Dehydration,,2022,Q4,2,F,20211225.0,20221125.0,20221118,20221207,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202211006058,ELI LILLY AND CO,,43.0,YR,,F,Y,94.0,KG,20221207,,CN,JP,JP,2022,Q4,Adult
216146052,21614605,3,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,"1 dosage form, daily",,,,,,,,,,,QD,2022,Q4,Nausea,,2022,Q4,2,F,20211225.0,20221125.0,20221118,20221207,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202211006058,ELI LILLY AND CO,,43.0,YR,,F,Y,94.0,KG,20221207,,CN,JP,JP,2022,Q4,Adult
216146052,21614605,3,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,,"1 dosage form, daily",,,,,,,,,,,QD,2022,Q4,Tubulointerstitial nephritis,,2022,Q4,2,F,20211225.0,20221125.0,20221118,20221207,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202211006058,ELI LILLY AND CO,,43.0,YR,,F,Y,94.0,KG,20221207,,CN,JP,JP,2022,Q4,Adult
216179222,21617922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Renal impairment,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Blood glucose abnormal,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Off label use,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Vascular stenosis,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,2,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,Y,,,,,,,Tablet,,2022,Q4,Renal impairment,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,2,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,Y,,,,,,,Tablet,,2022,Q4,Blood glucose abnormal,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,2,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,Y,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,2,SS,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,UNK,,,Y,,,,,,,Tablet,,2022,Q4,Vascular stenosis,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216225831,21622583,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,Tablet,QD,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,GB-MHRA-EMIS-8689-334a701f-d085-4986-9ed4-d239c8e876be,GB-JNJFOC-20221130765,JOHNSON AND JOHNSON,,40.0,YR,A,M,Y,170.1,KG,20221121,,PH,GB,GB,2022,Q4,Adult
216284161,21628416,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,100.0,MG,,QD,2022,Q4,PCO2 decreased,,2022,Q4,1,I,20221115.0,,20221121,20221121,DIR,639055,,FDA-CTU,,28.0,YR,,F,N,106.3,KG,20221121,N,PH,US,,2022,Q4,Young Adult
216284161,21628416,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,100.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,1,I,20221115.0,,20221121,20221121,DIR,639055,,FDA-CTU,,28.0,YR,,F,N,106.3,KG,20221121,N,PH,US,,2022,Q4,Young Adult
216284161,21628416,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,100.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20221115.0,,20221121,20221121,DIR,639055,,FDA-CTU,,28.0,YR,,F,N,106.3,KG,20221121,N,PH,US,,2022,Q4,Young Adult
216398581,21639858,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827266,TEVA,,76.0,YR,E,F,Y,,,20221124,,MD,CA,CA,2022,Q4,Elderly
216398581,21639858,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827266,TEVA,,76.0,YR,E,F,Y,,,20221124,,MD,CA,CA,2022,Q4,Elderly
216398581,21639858,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827266,TEVA,,76.0,YR,E,F,Y,,,20221124,,MD,CA,CA,2022,Q4,Elderly
216398581,21639858,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827266,TEVA,,76.0,YR,E,F,Y,,,20221124,,MD,CA,CA,2022,Q4,Elderly
216398581,21639858,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827266,TEVA,,76.0,YR,E,F,Y,,,20221124,,MD,CA,CA,2022,Q4,Elderly
216400221,21640022,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827315,TEVA,,17.0,YR,T,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Youth
216400221,21640022,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827315,TEVA,,17.0,YR,T,M,Y,,,20221124,,HP,CA,CA,2022,Q4,Youth
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216447771,21644777,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221121.0,20221125,20221125,EXP,,CA-BAUSCH-BL-2022-025974,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221125,,MD,CA,CA,2022,Q4,Elderly
216533461,21653346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Retinal haemorrhage,,2022,Q4,1,I,,20221118.0,20221128,20221128,EXP,,JP-JNJFOC-20221156523,JOHNSON AND JOHNSON,,53.0,YR,A,M,Y,,,20221129,,MD,JP,JP,2022,Q4,Adult
216533461,21653346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Diabetic retinopathy,,2022,Q4,1,I,,20221118.0,20221128,20221128,EXP,,JP-JNJFOC-20221156523,JOHNSON AND JOHNSON,,53.0,YR,A,M,Y,,,20221129,,MD,JP,JP,2022,Q4,Adult
216534871,21653487,100,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,100,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,100,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,100,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,100,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,101,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,102,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,103,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,123,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,123,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,123,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,123,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,123,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,124,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,124,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,124,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,124,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216534871,21653487,124,SS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221128,20221128,EXP,,CA-BAUSCHBL-BL-2019-065992,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221129,,CN,CA,CA,2022,Q4,Elderly
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Vitamin B12 decreased,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Antinuclear antibody,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Blood creatine phosphokinase increased,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Liver disorder,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Paraesthesia,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Immune-mediated myositis,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Vitamin D decreased,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Muscular weakness,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Sensory loss,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Suspected COVID-19,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216549431,21654943,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q4,Mobility decreased,,2022,Q4,1,I,,20221118.0,20221129,20221129,EXP,,CA-TEVA-2022-CA-2829568,TEVA,,64.0,YR,A,F,Y,72.0,KG,20221128,,CN,CA,CA,2022,Q4,Adult
216583841,21658384,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216583841,21658384,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221121.0,20221129,20221129,EXP,,CA-AstraZeneca-2022A388659,ASTRAZENECA,,76.0,YR,,F,Y,,,20221129,,MD,CA,,2022,Q4,Elderly
216589831,21658983,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,300.0,MG,Tablet,,2022,Q4,Peripheral arterial occlusive disease,,2022,Q4,1,I,20210802.0,20211103.0,20221129,20221129,EXP,GB-MHRA-WEBRADR-202111021202114430-BEKEO,GB-JNJFOC-20220917656,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20221129,,HP,GB,GB,2022,Q4,Elderly
216597031,21659703,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,MAL3L01,,,100.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,20221115.0,20221120.0,20221129,20221129,EXP,CN-NMPA-3302111061780202200301,CN-NOVOPROD-984021,NOVO NORDISK,,45.0,YR,,M,Y,81.0,KG,20221130,,HP,CN,CN,2022,Q4,Adult
216597031,21659703,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,MAL3L01,,,100.0,MG,,QD,2022,Q4,Abdominal distension,,2022,Q4,1,I,20221115.0,20221120.0,20221129,20221129,EXP,CN-NMPA-3302111061780202200301,CN-NOVOPROD-984021,NOVO NORDISK,,45.0,YR,,M,Y,81.0,KG,20221130,,HP,CN,CN,2022,Q4,Adult
216597031,21659703,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,MAL3L01,,,100.0,MG,,QD,2022,Q4,Nausea,,2022,Q4,1,I,20221115.0,20221120.0,20221129,20221129,EXP,CN-NMPA-3302111061780202200301,CN-NOVOPROD-984021,NOVO NORDISK,,45.0,YR,,M,Y,81.0,KG,20221130,,HP,CN,CN,2022,Q4,Adult
216597551,21659755,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300mg; ;,,,Y,U,,,204042.0,300.0,MG,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20221124.0,20221127.0,20221129,20221129,EXP,,GB-JNJFOC-20221160394,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,75.0,KG,20221130,,PH,GB,GB,2022,Q4,Elderly
216644691,21664469,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,300.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20200501.0,20211231.0,20221130,20221130,EXP,GB-MHRA-EYC 00270319,GB-JNJFOC-20220948390,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20221130,,PH,GB,GB,2022,Q4,Elderly
216644691,21664469,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,300.0,MG,Tablet,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20200501.0,20211231.0,20221130,20221130,EXP,GB-MHRA-EYC 00270319,GB-JNJFOC-20220948390,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20221130,,PH,GB,GB,2022,Q4,Elderly
216644701,21664470,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,Tablet,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20211224.0,20220102.0,20221130,20221130,EXP,GB-MHRA-EYC 00270399,GB-JNJFOC-20221015794,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,,,20221130,,PH,GB,GB,2022,Q4,Adult
216645211,21664521,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Taken Preferably Before Breakfast,100.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Skin ulcer,,2022,Q4,1,I,20220110.0,20220121.0,20221130,20221130,EXP,GB-MHRA-EMIS-4189-88a81b0c-b3f2-4379-8dba-8c4a93509a1b,GB-JNJFOC-20220947709,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,110.0,KG,20221130,,MD,GB,GB,2022,Q4,Elderly
216645211,21664521,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Taken Preferably Before Breakfast,100.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Skin necrosis,,2022,Q4,1,I,20220110.0,20220121.0,20221130,20221130,EXP,GB-MHRA-EMIS-4189-88a81b0c-b3f2-4379-8dba-8c4a93509a1b,GB-JNJFOC-20220947709,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,110.0,KG,20221130,,MD,GB,GB,2022,Q4,Elderly
216645211,21664521,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Taken Preferably Before Breakfast,100.0,MG,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Dermatitis bullous,,2022,Q4,1,I,20220110.0,20220121.0,20221130,20221130,EXP,GB-MHRA-EMIS-4189-88a81b0c-b3f2-4379-8dba-8c4a93509a1b,GB-JNJFOC-20220947709,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,110.0,KG,20221130,,MD,GB,GB,2022,Q4,Elderly
216645931,21664593,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220324.0,20220325.0,20221130,20221130,EXP,,GB-JNJFOC-20220955143,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,85.0,KG,20221130,,HP,GB,GB,2022,Q4,Elderly
216645931,21664593,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,1,I,20220324.0,20220325.0,20221130,20221130,EXP,,GB-JNJFOC-20220955143,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,85.0,KG,20221130,,HP,GB,GB,2022,Q4,Elderly
216645931,21664593,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220324.0,20220325.0,20221130,20221130,EXP,,GB-JNJFOC-20220955143,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,85.0,KG,20221130,,HP,GB,GB,2022,Q4,Elderly
216645931,21664593,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,Tablet,,2022,Q4,Dehydration,,2022,Q4,1,I,20220324.0,20220325.0,20221130,20221130,EXP,,GB-JNJFOC-20220955143,JOHNSON AND JOHNSON,,66.0,YR,E,F,Y,85.0,KG,20221130,,HP,GB,GB,2022,Q4,Elderly
216645941,21664594,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300mg,,,D,,,,204042.0,300.0,MG,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220314.0,20220315.0,20221130,20221130,EXP,,GB-JNJFOC-20221021579,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,81.0,KG,20221130,,PH,GB,GB,2022,Q4,Adult
216645971,21664597,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300mg OD,,,Y,,,,204042.0,300.0,MG,Tablet,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220404.0,20220407.0,20221130,20221130,EXP,,GB-JNJFOC-20220953912,JOHNSON AND JOHNSON,,37.0,YR,A,F,Y,119.0,KG,20221130,,HP,GB,GB,2022,Q4,Adult
216674174,21667417,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Tablets,,2022,Q4,Colitis,,2022,Q4,4,F,20221116.0,20221223.0,20221201,20221229,PER,,GB-Eisai Medical Research-EC-2022-129019,EISAI,,62.0,YR,A,M,Y,95.6,KG,20221229,,MD,GB,,2022,Q4,Adult
216679942,21667994,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,unknown,,,100.0,MG,Tablet,QD,2022,Q4,Gastrointestinal oedema,,2022,Q4,2,F,20221111.0,20221206.0,20221201,20221216,EXP,,JP-NOVOPROD-984684,NOVO NORDISK,,31.0,YR,,F,Y,74.0,KG,20221216,,MD,JP,JP,2022,Q4,Young Adult
216679942,21667994,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,,,unknown,,,100.0,MG,Tablet,QD,2022,Q4,Gastric dilatation,,2022,Q4,2,F,20221111.0,20221206.0,20221201,20221216,EXP,,JP-NOVOPROD-984684,NOVO NORDISK,,31.0,YR,,F,Y,74.0,KG,20221216,,MD,JP,JP,2022,Q4,Young Adult
216856121,21685612,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,100.0,MG,Tablet,,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20221120.0,20221130.0,20221206,20221206,EXP,,GB-JNJFOC-20221201938,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,109.0,KG,20221206,,PH,GB,GB,2022,Q4,Elderly
216871871,21687187,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 cp at breakfast,,,,,,,,100.0,MG,Film-coated tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220225.0,20221121.0,20221206,20221206,EXP,PT-INFARMED-T202205-246,PT-Accord-289636,ACCORD,,82.0,YR,E,M,Y,79.0,KG,20221206,,PH,PT,PT,2022,Q4,Elderly
216871871,21687187,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 cp at breakfast,,,,,,,,100.0,MG,Film-coated tablet,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,20220225.0,20221121.0,20221206,20221206,EXP,PT-INFARMED-T202205-246,PT-Accord-289636,ACCORD,,82.0,YR,E,M,Y,79.0,KG,20221206,,PH,PT,PT,2022,Q4,Elderly
216871871,21687187,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 cp at breakfast,,,,,,,,100.0,MG,Film-coated tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20220225.0,20221121.0,20221206,20221206,EXP,PT-INFARMED-T202205-246,PT-Accord-289636,ACCORD,,82.0,YR,E,M,Y,79.0,KG,20221206,,PH,PT,PT,2022,Q4,Elderly
217144181,21714418,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q4,Enteritis infectious,,2022,Q4,1,I,,20221206.0,20221212,20221212,EXP,,JP-DSJP-DSJ-2022-144472,DAIICHI,"Shibuya N, Sakurai T, Sano M, Kikuchi I, Iwashita Y, Ishikawa M, et al.. A case of valsartan-related drug-induced enterocolitis discovered as a result of infectious enteritis. The 60th Meeting of The Japanese Society of Small Intestinal Disease. 2022;75",79.0,YR,,M,Y,,,20221212,,MD,JP,JP,2022,Q4,Elderly
217144181,21714418,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q4,Enterocolitis,,2022,Q4,1,I,,20221206.0,20221212,20221212,EXP,,JP-DSJP-DSJ-2022-144472,DAIICHI,"Shibuya N, Sakurai T, Sano M, Kikuchi I, Iwashita Y, Ishikawa M, et al.. A case of valsartan-related drug-induced enterocolitis discovered as a result of infectious enteritis. The 60th Meeting of The Japanese Society of Small Intestinal Disease. 2022;75",79.0,YR,,M,Y,,,20221212,,MD,JP,JP,2022,Q4,Elderly
217145321,21714532,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,300.0,MG,,QD,2022,Q4,Blood potassium increased,,2022,Q4,1,I,20201021.0,,20221209,20221209,DIR,641030,,FDA-CTU,,59.0,YR,,M,N,58.95,KG,20221209,N,,US,,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Fatigue,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Blood alkaline phosphatase increased,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Thrombophlebitis migrans,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Aspartate aminotransferase increased,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Underdose,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Alanine aminotransferase increased,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217146762,21714676,9,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 DF, qd",,,,,,,,,,Tablet,QD,2022,Q4,Decreased appetite,,2022,Q4,2,F,20220621.0,20221223.0,20221212,20221227,EXP,,JP-DSJP-DSJ-2022-140685,DAIICHI,,63.0,YR,,M,Y,47.6,KG,20221227,,MD,JP,JP,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Synovitis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pain,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Osteolysis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rheumatoid arthritis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Red blood cell sedimentation rate abnormal,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Abdominal discomfort,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Skin injury,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Alanine aminotransferase abnormal,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Joint ankylosis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Psoriatic arthropathy,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein increased,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Arthropathy,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hepatic fibrosis,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Joint swelling,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Upper respiratory tract infection,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic product effect decreased,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug hypersensitivity,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Liver disorder,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Gastrointestinal infection,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Product use issue,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Transaminases increased,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Treatment failure,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug-induced liver injury,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Therapeutic response decreased,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Localised infection,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anti-cyclic citrullinated peptide antibody positive,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Infection,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Musculoskeletal stiffness,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hand deformity,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dyspepsia,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone erosion,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bone cyst,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217292661,21729266,38,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,C-reactive protein abnormal,,2022,Q4,1,I,,20221205.0,20221214,20221214,EXP,,CA-BAYER-2022A168101,BAYER,,50.0,YR,A,M,Y,,,20221214,,HP,CA,CA,2022,Q4,Adult
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Asthenia,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Vomiting,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Depressed mood,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Dysphagia,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Dementia,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217303622,21730362,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,Tablet,,2022,Q4,Off label use,,2022,Q4,2,F,,20221220.0,20221214,20221228,EXP,,JP-JNJFOC-20221227059,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,,,20221229,,PH,JP,JP,2022,Q4,Elderly
217348421,21734842,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,204042.0,,,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221206.0,20221215,20221215,EXP,,JP-JNJFOC-20221231605,JOHNSON AND JOHNSON,"Fujita T, Komatsubara Y, Noguchi G, Seshita A. P -211 -3 A case of euglycaemic ketoacidosis associated with oral SGLT -2 inhibitors developed after emergency surgery for gallstone cholecystitis. The 84th Annual Congress of Japan Surgical Association. 2022.11. 24, 25, 26; 2620",6.0,DEC,A,F,Y,,,20221215,,MD,JP,JP,2022,Q4,Child
217348421,21734842,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,204042.0,,,Tablet,,2022,Q4,Cholecystitis,,2022,Q4,1,I,,20221206.0,20221215,20221215,EXP,,JP-JNJFOC-20221231605,JOHNSON AND JOHNSON,"Fujita T, Komatsubara Y, Noguchi G, Seshita A. P -211 -3 A case of euglycaemic ketoacidosis associated with oral SGLT -2 inhibitors developed after emergency surgery for gallstone cholecystitis. The 84th Annual Congress of Japan Surgical Association. 2022.11. 24, 25, 26; 2620",6.0,DEC,A,F,Y,,,20221215,,MD,JP,JP,2022,Q4,Child
217348421,21734842,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,204042.0,,,Tablet,,2022,Q4,Abscess,,2022,Q4,1,I,,20221206.0,20221215,20221215,EXP,,JP-JNJFOC-20221231605,JOHNSON AND JOHNSON,"Fujita T, Komatsubara Y, Noguchi G, Seshita A. P -211 -3 A case of euglycaemic ketoacidosis associated with oral SGLT -2 inhibitors developed after emergency surgery for gallstone cholecystitis. The 84th Annual Congress of Japan Surgical Association. 2022.11. 24, 25, 26; 2620",6.0,DEC,A,F,Y,,,20221215,,MD,JP,JP,2022,Q4,Child
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217354821,21735482,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221212.0,20221215,20221215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-153349,BRISTOL MYERS SQUIBB,,73.0,YR,E,F,Y,101.0,KG,20221215,,HP,CA,CA,2022,Q4,Elderly
217418331,21741833,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 milligram,,,U,,,,,300.0,MG,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,,20221209.0,20221216,20221216,EXP,,CA-APOTEX-2022AP016747,APOTEX,,17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
217418331,21741833,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 milligram,,,U,,,,,300.0,MG,,,2022,Q4,Treatment noncompliance,,2022,Q4,1,I,,20221209.0,20221216,20221216,EXP,,CA-APOTEX-2022AP016747,APOTEX,,17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
217418331,21741833,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,,20221209.0,20221216,20221216,EXP,,CA-APOTEX-2022AP016747,APOTEX,,17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
217418331,21741833,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 milligram,,,U,,,,,100.0,MG,,,2022,Q4,Treatment noncompliance,,2022,Q4,1,I,,20221209.0,20221216,20221216,EXP,,CA-APOTEX-2022AP016747,APOTEX,,17.0,YR,,M,Y,,,20221216,,HP,CA,CA,2022,Q4,Youth
217500431,21750043,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221213.0,20221219,20221219,EXP,,CA-BAUSCH-BL-2022-027303,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221219,,HP,CA,CA,2022,Q4,Elderly
217500431,21750043,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221213.0,20221219,20221219,EXP,,CA-BAUSCH-BL-2022-027303,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221219,,HP,CA,CA,2022,Q4,Elderly
217500431,21750043,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221213.0,20221219,20221219,EXP,,CA-BAUSCH-BL-2022-027303,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221219,,HP,CA,CA,2022,Q4,Elderly
217500431,21750043,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221213.0,20221219,20221219,EXP,,CA-BAUSCH-BL-2022-027303,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221219,,HP,CA,CA,2022,Q4,Elderly
217500431,21750043,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221213.0,20221219,20221219,EXP,,CA-BAUSCH-BL-2022-027303,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20221219,,HP,CA,CA,2022,Q4,Elderly
217586731,21758673,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221214.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837758,TEVA,,76.0,YR,E,F,Y,,,20221221,,HP,CA,CA,2022,Q4,Elderly
217586731,21758673,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221214.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837758,TEVA,,76.0,YR,E,F,Y,,,20221221,,HP,CA,CA,2022,Q4,Elderly
217586731,21758673,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221214.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837758,TEVA,,76.0,YR,E,F,Y,,,20221221,,HP,CA,CA,2022,Q4,Elderly
217586731,21758673,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221214.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837758,TEVA,,76.0,YR,E,F,Y,,,20221221,,HP,CA,CA,2022,Q4,Elderly
217586731,21758673,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221214.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837758,TEVA,,76.0,YR,E,F,Y,,,20221221,,HP,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Intentional product use issue,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217586741,21758674,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221213.0,20221221,20221221,EXP,,CA-TEVA-2022-CA-2837273,TEVA,,73.0,YR,E,F,Y,101.0,KG,20221221,,MD,CA,CA,2022,Q4,Elderly
217617771,21761777,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,,20221212.0,20221221,20221221,EXP,,CA-APOTEX-2022AP016819,APOTEX,,64.0,YR,,M,Y,,,20221221,,HP,CA,CA,2022,Q4,Adult
217617771,21761777,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Extradural abscess,,2022,Q4,1,I,,20221212.0,20221221,20221221,EXP,,CA-APOTEX-2022AP016819,APOTEX,,64.0,YR,,M,Y,,,20221221,,HP,CA,CA,2022,Q4,Adult
217617771,21761777,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Post streptococcal glomerulonephritis,,2022,Q4,1,I,,20221212.0,20221221,20221221,EXP,,CA-APOTEX-2022AP016819,APOTEX,,64.0,YR,,M,Y,,,20221221,,HP,CA,CA,2022,Q4,Adult
217642171,21764217,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,300.0,MG,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,,20221214.0,20221222,20221222,EXP,,CA-TEVA-2022-CA-2837757,TEVA,,17.0,YR,T,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Youth
217642171,21764217,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,300.0,MG,,,2022,Q4,Treatment noncompliance,,2022,Q4,1,I,,20221214.0,20221222,20221222,EXP,,CA-TEVA-2022-CA-2837757,TEVA,,17.0,YR,T,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Youth
217642171,21764217,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,,20221214.0,20221222,20221222,EXP,,CA-TEVA-2022-CA-2837757,TEVA,,17.0,YR,T,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Youth
217642171,21764217,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,,2022,Q4,Treatment noncompliance,,2022,Q4,1,I,,20221214.0,20221222,20221222,EXP,,CA-TEVA-2022-CA-2837757,TEVA,,17.0,YR,T,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Youth
217672041,21767204,19,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,Unknown,,,,,Tablet,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221213.0,20221222,20221222,EXP,,CA-TAKEDA-2022TUS100232,TAKEDA,,76.0,YR,,F,Y,,,20221222,,HP,CA,CA,2022,Q4,Elderly
217672041,21767204,19,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,Unknown,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221213.0,20221222,20221222,EXP,,CA-TAKEDA-2022TUS100232,TAKEDA,,76.0,YR,,F,Y,,,20221222,,HP,CA,CA,2022,Q4,Elderly
217672041,21767204,19,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,Unknown,,,,,Tablet,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221213.0,20221222,20221222,EXP,,CA-TAKEDA-2022TUS100232,TAKEDA,,76.0,YR,,F,Y,,,20221222,,HP,CA,CA,2022,Q4,Elderly
217672041,21767204,19,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,Unknown,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221213.0,20221222,20221222,EXP,,CA-TAKEDA-2022TUS100232,TAKEDA,,76.0,YR,,F,Y,,,20221222,,HP,CA,CA,2022,Q4,Elderly
217672041,21767204,19,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,Unknown,,,,,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221213.0,20221222,20221222,EXP,,CA-TAKEDA-2022TUS100232,TAKEDA,,76.0,YR,,F,Y,,,20221222,,HP,CA,CA,2022,Q4,Elderly
217695171,21769517,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300mg mane; ;,,,N,U,,,204042.0,300.0,MG,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221221.0,20221222.0,20221223,20221223,EXP,,GB-JNJFOC-20221249279,JOHNSON AND JOHNSON,,62.0,YR,A,M,Y,,,20221223,,HP,GB,GB,2022,Q4,Adult
217695981,21769598,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,U,U,,,204042.0,100.0,MG,Tablet,QD,2022,Q4,Cardiac failure,,2022,Q4,1,I,,20221214.0,20221223,20221223,EXP,,JP-JNJFOC-20221247424,JOHNSON AND JOHNSON,,7.0,DEC,E,M,Y,,,20221223,,MD,JP,JP,2022,Q4,Child
217761791,21776179,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300mg daily; ;,,,N,U,,,204042.0,300.0,MG,Tablet,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221220.0,20221223.0,20221226,20221226,EXP,,GB-JNJFOC-20221251987,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221226,,HP,GB,GB,2022,Q4,Adult
217764501,21776450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q4,Urine ketone body present,,2022,Q4,1,I,20221101.0,20221215.0,20221226,20221226,EXP,JP-MHLW-I2210005791,JP-NOVOPROD-1004004,NOVO NORDISK,,49.0,YR,,F,Y,,,20221226,,PH,JP,JP,2022,Q4,Adult
217764501,21776450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, qd",,,Y,,,,,100.0,MG,Tablet,QD,2022,Q4,Vomiting,,2022,Q4,1,I,20221101.0,20221215.0,20221226,20221226,EXP,JP-MHLW-I2210005791,JP-NOVOPROD-1004004,NOVO NORDISK,,49.0,YR,,F,Y,,,20221226,,PH,JP,JP,2022,Q4,Adult
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217777401,21777740,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,1,I,,20221214.0,20221226,20221226,EXP,,CA-APOTEX-2022AP016909,APOTEX,,73.0,YR,,F,Y,101.0,KG,20221226,,HP,CA,CA,2022,Q4,Elderly
217803621,21780362,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,STRENGTH: 150+1000 mg,,,Y,,UNKNOWN,,204353.0,,,Film-coated tablet,QD,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20221001.0,20221223.0,20221227,20221227,EXP,DK-DKMA-WBS-1002831,DK-JNJFOC-20221252806,JOHNSON AND JOHNSON,,62.0,YR,A,M,Y,,,20221227,,MD,DK,DK,2022,Q4,Adult
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217829611,21782961,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221219.0,20221227,20221227,EXP,,CA-AstraZeneca-2022A412817,ASTRAZENECA,,73.0,YR,,F,Y,101.0,KG,20221227,,MD,CA,,2022,Q4,Elderly
217967991,21796799,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Renal impairment,,2022,Q4,1,I,20221028.0,20221223.0,20221230,20221230,EXP,,NVSJ2022JP275473,NOVARTIS,,82.0,YR,,M,Y,,,20221230,,MD,JP,JP,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Asthma,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Wheezing,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Rhinorrhoea,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Nasal congestion,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Off label use,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Bronchiectasis,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Blood immunoglobulin E increased,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Malignant mediastinal neoplasm,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
217990951,21799095,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221226.0,20221230,20221230,EXP,,CA-BAUSCH-BL-2022-028162,BAUSCH AND LOMB,,73.0,YR,,F,Y,101.0,KG,20221230,,HP,CA,CA,2022,Q4,Elderly
